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Gametocytes, the transmission stage of malaria parasites, are generally rare in 
infections. I explore whether this may be a parasite adaptation that paradoxically 
maximises fitness. 
The fitness consequences of different levels of gametocyte investment have 
previously been investigated with continuously formulated mathematical models. I 
show that these models generally describe gametocyte dynamics inaccurately and 
that this can substantially affect the level of investment that maximises fitness. I 
present an optimality analysis of gametocyte investment based on a discretely 
formulated within-host model. I show that low gametocyte investment is predicted as 
a result of the trade-off that exists between producing gametocytes and increasing 
parasite numbers. I predict that gametocyte investment should decrease as maximum 
asexual density occurs later in infections and also as parasite fecundity rises. These 
two effects are asymmetrical. The time of maximum asexual density is predicted to 
have a much larger effect than parasite fecundity. 
I address statistical problems with estimating gametocyte investment from blood 
smears. I also consider the simpler case of estimating parasitaemias and 
gametocytaemias. Traditional methods of counting parasites in smears can produce 
biased estimates of parasitaemia, gametocytaemia and gametocyte conversion. I 
introduce an alternative method of counting based on inverse sampling. This method 
is unbiased, gives estimates of constant precision and is the most time-efficient 
method of counting. 
I used the inverse sampling method to estimate gametocyte conversion (the observed 
outcome of investment) in P. chabaudi infections in mice, which had been 
manipulated to alter the time of maximum asexual density. Gametocyte conversion 
showed two peaks. The timing of the second peak depended on the time of maximum 
asexual density. Maximum conversion decreased as the time to maximum asexual 
density rose as I had predicted. An interesting finding was that gametocyte 
conversion decreased after reaching a maximum. This result is counter to most life 
history theory. I suggest this indicates that survival of infections into a chronic phase 
may be an important component of fitness. Maximum conversion occurred after 
maximum asexual density. This leads me to propose that contrary to the common 
view, gametocyte investment may be suppressed at times when there is a high risk of 
parasite clearance. 
Understanding the reasons for gametocyte rarity may help to predict how P. 
falciparum will respond to intervention and suggest new methods of malaria control. 
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1. Introduction 
Malaria is one of the most prevalent diseases of man. An estimated 300-500 million 
cases occur annually (Sachs and Malaney, 2002). Malaria caused by the parasite 
Plasmodiumfalciparum is also one of the most dangerous human infections. 
Approximately 1-2% of P. falciparum cases in children have acute symptoms 
(Greenwood and Mutabingwa, 2002) including fits, extreme anaemia, coma, 
pulmonary oedema and renal failure (Knell, 1991). Up to two million people, mostly 
children, are estimated to die from P. falciparum annually (Knell, 1991). Repeated 
malaria attacks are believed to lead to malnutrition, persistent anaemia and splenic 
enlargement, suppress growth and development in children and carry the risk of 
serious complications such as Burkitt's lymphoma (Knell, 1991). In pregnant 
women, malaria can cause death, foetal death, and low birth weight of the baby, 
which probably reduces survival of the infant (Greenwood and Mutabingwa, 2002). 
Malaria also imposes a considerable economic cost on the tropical and subtropical 
nations where it occurs. This cost includes money spent on treatment and prevention 
and lost income because of days off work and premature mortality, but also the 
financial consequences of impaired education, higher birth rates to compensate for 
child deaths, reduced foreign investment and suppressed tourism (Sachs and 
Malaney, 2002). Sachs and Malaney (2002) estimated that P. falciparum reduces the 
gross national product per capita by more than half. Decreasing the range of P. 
falciparum and the severity of P. falciparum infections is therefore an important 
healthcare objective. Understanding what drives P. falciparum transmission and 
virulence could aid this goal. 
Gametocytes are the transmission stage of malaria parasites. Available evidence 
suggests that the number of new infections started by an infected host increases with 
gametocyte density, as reviewed later. Yet, as described later, gametocytes are 
typically only found in around a fifth of P. falciparum infections at any one time and 
average gametocyte densities are usually less than 10% of the density of other blood 
stages. Given the importance of gametocytes to parasite fitness, the rarity of 
gametocytes is puzzling (Taylor and Read, 1997). In this thesis, I explore the 
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hypothesis that the rarity of gametocytes is a life history strategy of the parasite, 
favoured by natural selection. 
1.1. Life cycle of malaria parasites and related Coccidea 
I describe the life cycle of malaria parasites with reference to P. falciparum, with 
details of other species included where indicated. 
Malaria infections begin with the inoculation of sporozoites into host tissue or blood 
by a feeding female mosquito (Figure 1.1). Many sporozoites are killed by the 
immune system but those surviving enter liver cells around half an hour after 
inoculation. Parasites grow and divide internally within parenchymal cells of the 
liver for about six days before rupturing to each release approximately 30,000 
merozoites into the blood (Bruce-Chwatt, 1985). Merozoites rapidly invade red 
blood cells to become ring stages. Parasites enlarge within the red blood cells and are 
then known as trophozoites. Twenty-four hours after merozoites enter red blood 
cells, the cells usually sequester in capillaries and are no longer visible in blood 
smears. The parasites replicate asexually, forming a schizont that contains, on 
average, 16 merozoites (Bruce-Chwatt, 1985). Schizonts burst to release the 
merozoites. Each asexual cycle, from a merozoite invading a red blood cell to the 
schizont releasing more merozoites, takes 48 hours. Cycles of asexual replication 
continue for the duration of the infection. Parasites usually closely synchronise their 
development and schizont rupture is associated with the characteristic periodic chills 
and fever of malaria. 
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Figure 1 .1 . The life cycle of P. falciparum. 
Some rings develop into gametocytes instead of asexuals. Commitment to one of 
these pathways appears to be determined by the parent parasite (Dyer and Day, 
2000), with all merozoites from one schizont developing in the same way (Bruce et 
al., 1990; Silvestrini et al., 2000; Smith et al., 2000). Immature gametocytes are not 
distinguishable from trophozoites and also sequester. Identifiable gametocytes are 
believed to re-enter the circulation approximately 8-10 days after merozoite invasion 
(Carter and Graves, 1988) although more recently the lapse has been estimated to be 
4-12 days with a mean of 7 days (Eichner et al., 2001). Gametocytes can persist for a 
further 17 (Hogh et al., 1995) or 24 days (Smalley and Sinden, 1977) with average 
circulation time being alternately estimated as 3.6 days (calculated from relationship 
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given in Fig. 2 in Smalley and Sinden, 1977) and 6.4 days (Eiclmer et al., 2001). 
More recent data from synchronised gametocytes in vitro suggests that the average 
lifespan of mature gametocytes is 5.7 days (Lensen et al., 1999, calculated by fitting 
an exponential relationship to data in their Fig. 2). During the course of infection, the 
density of mature gametocytes in the blood is nearly always less than 10% of the 
density of other parasite stages (Figure 1.2). 
mature gametocytes 	 other blood stages 
100 	 120 	140 	 160 	 180 	200 
day of infection 
Figure 1.2. Dynamics of P. falciparum infection in a non-immune host. Infection was induced 
with sporozoites for the treatment of neurosyphilis. Solid line represents the density of 
asexuals and immature gametocytes that are too young to distinguish. Dotted line is the 
density of mature gametocytes. Data reproduced from Collins and Jeffery, 1999, their figure 
A19. 
When red blood cells infected with mature gametocytes are ingested by an Anopheles 
mosquito, gametocytes escape the host cells and transform into gametes. Male 
gametocytes rapidly divide into about eight flagellated gametes, search for female 
gametes. Fertilisation results in a diploid zygote. Zygotes develop into elongated 
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motile stages called ookinetes, which move to the mid-gut wall and penetrate it. 
After reaching the outside surface of the mid-gut, ookinetes round up to form 
oocysts. Work on P. berghei suggests that the first meiotic division probably occurs 
in the zygote but a second meiotic division was not observed (Sinden and Hartley, 
1985). However haploid sporozoites are produced within the oocyst wall after oocyst 
expansion and nuclear and cytoplasmic division. Genetic recombinants can be 
generated during meiosis (Walliker et al., 1987). Mature oocysts are estimated to 
contain 1000 sporozoites (Bruce-Chwatt, 1985). Sporozoites emerge from oocysts 
into the mosquito body cavity and migrate to the salivary glands. Development time 
within the mosquito depends on temperature, taking 9-10 days at 28°C and 15-17 
days at 23°C (Bruce-Chwatt, 1985). 
There are more than 125 species of Plasmodium (Knell, 1991), which infect 
mammals, reptiles and birds. Other species differ from P. falciparum in the period of 
their asexual cycle, number of merozoites per schizont, gametocyte development 
time and gametocyte longevity. P. chabaudi, which infects rodents, has a cycle 
period of 24 hours and produces an average of six merozoites per schizont in mice 
(Landau and Boulard, 1978). P. chabaudi gametocytes can be identified after 36 
hours (Gautret et al., 1996a) and have been estimated to have a half-life of 14 hours 
(Reece et al., 2003). Commitment to gametocyte development may not always be 
determined by the parental schizont (Mons, 1986). In some species, including the 
human parasite P. vivax, parasites can develop into dormant stages in the liver, which 
produce relapses of infection (Garnham, 1988). 
In lizards, malaria parasites probably undergo two cycles of replication in the liver 
(Schall, 1996). Parasites then invade and replicate inside macrophages, which 
disperse to the endothelium (Schall, 1996). After replicating in endothelial cells, 
parasites are released into the blood stream. Some parasites encyst in the endothelia, 
which provides a continued source of new blood stage parasites (Schall, 1996). 
In malaria infections of birds, sporozoites enter skin macrophages rather than liver 
cells (McGhee, 1988). Parasites replicate in the macrophages and then a second 
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replication cycle occurs in macrophages and endothelial cells throughout the host 
(McGhee, 1988). Merozoites from the second replication can invade red blood cells 
(McGhee, 1988). However, parasite development continues in the organs, concurrent 
with the blood stage infection (Gamham, 1966). The two phases of development are 
not distinct, as merozoites from blood stage parasites can also infect tissue cells 
(McGhee, 1988). 
Malaria parasites belong to the family Plasmodiidae in the order Haemosporida 
(Smith et al., 2002). The Haemosporida also contains the families Haemoproteidae 
and Leucocytozoidae (Carter and Graves, 1988). In species of Haemoproteidae, 
parasites replicate asexually once in tissue cells and then all merozoites that enter red 
blood cells develop as gametocytes (Carter and Graves, 1988). Gametocyte 
production in the Leucocytozoidae is more complex, with two types of gametocytes 
developing. After one asexual replication in the liver, some merozoites invade red 
blood cells and develop into 'round' gametocytes and others enter macrophages, 
where they replicate (Carter and Graves, 1988). The merozoites from this second 
replication then invade red blood cells and leucocytes to become 'elongate' 
gametocytes (Carter and Graves, 1988). 
A related order to the Haemosporida is the Eimeriida (Smith et al., 2002). The 
Eimeriida differ from the Haemosporida in that gametocyte production, gamete 
fertilisation and oocyst formation take place in a single host (Carter and Graves, 
1988). Infections begin either by ingestion of oocysts from the environment, or 
ingestion of an intermediate host (Carter and Graves, 1988; Smith et al., 2002). 
Parasites belonging to the Eimeriida complete a fixed number of asexual replication 
cycles in cells of the gut, and then all merozoites invade epithelial cells and 
differentiate into gametocytes (Smith et al., 2002). 
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1.2. Prevalence and level of gametocytes in P. falciparum 
infections 
The relative frequency of gametocyte carriers amongst people infected with P. 
falciparum is about 20% at any one time (Table 1.1). 





Burkina Fasoa over 4years 77% Boudin etal., 1993 
Indonesian New Guinea 2-60 years 21% Baird etal., 1991 
Kenya' 0-14 years 42% Giltheko etal., 1992 
Maliab over 1 year 22% Toure etal., 1998 
Papua New Guinea' all ages 13% Cattani etal., 1986 
Papua New G u i neaa ,d all ages 10% Graves etal., 1988 
The Gambia 4 months to 9 years 22% Smalley etaL, 1981 
Table 1.1. Relative prevalence of gametocytes in natural P. falciparum infections. Results 
are from random surveys and are weighted means across age based on the age structure of 
the population. Prevalence was determined by light microscopy. Although gametocytes 
would be detected at lower densities by PCR, the volume of blood sampled by microscopy is 
likely to more closely correspond to blood meal size. All surveys were of at least 100 
individuals, a  Result is ratio of number of infections with gametocytes to number of infections 
with asexual parasites. b  Result is mean of two surveys. C  Result is mean of four surveys. 
ci  Result is mean of three villages each averaged over six surveys. 
Within gametocyte-positive infections, gametocyte densities are usually less than 
10% of the densities of asexuals (Table 1.2). 
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gametocyte 
study area ages 




Burkina Faso over 4 years 0.6% Boudin etal., 1993 
Kenya' 0-14 years 5% Giltheko etal., 1992 
Mozambique 6-16 years 7% Hogh etal., 1995 
Table 1.2 Level of gametocytes in natural, gametocyte-positive, P. falciparum infections. 
Results are from random surveys and are weighted means across age based on the age 
structure of the population. The lowest number of people examined was 92. a  Ratio of 
geometric mean densities. 
1.3. Could there be a non-adaptive explanation for 
gametocyte rarity? 
Parasites from closely related families to the Plasmodiidae differentiate completely 
into gametocytes in red blood cells, after one or two cycles of asexual replication in 
host tissues (as described previously). A closely related order to the Haemosporida 
also consists of parasites that differentiate completely into gametocytes after a fixed 
number of asexual cycles. Therefore it seems unlikely that a historical constraint has 
prevented malaria parasites from producing gametocytes at a higher frequency. 
Instead, the phylogenetic data suggest that low investment into gametocytes is a 
derived characteristic that has evolved in Plasmodium (Smith et al., 2002). In a 
related dade, asexual blood stage replication appears to have evolved at least three 
times from species that produce only gamonts (sexual stages) in the blood (Smith et 
al., 2002). These data strengthen the hypothesis that gametocyte rarity is a parasite 
adaptation. 
Isolates of P. falciparum vary in the number of gametocytes that they produce in 
culture (Ponnudurai et al., 1982). Cloned lines of P. falciparum also differ in the 
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number of gametocytes that they produce in vitro (Graves et al., 1984). Therefore 
there is no evidence to suggest that the evolution of gametocyte production has been 
limited by a lack of genetic variation. 
One potential explanation for gametocyte rarity is that gametocytes are preferentially 
cleared by a host immune response. There is very little evidence for any immune 
responses that are effective against gametocytes, as I discuss later. It seems unlikely 
that the host immune response is the reason for gametocyte rarity (Taylor and Read, 
1997). 
1.4. Benefits of setting gametocyte investment in an 
adaptive framework 
If gametocytes are rare because parasites have evolved to invest little in gametocyte 
production, then understanding the selective pressures that have shaped this 
evolution might help us to predict how the parasite will respond to intervention. 
Beginning with the malaria eradication campaigns of the 1950's (Knell, 1991), the 
environment of P. falciparum has been altered by the widespread application of 
insecticides, use of prophylactic and therapeutic drugs and bednets. In vitro, P. 
falciparum is able to increase gametocyte conversion in response to a number of 
factors (Carter and Miller, 1979; Kaushal et al., 1980; Bruce et al., 1990; Williams, 
1999; Dyer and Day, 2000; Dyer and Day, 2003) including subcurative chioroquine 
treatment (Buckling et al., 1999a). Therefore drug treatment of infections may have 
caused increased gametocyte investment. P. chabaudi was found to increase 
gametocyte conversion when infections were treated with antimalarial drugs 
(Buckling et al., 1999). Increased gametocyte investment would counteract the 
expected reduction in transmission achieved by treatment. In P. chabaudi, the net 
effect of chioroquine on transmission to mosquitoes was negligible (Buckling et al., 
1997). As well as immediate responses to chemotherapy, P. falciparum may be 
adapting to intervention, which could create long-term problems for malaria control. 
This is a realistic concern given that P. falciparum has evolved resistance to the two 
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most commonly used antimalarials, chioroquine and suiphadoxine-pyrimethamine 
(Ridley, 2002). 
Low investment into gametocytes has implications for parasite virulence as well as 
transmission. It is the rapid expansion in the number of infected red blood cells, as a 
result of asexual replication, that underlies severe malarial disease (Miller et al., 
2002). Gametocytes, in contrast, do not seem to cause pathology. This raises the 
intriguing possibility that increasing parasite investment into gametocytes might 
reduce the symptoms of malaria (McKenzie and Bossert, 1998a). By considering 
gametocyte investment in an evolutionary framework, it may be possible to design an 
intervention programme to reduce P. falciparum virulence by stimulating gametocyte 
production. In the long-term, such a strategy might also lead to the evolution of 
higher gametocyte investment and concomitantly, lower virulence. Whilst clearly the 
consequences would have to be very carefully evaluated, an advantage of such an 
approach would be the continued circulation of parasites in the community, which 
would maintain levels of immunity. Similar approaches could identify properties of 
vaccines and antimalarial drugs that should promote favourable short and long-term 
parasite changes, and help direct future vaccine and drug development (for an 
example from the perspective of the evolution of virulence see Gandon et al., 2001). 
1.5. Thesis outline 
I investigated whether low gametocyte investment could be a parasite adaptation by 
predicting the level of investment that maximises fitness with an optimality analysis. 
I then evaluated the predictions and assumptions of my theoretical work against data 
from malaria infections. 
There have been two previous optimality analyses of gametocyte investment in 
malaria (Koella and Antia, 1995; McKenzie and Bossert, 1998b). Both incorporated 
models of parasite within-host dynamics that were formulated continuously. 
Recently, it has been suggested that within-host malaria models should be discretely 
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formulated (Molineaux and Dietz, 1999). In chapter 2, I show that Koella and 
Antia's (1995) and McKenzie and Bossert's (1998b) models are rather poor 
descriptions of gametocyte production and that this is likely to have had an impact on 
their results. I show that other continuous models of gametocyte production are also 
inaccurate. Furthermore, I found that nearly all continuous within-host malaria 
models would have similar problems if they were extended to include gametocytes. 
In all these cases, Idemonstrate that the optimum gametocyte investment under these 
models is likely to be too low. 
Chapter 3 details my optimality analysis. My primary aim was to explore whether the 
constraint that gametocytes develop from asexuals could explain low gametocyte 
investment. Gametocyte production reduces asexual numbers and therefore the rate 
at which the asexual population can grow within the host. Hence gametocyte 
production at one stage of infection can decrease the number of gametocytes that can 
be produced subsequently. I modelled this cost of gametocyte production with a 
simple discrete within-host model. I treated the immune response to infection in a 
different way from Koella and Antia (1995), McKenzie and Bossert (1998b) and 
most malaria models. I assumed that gametocyte investment was fixed over the 
course of infection. I was able to find analytical results. Low gametocyte investment 
was predicted for a range of malaria species. I found that optimal gametocyte 
investment decreased as the maximum asexual density occurred later and as parasite 
fecundity rose. However these effects were asymmetrical, with the time of maximum 
asexual density having a larger effect than parasite fecundity. 
In chapter 3, I make quantitative predictions of gametocyte investment for several 
malaria species. Although estimates of gametocyte investment have been made, 
much of the data for P. falciparum has been collected in vitro. There are also 
problems with the methods that have been used to estimate investment, which I 
review later in the thesis. One way of estimating gametocyte investment in vivo is to 
count gametocytes in blood smears and asexuals (taken to mean asexuals and 
indistinguishable young gametocytes) in blood smears made an appropriate time 
earlier (Carter and Miller, 1979; Buckling et al., 1999b). A large set of such data 
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exists for P. falciparum infections that were used as a treatment for neurosyphilis 
(Collins and Jeffery, 1998). Large amounts of such data have also been collected 
from experimental infections of other malaria species in animal models. However the 
problem with estimating gametocyte investment in this way is that it requires 
estimation of the ratio of measured values. Ratios of uncorrelated measurements are 
less precise than the least precise of the component measurements and are biased 
(Lynch and Walsh, 1997; Sokal and Rohif, 1995). 
Measurements of parasitaemia and gametocytaemia from smears also involves ratio 
estimation. Parasitaemia is much more commonly estimated than gametocyte 
investment. Therefore, I begin, in chapter 4, by considering bias and precision in 
estimating parasitaemias and gametocytaemias. I examine three methods of counting 
parasites in smears using sampling theory. Two are traditional methods but the third 
is novel. The new method involves searching smears until a fixed number of 
parasites have been observed, rather than sampling a fixed number of red blood cells 
or fields. I show that traditional counting methods can be biased and that the 
precision of parasitaemia (and gametocytaemia) estimates depends on the level of 
parasitaemia (gametocytaemia). The new sampling method gives unbiased estimates 
of constant precision. It is also the most time-efficient method of counting. 
I evaluate the same three counting methods in chapter 5, this time for estimating 
gametocyte investment. The novel method of inverse sampling is shown to be the 
best technique for estimating investment. It is the only method of the three that gives 
unbiased estimates. Again, estimates made with this method have a constant level of 
precision, whilst precision is highly variable for the other two approaches, depending 
on gametocytaemia. A serious problem with the traditional counting methods is that 
the bias in investment estimates increases when gametocytaemia is high relative to 
the asexual parasitaemia. As before, inverse sampling is the most time-efficient 
method. 
In chapter 6, I apply the new counting technique to estimating gametocyte 
investment during P. chabaudi infections in mice. The time of maximum asexual 
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density in the infections was manipulated by varying the inoculating dose (Timms et 
al., 2001). I was therefore able to test the prediction from chapter 3 that gametocyte 
investment should decrease as the time to maximum asexual density occurs later. I 
was also able to examine whether gametocyte investment was constant throughout 
infection. 
As gametocytes are counted when they are mature, estimates of gametocyte 
investment from smears can be affected by gametocyte mortality during 
development. For this reason I refer to such empirical estimates as gametocyte 
conversion. In chapter 6, I show that gametocyte conversion was not constant during 
infections. There were two peaks in conversion. However, maximum gametocyte 
conversion did decline as the time to maximum asexual density increased. The shape 
of this relationship was not significantly different from my prediction. A particularly 
interesting result was that after reaching a maximum, gametocyte conversion 
decreased. I suggest that this may be an indication that prolonged production of 
gametocytes is important for parasite fitness. 
In chapter 7, I discuss some possible future directions for this work. I suggest ways 
in which my within-host model could be developed. I consider whether there is any 
potential for estimating gametocyte investment from neurosyphilis data sets, given 
the results of chapters 5 and 6. I also mention some possible technological advances 
that could contribute to this field. 
Introduction 	 13 
2. Problems with using continuous malaria models to 
describe gametocyte production 
2.1. Introduction 
The majority of within-host malaria models describe parasite replication as occurring 
continuously (Molineaux and Dietz, 1999). This is a questionable approach as a well-
defined characteristic of malaria infections is the simultaneous release of merozoites 
at discrete intervals (Garnham, 1988). But a more important problem with these 
models is that they relate the rate of parasite production to the number of asexuals (or 
subgroup of asexuals) and not asexuals of a specific age (with the exception of 
Hoshen et al.'s (2000a) model). Asexuals release merozoites a fixed time after they 
invade red blood cells (Knell, 1991). Therefore, the number of asexuals of the 
appropriate age is the correct determinant of parasite production, as argued by 
Hoshen etal. (2000a). Saul (1998) showed that as a consequence of not limiting 
replication by age, one of the main continuous malaria models generated greatly 
inflated parasite growth rates. Published versions of the model did not have this fault, 
but Molineaux and Dietz (1999) point out that this is because either the replication 
rate or the number of merozoites that invaded new cells were unrealistically low. 
Gravenor and Lloyd (1998) highlight the underlying problem of very variable ages of 
reproduction, and suggest reducing this variation by splitting the asexual dynamics 
into several equations rather than just one. 
Most within-host malaria models ignore gametocyte production. Here, I investigate 
those continuous within-host models that describe gametocyte production, and 
consider the effects of incorporating gametocyte production into the other models. I 
show that nearly all continuous malaria models that do not explicitly link parasite 
replication to age are fundamentally inaccurate once gametocyte production is 
included. I also demonstrate that using these models to describe gametocyte 
production is likely to have a significant impact on the outcome of optimality 
analyses of gametocyte investment. 
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2.2. Methods 
I consider the most basic form of the models, excluding immune responses, changes 
in uninfected red blood cell numbers, invasion of already infected cells, fever, drug 
treatment, asexual mortality prior to merozoite release and infection with more than 
one parasite strain or species. 'Where models produce transient dynamics at the start 
of infection I only investigate their behaviour under steady parasite growth. In one of 
the models, gametocyte production was modelled by a fixed proportion of asexuals 
becoming gametocytes at the point where they would otherwise replicate (Koella and 
Antia, 1995). Some of the other models included gametocyte production by asexuals 
converting to gametocytes at a fixed rate (Hellriegel, 1992; McKenzie and Bossert, 
1997, 1998a, b; Mason et al., 1999; Mason and McKenzie, 1999), but this can be 
interpreted as, depending on the model, either a fixed proportion of merozoites being 
gametocytes or a fixed proportion of asexuals becoming gametocytes before 
replicating, which is the approach that I took here. I incorporated gametocyte 
production into those models that did not originally include it, by similarly 
designating a fixed proportion of merozoites as gametocytes or asexuals to become 
gametocytes. 
Most of the models were formulated for P. falciparum (Anderson et al., 1989; 
Hellriegel, 1992; Gravenor etal., 1995; McKenzie and Bossert, 1997, 1998a, b; 
Austin et al., 1998; Gravenor and Kwiatkowski, 1998; Gravenor et al., 1998, 2002; 
Hoshen etal., 1998, 2001; Mason etal., 1999; Mason and McKenzie, 1999; Simpson 
et al., 2002). I consider the behaviour of the models for parameters values 
appropriate to P. falciparum. 
I divide the models into three types. Type 1 models represent asexual dynamics by a 
single equation. Type 2 models include an additional equation for merozoite 
dynamics. Type 3 models describe asexual dynamics by a set of equations, which 
represent the movement of parasites through a series of compartments. A fourth type 
of model has been proposed but not fully characterised, and I address this model in 
the discussion. 
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2.2.1. 	Key to symbols 
A key to the symbols used in this chapter is given in Table 2.1. 
X 	factor by which the number of asexuals increases per cycle period 
M 	number of merozoites produced per asexual 
g gametocyte investment 
P 	gametocytes produced per asexual over one cycle period 
w parasite fitness 
1 	time of maximum asexual density 
B fitness benefit of increased gametocyte investment 
C 	per cycle period fitness cost of increased gametocyte investment 
A[t] number of asexuals at time t 
r 	rate at which asexuals rupture to release merozoites 
G[t] number of gametocytes produced up to and including time t 
T 	cycle period 
rate at which merozoites infect new red blood cells 
M[t] 	number of merozoites at time t 
V 	 rate at which merozoites die 
K, a constant 
y, 	a root of. auxiliary quadratic equation 
YD 	most positive root of auxiliary quadratic equation 
A i [t] number of asexuals in compartment i 
a, 	rate at which asexuals move from compartment i to compartment i + 1 





n-dimensional column vector -- , -----,• . . ,......... 
	
dt dt dt 
S 	n x n-dimensional population projection matrix 
a n-dimensional column vector {A 1 ,A 2 ,.. 
an eigenvalue of S 
Vk 	eigenvector of S corresponding to A k  
AD eigenvalue with the most positive real part 
VD fl 	n 
th  entry in vector VD 
s11 entry in the first row and 	column of S 
determinant of matrix produced from S by deleting first row and i th column 
Table 2.1. Key to symbols. 
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2.2.2. 	Parasite dynamics 
I assess the parasite dynamics of the models by the increase in the number of 
asexuals over one cycle period and the number of gametocytes produced over one 
cycle period. I define cycle period as the time from an asexual invading a red blood 





per cycle period, where m is the number of merozoites produced per asexual and g 
is the gametocyte investment (the proportion of asexuals that become gametocytes or 
merozoites that are gametocytes). Hence the asexual multiplication factor should 
decrease linearly as gametocyte conversion rises. When a proportion of asexuals 
become gametocytes, the number of gametocytes produced over one cycle period 
should be: 
P=g 	 2.2a) 
per asexual at the start of the period. When instead a proportion of merozoites are 
gametocytes, the number of gametocytes produced over one cycle period should be: 
P=mg 	 2.2b) 
per asexual. Hence gametocyte production per asexual over one cycle period should 
increase linearly with the gametocyte conversion ratio. 
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2.2.3. 	Optimum gametocyte investment 
I investigated the possible implications of using continuous models in optimality 
analyses of gametocyte investment by approximating parasite fitness with the 
number of gametocytes produced in the 1 th cycle period of infection. I is the time of 
maximum asexual density. Assuming that parasite numbers first increase rapidly and 
then after reaching a maximum, decrease rapidly, considerably more gametocytes 
will be produced in 1  t cycle period than at any other time. The number of 
gametocytes produced in 1th  cycle period is therefore a first approximation of the 
total number of gametocytes produced by an infection. The advantage of using this 
approximation of fitness is that the cost and benefit of increased gametocyte 
investment can be easily understood in biological terms. Fitness is given by: 
= PX'A[O] 	 2.3) 
where A[O] is the number of asexuals at the start of the infection. Differentiating 
equation 2.3) with respect to g produces: 
dco  = .!.X11A[O] + 	- 1)x2 dXA[o] 	 2.4) 
dg dg 	 dg 
Maximum fitness therefore occurs when: 
2.5) 
Pdg 	Xdg 
The left hand side of equation 2.5) is the proportional rate of increase in gametocyte 
production per cycle period with an increase in gametocyte investment and I define 
this as the fitness benefit of increased gametocyte investment. I define the 
corresponding proportional rate of decrease in asexual multiplication per cycle 
period, on the right hand side of equation 2.5), as the per cycle period fitness cost of 
increased gametocyte investment. 
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Hence: 
B=! dP  
Pdg 2.6) 
where B is the fitness benefit of increased gametocyte investment, and: 
Xdg 
	 2.7) 
where C is the per cycle period fitness cost of increased gametocyte investment. 




From differentiating equation 2.2a) or equation 2.2b) with respect to g, the fitness 
benefit of increased gametocyte conversion should be: 
1 
B=— 	 2.9) 
g 
Hence the benefit of increased gametocyte investment should be highest when 
investment is zero, and decline as investment increases. From differentiating 
equation 2.1) with respect to g, the per cycle period fitness cost of increased 
gametocyte investment should be: 
C=j_Lg 	 2.10) 
Therefore the cost of increased gametocyte investment should be lowest when 
investment is zero and increase with investment. For P. falciparum, I has been 
estimated as four (Collins and Jeffery, 1999, average of given times to maximum 
parasitaemia divided by two). 
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2.3. Type 1 models 
These models represent asexual dynamics by a single equation. Models in this group 
are those of Koella and Antia (1995), McKenzie and Bossert (1997, 1998a, b), 
Hoshen et al. (1998, 2001), Mason et al. (1999), Mason and McKenzie (1999) and 
Simpson et al. (2002). Gametocyte investment was included in some of these models 
(Koella and Antia, 1995; McKenzie and Bossert, 1997, 1998a, b; Mason et al., 1999; 
Mason and McKenzie, 1999), although Mason et al. (1999) and Mason and 
McKenzie (1999) did not model the number of gametocytes produced. Koella and 
Antia (1995) modelled a fixed proportion of asexuals becoming gametocytes 
whereas McKenzie and Bossert's (1997, 1998a [their type A], b) treatments 
correspond to a fixed proportion of merozoites being gametocytes. For identity with 
McKenzie and Bossert's (1997,1998a [their type A], b) models, I incorporated 
gametocyte production into the remaining models by designating a fixed proportion 
of merozoites as gametocytes. 
The asexual dynamics can be represented by: 
dA[t] = r(m(1 - g) - 1)A[t] 
dt 
2.11) 
where A[t] is the number of asexuals at time t and r is the rate at which asexuals 
rupture to release merozoites. Gametocyte production in Koella and Antia's (1995) 
model, is given by: 
dG[t] = rgA[t] 
dt 
2.12a) 
where G[t] is the number of gametocytes produced up to and including time t. The 
r in equation 2.12a) is actually missing in Koella and Antia (1995) but is implied by 
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their text. Gametocyte production in all the other models can be described by: 
dG[t] 
dt 
= rmgA[t] 	 2.12b) 
The solution to equation 2.11) is: 
A[t] = A[O]e?(m(1_1)t 	 2.13) 
Substituting from equation 2.13), the solutions to equations 2.12a) and 2.12b) are 
respectively: 
G[t] 
= 	g 	A[O](em(1__t)t - i) 	 2.14a) 
m(1—g)-1 
G[t] = 
	mg 	A[O](em(1_)t - i) 	 2.14b) 
m(1—g)-1 
Hence, per cycle period the number of asexuals increases by a factor: 
v- 	r(m(I-g)-1)T 2.15) 
where T is the cycle period. The number of gametocytes produced per asexual over 
one cycle period in Koella and Antia's (1995) model is: 
= 	g 
	(e r(m(I-g)-I)T 	 2.16a) 
m(1 - g) —1 
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In all the other models, the number of gametocytes produced per asexual over one 
cycle period is: 
= 	mg (r(m(t_)_1)T 
- i) 
m(1 - g) - 1 
2.16b) 
From differentiating equation 2.16a) or equation 2.16b) with respect to g, the benefit 
of increased gametocyte investment is: 
rn-i 	rmT 
B= 	 + 
9(m(1-9)-1) e 
2.17) 
From differentiating equation 2.15) with respect to g, the per cycle period cost of 




Hence, the cost of increased gametocyte investment per cycle period is independent 
of g. 
2.3.1. 	Koella and Antia's (1995) model 
Koella and Antia's (1995) model is a general one, intended to apply to any 
microparasite (parasite that replicates extensively within the host (Anderson and 
May, 1979). They describe parasite replication by division into two, therefore in their 
model m = 2. Because m = 2, in their model, r is actually the exponential rate at 
which asexuals increase when no gametocytes are produced. As P. falciparum 
asexuals produce, on average, 16 merozoites in two days e 2 ' = 16 and hence 
r = In [16]/2. The cycle period for P. falciparum is two days, therefore T = 2. For 
nearly all levels of gametocyte investment the asexual multiplication factor is 
considerably too low in Koella and Antia's (1995) model (Figure 2.1a)). The biggest 
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multiplication 
per cycle 	8 
period 
discrepancy between the model value and the correct asexual multiplication factor is 
approximately eight (half the maximum multiplication factor) and occurs when 
gametocyte investment is about 30%. Under Koella and Antia's (1995) model, the 
asexual multiplication factor does not quite go to zero when gametocyte investment 
is 100%. The number of gametocytes produced over one cycle period is nearly 
always substantially too high in Koella and Antia's (1995) model (Figure 2. ib)). The 
biggest difference occurs when gametocyte investment is 25%. At this level of 
investment, the number of gametocytes produced under Koella and Antia's (1995) 
model differs from the correct value by 1.25, which is one and a quarter times the 
maximum number of gametocytes that should be produced. Increased investment 
into gametocytes does not always lead to more gametocytes being produced under 
Koella and Antia's (1995) model. When gametocyte investment is more than 
approximately 30%, gametocyte production drops with increasing investment. 
	
—Koella and Antia's (1995) model 
	
correct value 
a) 	 b) 
gametocyte investment 	 gametocyte investment 
Figure 2.1. Parasite dynamics in Koella and Antia's (1995) model. Gametocyte production is 
given per asexual at the start of the cycle period. The asexual dynamics are represented in 
a) and the gametocyte dynamics in b). Model results were calculated from equations 2.15) 
and 2.16a) with r = ln[16]/2 , m = 2 and T= 2. The correct values were calculated from 
equations 2.1) and 2.2a) with m = 16. 
The fitness cost of increased gametocyte investment in Koella and Antia's (1995) 
model is independent of the level of investment (Figure 2.2) instead of increasing 
with investment. The model cost is substantially too high when gametocyte 









investment is less than 75%. The benefit of increased gametocyte investment for 
Koella and Antia's (1995) model varies with investment in a similar way to the 
correct benefit curve (Figure 2.2) but the benefit is considerably too low in their 
model when investment is over 5%. As indicated by the maximum in gametocyte 
production in Figure 2. ib), Koella and Antia's (1995) model wrongly creates an 
negative fitness benefit, and hence extra fitness cost, of increased gametocyte 
investment when investment is over 30%. Consequently, under the conditions 
considered, only investments of less than 30% are beneficial in Koella and Antia's 
(1995) model and this is the maximum level that will be predicted. As a result of the 
too low fitness benefit and too high fitness cost, the optimum gametocyte investment 
in Koella and Antia's (1995) model is too low. The optimum investment under 
Koella and Antia's (1995) model is only 5%, whereas the correct value is 25%. 
benefit in Koella 
and Antia's (1995) 
model 





Figure 2.2. Fitness cost and benefit of increased gametocyte investment in Koella and 
Antia's (1995) model. Fitness is defined as the number of gametocytes produced in the 
fourth cycle period. The position on the x-axis where the cost and corresponding benefit 
curves cross (indicated by arrows) is the optimum gametocyte investment. Model results 
were calculated from equation 2.17), and equation 2.18) multiplied by 3, with r = ln[16]/2, 
m = 2 and T = 2. The correct values were calculated from equation 2.9), and equation 2.10) 
multiplied by 3. 
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2.3.2. 	The models of McKenzie and Bossert (1997, 1 998a, b), 
Hoshen etal. (1998, 2001), Mason etal. (1999), Mason and 
McKenzie (1999) and Simpson etal. (2002) 
I describe the results with reference to McKenzie and Bossert's (1997) model but 
they apply equally to all the models listed above. In McKenzie and Bossert's (1997) 
model, r is the exponential rate at which asexuals increase when no gametocytes are 
produced divided by rn—i and m = 16. Hence r = ln[16]/(2 x 15). As before T = 2. 
The asexual multiplication factor in McKenzie and Bossert's (1997) model is 
considerably too low for most levels of gametocyte investment (Figure 2.3a)), 
although not as low as in Koella and Antia's (1995) model. The biggest difference in 
asexual multiplication between the model and the correct value is when gametocyte 
investment is about 40%; the difference is nearly 5 (a third of the maximum 
multiplication factor). As with Koelia and Antia's (1995) model, asexual 
multiplication is not zero when gametocyte investment is 100%. Gametocyte 
production is substantially too low in McKenzie and Bossert's (1997) model when 
the gametocyte investment is greater than 15%, (Figure 2.3b)). The discrepancy 
increases with increasing investment. The number of gametocytes produced under 
McKenzie and Bossert's (1997) model is 13 less than the correct number (80% less) 
when there is complete gametocyte investment. However, in relative terms, this 
discrepancy is less than the maximum discrepancy in Koella and Antia's (1995) 
model. Gametocyte production drops with increasing gametocyte investment under 
McKenzie and Bossert's (1997) model when investment is over 60%. 
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Mckenzie and Bossert's (1997) model 
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Figure 2.3. Parasite dynamics in McKenzie and Bossert's (1997) model. Gametocyte 
production is given per asexual at the start of the cycle period. The asexual dynamics are 
represented in a) and the gametocyte dynamics in b). Model results were calculated from 
equations 2.15) and 2.16b) with r = ln[16]/(2 x 15), m = 16 and T = 2. The correct values 
were calculated from equations 2.1) and 2.2b) with m = 16. 
The fitness cost of increased gametocyte investment in McKenzie and Bossert's 
(1997) model is constant for all levels of investment (Figure 2.4) and is considerably 
too high when investment is less than 55%. The cost is not as high as in Koella and 
Antia's (1995) model. The fitness benefit curve has approximately the correct shape, 
but is substantially too low when the gametocyte investment is more than 15% 
(Figure 2.4). However, the fitness benefit under McKenzie and Bossert's (1997) 
model is not as low as the benefit in Koella and Antia's (1995) model. As with 
Koella and Antia's (1995) model, at high gametocyte investments there is a negative 
fitness benefit of further investment although this occurs at higher values (over 60%) 
than under Koella and Antia's (1995) model. The optimum gametocyte investment is 
too low in McKenzie and Bossert's (1997) model, but not as low as for Koella and 
Antia's (1995) model. The optimum is 9%. 








• benefit in McKenzie 
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Figure 2.4. Fitness cost and benefit of increased gametocyte investment in McKenzie and 
Bossert's (1997) model. Fitness is defined as the number of gametocytes produced in the 
fourth cycle period. Arrows indicate optimum gametocyte investment. Model results were 
calculated from equation 2.17), and equation 2.18) multiplied by 3 with r = ln[16]/(2 x 15), 
m = 16 and T = 2. The correct values were calculated from equation 2.9), and equation 
2.10) multiplied by 3. 
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2.4. Type 2 models 
Type 2 models have an equation for asexual dynamics and an equation for merozoite 
dynamics. Models in this group are those by Anderson et al. (1989), Hellriegel 
(1992), Gravenor et al. (1995), Hetzel and Anderson (1996), Swinton (1996), 
Anderson (1998) and Austin et al. (1998). Gametocyte production was included in 
Heliriegel's (1992) model. Heliriegel's (1992) model corresponds to a fixed 
proportion of asexuals becoming gametocytes. I therefore incorporated gametocyte 
investment in the other models by designating a fixed proportion of asexuals as 
gametocytes. 
The asexual and merozoite dynamics of Heliriegel's (1992) model can be represented 
by: 
dA[t] = 
OM[t] - rA[t] - rgA[t] 	 2.19a) 
dt 
dM[t] 
= rmA[t] - vM[t] - iM[t] 	 2.20a) 
dt 
where it is the rate at which merozoites infect new red blood cells, M[t] is the 
number of merozoites at time t and v is the rate at which merozoites die. 
Hellriegel's (1992) model does not constrain asexuals to either produce merozoites 
or become gametocytes. The net loss rate of asexuals should be independent of 
gametocyte investment and the number of merozoites produced should decrease as 
gametocyte investment rises. Hence, for the other models, I represent the asexual 
dynamics by: 
dA[t] - 
iIM[t]—rA[t] 	 2.19b) 
dt - 
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and the merozoite dynamics, except for Anderson's (1998) model, by: 
dM[t]  
dt - rm(1 - g)A[t] - vM[t] - i9M[t] 	 2.20b) 
- 
For Anderson's (1998) model the merozoite dynamics are given by: 
dM[t]  
dt - rm(l - g)A[t] - vM[t] 	 2.20c) 
- 
Anderson's (1998) description of merozoite dynamics is incorrect, because 
merozoites that infect red blood cells are not removed from the merozoite population 






Equations 2.19) and 2.20) for each model can be reduced to a single second order 
equation in A[t]. Hence from equations 2.19a) and 2.20a), for Hellriegel's (1992) 
model: 
d2A[t] 	 dA[t] 
+ (r(1 + g) + v + 0') 	+ r((v + 	+ g) - ml)')A[t] = 0 	 2.22a) 
dt2 dt 
For all the other models except Anderson's (1998) model, from equations 2.19b) and 
2.20b): 
d2A[t] 	 dA[t] 
+ (r + v + 	+ r(v + - mi(1 - g))A[t] =0 	 2.22b) dt 2 dt 
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For Anderson's (1998) model, from equations 2.19b) and 2.20c): 
d2A[t] 	dA[t] 
+ (r + v) 	+ r(v - m6(1 - g))A[t] = 0 	 2.22c) 
dt 2 dt 
All the versions of equation 2.22) have a solution of the form: 
A[t] = K1e t + K2e12t 	 2.23) 
(Bostock et a!, 1982), where K, is a constant and y is a root of the respective 
auxiliary quadratic equation. After some transient dynamics, the model will be 
dominated by the term incorporating the most positive root. Therefore, when the 
dynamics are stable, the number of asexuals is given by: 
A[t] = A[O]e)'-' 
	
2.24) 
where YD  is the most positive root. For Hellriegel's (1992) model, equation 2.24) is: 
MO 	
_I+!(r(1+g)+u 	)2 -(r(1+g)+v +))t 








For all the other models, except Anderson's (1998) model, equation 2.24) is: 






For Anderson's (1998) model, equation 2.24) is: 
4
_i +—(r+u) __  
A[t] = A[O]e 	
2 	
2.25c) 
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Substituting from equation 2.25a), the solution to equation 2.21) for Hellriegel's 
(1992) model is: 
G[t]= 
	







r(1 + g)(v + )( 	
m 
((v+O')(i+g) 




- 	 + g)+ v + 2 
2.26a) 
For all the other models, except Anderson's (1998) model, substituting from equation 
2.25b), the solution to equation 2.21) is: 
t r(v 	 +0) 2 _!(r+v +0) 
rgA{O]e ) 
4 	2 	 - 
rgA[O] 
G[t] 	 2.26b) 





- 1) + —(r ~ v+O 
For Anderson's (1998) model, substituting from equation 2.25c), the solution to 
equation 2.21) is: 
I ru 















Hence, per cycle period in Hellriegel's (1992) model, the number of asexuals 
increases by a factor: 
m8
_l+!(r(1+g)+u 0)2  -(r(1+g)+u +0))T 
- 
X eW ((v+t$)(I+g)  ) 4 2.27a) 
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Per cycle period for all the other models, except Anderson's (1998) model, the 
number of asexuals increases by a factor: 
W(V 	 +)2 _!(r+u 
X=e V +0 	4 	 2 	 2.27b) 
Per cycle period for Anderson's (1998) model, the number of asexuals increases by a 
factor: 
( Irv ( m ( 1__I) ~!( r+o) 2 _!( r+u))T 
X=e 	
u 	4 	2 	) 	 2.27c) 
The number of gametocytes produced per asexual over one cycle period in 
Heliriegel's (1992) model is: 
IM 
(ir(i+g)(v 	m  -1 + I _(r(1+g)+v 	)2 J(r(i+g)+v +)) -T 
rge 
	,4 
r(1 + g)(v + )( 	
m 
((v + 01 + g) 
—i+ 
4 ' 
(r(1+ )+ v + 
) 
 
- i(r(1 + g)+ v + 
2' 
2.28a) 
For all the other models, except Anderson's (1998) model, the number of 
gametocytes produced per asexual over one cycle period is: 
W(V  + 	m(I-g) 1 i ( 	+)2 _!(r+v  +))T 
rge 	(
v+8 _)__4__2 	—rg 
P= 	 2.28b) 
lJr( 	
fm6(1—g) 	1 	)2 1 
—1 +—(r+v ~ 9 	(r 	6) 
	
) 
4 	 2 
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2 
For Anderson's (1998) model, the number of gametocytes produced per asexual over 
one cycle period is: 
rv( (r+v _1)+) 
2 	
- rg 




m(1_)) 1 	2 
	(r '+ v) 1 +—(r+v) 
2 
From differentiating equation 2.28a) with respect to g, the fitness benefit of 
increased gametocyte investment in Heliriegel's (1992) model is: 









r(1+ g)(v+ )( 	
m 	
—i+ i(r(i+ g)+v 
+ 0)2 
(v+0)(1+g) ) 4 
- !(r(1 + g) + v + 2' 
2.29a) 
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The benefit of increased gametocyte investment for all the other models, except 







— fm0(1g) 1 i (0)2 
2.29b) 
I Ir(v 	 i( 	+8) 2 _!(r+U +8)T 
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v+8 )4 2 
- ( 
Ir(v+8) _ 	
I 	)2 1 ( 
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—!( r+v  +0) 
v+0 	) 4 	 2 
For Anderson's (1998) model, the benefit of increased gametocyte investment, from 
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From differentiating equation 2.27a) with respect to g, the per cycle period fitness 




4r(l+ )(v+ ) 	m6 	_1+1(r(1+g)
+v+)2 2 ((v+)(l+g) 
) 4 
The per cycle period cost of increased gametocyte investment for all the other 
models, except Anderson's (1998) model, from differentiating equation 2.27b) with 





v + i9l 




For Anderson's (1998) model, the per cycle period cost of increased gametocyte 
investment, from differentiating equation 2.27c) with respect to g is: 
rmOT 








2.4.1. 	Hellriegel's (1992) model 
In Hellriegel's (1992) model, r is the inverse of the cycle period, therefore r = 1/2. 
Hellriegel (1992) sets v = 72 and m = 16. An estimate of 6 for P.falciparum is 24 
(Gravenor et al., 1995, their estimate of 13/v multiplied by v and their value for the 
density of red blood cells in an uninfected individual). As before T = 2. The asexual 
multiplication factor is considerably too high in Heliriegel's (1992) model (Figure 
2.5a)). When there is complete investment into gametocytes, the number of asexuals 
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still increases seven-fold per cycle period. The number of gametocytes produced is 
nearly always considerably too high (Figure 2.5b)). 
—Hellriegel's (1992) model 	- correct value 
a) 
0% 25% 50% 75% 100% 
gametocyte investment 
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Figure 2.5. Parasite dynamics in Hellriegel's (1995) model. Gametocyte production is given 
per asexual at the start of the cycle period. The asexual dynamics are represented in a) and 
the gametocyte dynamics in b). Model results were calculated from equations 2.27a) and 
2.28a) with r = 1/2, v = 72, 6 = 0.0028 x 72 x 120 and m = 16. The correct values were 
calculated from equations 2.1) and 2.2a) with m = 16. 
The fitness cost of increased gametocyte investment in Hellriegel's (1992) model is 
substantially too low for investments over about 20% (Figure 2.6). The fitness 
benefit of increased investment is considerably too low for gametocyte investments 
higher than around 30% (Figure 2.6). However the combined effect of too low a 
fitness cost with too low a fitness benefit, results in the optimum gametocyte 
investment under Heliriegel's (1992) model being very close to the correct value. 
The optimum gametocyte investment in Heliriegel's (1992) model is 28%. 
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Figure 2.6. Fitness cost and benefit of increased gametocyte investment in Heliriegel's 
(1992) model. Fitness is defined as the number of gametocytes produced in the fourth cycle 
period. Arrows indicate optimum gametocyte investment. Model results were calculated from 
equation 2.29a), and equation 2.30a) multiplied by 3, with r = 1/2, v = 72, 
= 0.0028 x 72 x 120 and m = 16. The correct values were calculated from equation 2.9), 
and equation 2.10) multiplied by 3. 
2.4.2. 	The models of Anderson etal. (1989), Gravenor etal. (1995), 
Hetzel and Anderson (1996), Swinton (1996) and Austin etal. 
(1998) 
Hetzel and Anderson's (1996) model was expressed with values for P. berghei 
infections in mice. However, here I explore the model behaviour with parameter 
values appropriate for P. falciparum. I describe the results with reference to 
Anderson et al.'s (1989) model but they apply equally to all the models listed above. 
I use the same parameter values as for Hellriegel's (1992) model, given previously. 
Asexual multiplication is considerably too low for Anderson et al.'s (1989) model 
when gametocyte investment is between 15% and 95% (Figure 2.7a)). However the 
multiplication factor is too high when gametocyte investment is very small and when 
investment is 100%. The asexual multiplication factor is less than in Heliriegel's 
(1992) model, except when there is no gametocyte production. Gametocyte 
production is substantially too high for Anderson et al.'s (1989) model for between 
0% and 65% gametocyte investment (Figure 2.7b)). When gametocyte investment is 
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over about 40%, gametocyte production drops with increasing investment. 
Gametocyte production is considerably too low when gametocyte investment is over 
90%. Gametocyte production is less for Anderson et al.'s (1989) model than for 
Heliriegel's (1992) model (except when gametocyte investment is zero). 
—Anderson etal.'s (1989) model 
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Figure 2.7. Parasite dynamics for Anderson et aI.'s (1989) model. Gametocyte production is 
given per asexual at the start of the cycle period. The asexual dynamics are represented in 
a), and the gametocyte dynamics in b). Model results were calculated from equations 2.27b) 
and 2.28b) with r = 1/2, v = 72, 0 = 0.0028 x 72 x 120 and m = 16. The correct values 
were calculated from equations 2.1) and 2.2a) with m = 16. 
In contrast to Heliriegel's (1992) model, the fitness cost of increased gametocyte 
investment is mostly too high for Anderson et al.'s (1989) model. The cost is 
substantially too high for investments up to 70% (Figure 2.8). The fitness benefit of 
increased gametocyte investment is considerably too low for Anderson et al.'s 
(1989) model for investments above 10% (Figure 2.8) and there is a negative benefit 
when investment exceeds around 40%. The fitness benefit is less for Anderson et 
al.'s (1989) model than in Hellriegel's (1992) model. As a result of too high a fitness 
cost and too low a fitness benefit, the optimum gametocyte investment for Anderson 
et al.'s (1989) model is too low. The optimum investment is therefore much lower 
than it is under Heliriegel's (1992) model. The optimum investment is 7%. 
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Figure 2.8. Fitness cost and benefit of increased gametocyte investment for Anderson et aI.'s 
(1989) model. Fitness is defined as the number of gametocytes produced in the fourth cycle 
period. Arrows indicate optimum gametocyte investment. Model results were calculated from 
equation 2.29b), and equation 2.30b) multiplied by 3, with r = 1/2, v = 72, 
= 0.0028 x 72 x 120 and m = 16. The correct values were calculated from equation 2.9), 
and equation 2.10) multiplied by 3. 
2.4.3. 	Anderson's (1998) model 
I use the same parameter values as for Heliriegel's (1992) model, given previously. 
The asexual multiplication factor is substantially too high for Anderson's (1998) 
model when gametocyte investment is less than 30% (Figure 2.9a)). Over this range 
of gametocyte investment, asexual multiplication is higher than in Hellriegel's 
(1992) model. Asexual multiplication is considerably too low for Anderson's (1998) 
model when gametocyte investment is between 45% and 95%, but not as low as for 
Anderson et al. 's (1989) model. Asexual multiplication is not zero when there is 
complete gametocyte investment. Gametocyte production is considerably too high 
for Anderson's (1998) model when gametocyte investment is between 0% and 70% 
(Figure 2.9b)). Gametocyte production is higher for Anderson's (1998) model than 
for Anderson et al. 's (1989) model, except when investment is zero or 100%. It is 
also higher than in Heliriegel's (1992) model when investment is between 0% and 
30%. When gametocyte investment is -greater than 30%, the number of gametocytes 
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produced drops as investment increases. As in Anderson et al.'s (1989) model, 
gametocyte production is substantially too low in Anderson's (1998) model when 
gametocyte investment is above 90%. 
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Figure 2.9. Parasite dynamics in Anderson's (1998) model. Gametocyte production is given 
per asexual at the start of the cycle period. The asexual dynamics are represented in a) and 
the gametocyte dynamics in b). Model results were calculated from equations 2.27c) and. 
2.28c) with r = 1/2, v = 72, i' =0.0028 x 72 x120 and m = 16. The correct values were 
calculated from equations 2.1) and 2.2a) with m = 16. 
The fitness cost of increased gametocyte investment is substantially too high for 
Anderson's (1998) model when investment is less than 75% (Figure 2.10). The cost 
is higher than for Anderson et al.'s (1989) model. The fitness benefit of increased 
gametocyte investment is considerably too low in Anderson's (1998) model when 
gametocyte investment is greater than 10%. There is also a negative benefit when 
investment is more than 30%. The fitness benefit is less for Anderson's (1998) model 
than for Anderson et al.'s (1989) model. As the fitness cost is higher for Anderson's 
(1998) model than for Anderson et al.'s (1989) model and the fitness benefit lower, 
the optimum investment is lower than for Anderson et al.'s (1989) model. The 
optimum investment is 5%. 
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Figure 2.10. Fitness cost and benefit of increased gametocyte investment in Anderson's 
(1998) model. Fitness is defined as the number of gametocytes produced in the fourth cycle 
period. Arrows indicate optimum gametocyte investment. Model results were calculated from 
equation 2.29c), and equation 2.30c) multiplied by 3, with r = 1/2, v = 72, 
= 0.0028 x 72 x 120 and m = 16. The correct values were calculated from equation 2.9), 
and equation 2.10) multiplied by 3. 
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2.5. Type 3 models 
These models split asexuals between several compartments. There are, a series of 
equations describing the movement of parasites through each compartment. Parasites 
replicate when they are in the last compartment. There is no equation for merozoite 
dynamics. Models in this group are those by Gravenor et al. (1998, 2002) and 
Gravenor and Kwiatkowski (1998). Gametocyte production was not included in any 
of the models. I incorporated gametocyte production by designating a fixed 
proportion of asexuals in the last compartment to become gametocytes. 
The parasite dynamics can be represented by: 
dA 1 [t]  
dt = 
am(1 - g)A[t] - a 1 A 1 [t] 2.31) 
dA[t]  
dt = a
1 A 1 [t] - aA[t] 	2:5 i .!-. n 	 2.32) 
dG[t]  
dt — -
agA[t] 	 2.33) 
where A i [t] is the number of asexuals in compartment i, a is the rate at which 
asexuals move from compartment i to compartment i + 1 (when i = n, the rate at 
which asexuals replicate or become gametocytes) and n is the number of 
compartments. Equation 2.31) and the series of equations represented by equation 
2.32) can be expressed as the matrix equation: 
à=Sa 	 2.34) 
I , where a 	 dA 1 dA 1 	dA 	a is the n- is the n-dimensional column vector 	i 	,- 
	
dt dt  
dimensional column vector {A 1 ,A 2 ,. ' ., A,, I and S is the n x n-dimensional square 
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matrix given by: 
-a 1 0 0 0 am(1-g) 
a 1 -a 2 0 0 0 
0 a2 0 0 
2.35) 
0 0 0 ... 	—a 1 0 
0 0 0 a 1 -a 
Provided S has n distinct eigenvalues the solution of equation 2.34) is: 
a = Kte1tvj + K2e'v2 +...+  Kev 	 2.36) 
(Williamson, 1997) where Ak  is an eigenvalue of S and Vk  is the corresponding 
eigenvector. After a period of transient dynamics, the system will be dominated by 
the term incorporating the eigenvalue with the most positive real part (Bulmer 1994). 
Hence, when the dynamics are stable, the numbers of asexuals in each compartment 
is given by: 
a = A[0]e"vD 
	 2.37) 
where AD  is the dominant eigenvalue and VD  is scaled so that the sum of the entries 
equals one. Hence: 
A[t]=A[0]e° 	 2.38) 
by summing across all the compartments, and: 
A[ t] = A[0]eAot v Dfl 	 2.39) 
where VDfl  is the n h entry in vector VD.  Substituting from equation 2.39), the 
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solution to equation 2.33) is: 
G[t] = 
aflgA[0]vDfl 
(et - i) 
AD 
The eigenvalues of S are found by solving: 
-a1 - Ak  0 0 0 am(1 - g) 
a1 -a2 -A k  0 0 0 
o a2 -a3-Ak 	•.. 0 0 
=0 
0 0 0 	... -a 1 -A, 0 
0 0 0 a 1 -afl  - -A k  
(Williamson, 1997). Using II= 	(-1)1siISj1I, where sli is the entry in the first row 
and ith  column of S and IS,, I is the determinant of the matrix formed by deleting the 
first row and i column of S (Williamson, 1997), the determinant in equation 2.41) 
can be expanded by the first row as: 
a2 A k 	0 	... 	0 
a2 -a3-Ak ... 0 
-(aI+Ak) 
0 	0 	afll Ak 
0 0 •.. 	a 1 
a1 -a2 -)'k  
0 	a2 
1+n 








-a - A k  
0 	... 	0 
0 	•.. 	afll A k  
0 a 1 
2.42) 
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The determinant can be further simplified by adding the 1st  row of the first matrix 
multiplied by 
a2 
 to the 2 d  row, then the new 2nd  row multiplied by 
a3 	
to 
the Prow and so on, and for the second matrix, adding the last row multiplied by 
+ Ak 
to the second to last row, then the new second to last row multiplied by 
afl .2 Ak to the next row up and so on, giving: 
a2 -A k 	0 	... 	0 	0 
o -a3 -A k 0 0 
-(al+Ak) 
o 	0 	afl lAk 	0 
o 0 ••• 	0 	afl Ak  
2.43) 
a1 	0 0 ••• 	0 
	
0a2 0••• 0 
n+1 
+(-i) am(1-g) 	. 	: =0 
000... 0 
0 	0 0 ... a 1 
Repeated expansion of the matrices in equation 2.43) by their first row gives: 
n 	 n 
(-i)'fl(a + Ak ) + (-.1)
n+1 
 m(1 - g)fJa = 0 	 2.44) 
X-1 	 x1 
as the determinant of a 1 by 1 matrix is the value of its single entry (Williamson, 
1997). Therefore, the eigenvalues of S are the solutions of: 
fl(a + Ak ) = m(1 - g){Ja 	 2.45) 
In Gravenor et al. 'S (1998, 2002) models, the rate of movement between 
compartments is the same for each compartment. 
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Hence for Gravenor et al. 's (1998, 2002) models the eigenvalues are given by: 
J2 
( a+A 	
1 	 2.45a) 
a(Jm(1 
- g))) 
Equation 2.45a) has n distinction solutions of the form: 




I-a+ta _g))SznIl 	 2.46)  9)) ~ n, n) 




Therefore in Gravenor et al. 's (1998, 2002) models, substituting into equation 2.38), 
the asexual dynamics are given by: 
A[t] = 	 2.48) 
The entries in VD  satisfy: 
—a1 
- AD 0 0 .. 	 0 am(1 - g) VDI 0 
a1 —a 2 —A D 0 0 0 VD2 0 
a2 —a 3 —A D 0 0 VD3 
=? 2.49) 
0 0 0 ... 	 -a1 - AD 0 VDfl I 0 
0 0 0 a —a - A D  I VDfl 0 
(Williamson, 1997). 
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Hence: 
(a1  + AD)VD, = am(1 - g)v fl  
aIvDI = (a2 + AD )vD2 
a2vD2 _.(a3 + 
	
2.50) 
a fl lvDfl l = (a + )D)vD fl  
Therefore: 
n-I r-ra 1  + AD 
VDj=VDflII 	 l<n 	 2.51) 
Scaling the entries so that their sum equals one gives: 
1 
VDfl = 	n-i n-I 
1+ (j—ja




For Gravenor et al. ' s (1998, 2002) models, where the rate of movement between 
compartments is the same for each compartment, equation 2.52) becomes: 




as equation 2.52) represents the inverse of the sum of a geometric progression. 
Substituting from equation 2.47), for Gravenor et al. ' s (1998, 2002) models: 
VDfl = iJm -(1- g) —1 
m(1—g)-1 
2.53) 
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Therefore, for Gravenor et al. 's (1998, 2002) models, substituting into equation 




—1) 	 2.54) 
From equation 2.48), per cycle period for Gravenor et al. 's (1998, 2002) models, the 
number of asexuals increases by a factor: 
X = 	 2.55a) 
Per cycle period for Gravenor and Kwiatkowski's (1998) model, the number of 
asexuals increases by a factor: 
X = e AT 
	
2.55b) 
where AD  is the solution of equation 2.45) with the most positive real part (provided 
there are n distinct solutions). The number of gametocytes produced per asexual 
over one cycle period for Gravenor et al. 's (1998, 2002) models is: 
(e P 	
g 	a(m(1_g)_I)T 
—1) 	 2.56a) :=  
m(1 - g) —1 
The number of gametocytes produced per asexual over one cycle period for 
Gravenor and Kwiatkowski's (1998) model is: 
= aflgvfl (eT 	 2.56b) 
A D 
where vDfl  is the solution of equation 2.52) and AD  is the solution of equation 2.45) 
with the most positive real part (provided there are n distinct solutions). 
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By differentiating equation 2.56a) with respect to g, the fitness benefit of increased 
gametocyte investment for Gravenor etal. 's (1998, 2002) models is: 
B = 
	m 1 	- 	amT 	
( a(qjm(1-g)-1)r \ 
	
g(H(1 - g) - i) n(m(l - g))fll a(m(1-g)-1)T - i) 	
2.57a) 
The benefit of increased gametocyte investment for Gravenor and Kwiatkowski's 
(1998) model is: 
B=-1-+--'1"" _iP + 4P(_eT  
g VD fl dg 	AD  dg 	dg e ADT  -1 
2.57b) 
where VDfl  is the solution of equation 2.52) and AD  is the solution of equation 2.45) 
with the most positive real part (provided there are n distinct solutions). From 
differentiating equation 2.55a) with respect to g, the fitness cost of increased 





The cost of increased gametocyte investment for Gravenor and Kwiatkowski 's 
(1998) model is: 
C=-T dAD 	 2.58b) 
dg 
where AD  is the solution of equation 2.45) with the most positive real part (provided 
there are n distinct solutions). 
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2.5.1. 	Gravenor et al.'s (1998) model 
In Gravenor et al.'s (1998) model, n = 2 and a = 1. Gravenor et al. (1998) specified 
m = 10 in their model. However as the average number of merozoites per schizont is 
generally considered to be 16 for P. falciparum, and for comparison with the other 
models, I use m = 16 here. As before T = 2. The asexual multiplication factor is 
greatly inflated for Gravenor et al.'s (1998) model when gametocyte investment is 
low (Figure 2.11 a)) - Substantially too many asexuals are generated for gametocyte 
investments up to 80%. Gametocyte production is considerably too high for 
Gravenor etal. 's (1998) model when gametocyte investment is between 0% and 85% 
(Figure 2.1 ib)). When gametocyte investment is over 30% gametocyte production 
drops with increasing investment until investment is nearly 100%. 
—Gravenor et al.'s (1998) model 	—correct value 
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Figure 2.11. Parasite dynamics for Gravenor et al.'s (1998) model. Gametocyte production is 
given per asexual at the start of the cycle period. The asexual dynamics are represented in 
a) and the gametocyte dynamics in b). Model results were calculated from equations 2.55a) 
and 2.56a) with n = 2, a = 1, m = 16 and T = 2. The correct values were calculated from 
equations 2.1) and 2.2a) with m = 16. 
The fitness cost of increased gametocyte investment is substantially too high for 
Gravenor et al.'s (1998) model for investments up to 90% (Figure 2.12). The fitness 
benefit of increased gametocyte investment for Gravenor et al. 's (1998) model is 
considerably too low when investment is between 10% and 95% (Figure 2.12). There 
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is a negative benefit of increased investment when investment is over 30% but not 
quite 100%. As a result of too high a fitness cost and too low a fitness benefit, the 
optimum gametocyte investment is too low for Gravenor et al.'s (1998) model. The 
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Figure 2.12. Fitness cost and benefit of increased gametocyte investment for Gravenor et 
aI.'s (1998) model. Fitness is defined as the number of gametocytes produced in the fourth 
cycle period. Arrows indicate optimum gametocyte investment. Model results were calculated 
from equation 2.57a) and equation 2.58a) multiplied by 3, with n = 2, a = 1, m = 16 and 
T = 2. The correct values were calculated from equation 2.9), and equation 2.10) multiplied 
by 3. 
2.5.2. 	Gravenor and Kwiatkowski's (1998) model 
In Gravenor and Kwiatkowski 's (1998) model, n = 5, a1 = 1.96, a 2 = 3.78, 
a3 = 2.86, a4 = 1.76 and a 5 = 3.26. Gravenor and Kwiatkowski (1998) chose 
m =10 for their model but I use m =16 here. As before T =2. I used 
MATHEMATICA® (v. 4.1.2.0, Wolfram Research) to find the eigenvalues of S. 
There were five distinct eigenvalues. The asexual multiplication factor is 
considerably too high for Gravenor and Kwiatkowski's (1998) model for gametocyte 
investments less than 65% (Figure 2.13a)). However the multiplication factor is not 
as high as for Gravenor etal. 's (1998) model. Substantially too many gametocytes 
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are produced for Gravenor and Kwiatkowski's (1998) model when gametocyte 
investment is between 0% and 80% (Figure 2.13b)). But gametocyte production is 
less over this range than for Gravenor et al.'s (1998) model. As with Gravenor et 
al.'s (1998) model, there is a range of gametocyte investment for which gametocyte 
production drops as investment increases. For Gravenor and Kwiatkowski's (1998) 
model this occurs for gametocyte investments over 75% and up to nearly 100%. 
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Figure 2.13. Parasite dynamics for Gravenor and Kwiatkowski's (1998) model. Gametocyte 
production is given per asexual at the start of the cycle period. The asexual dynamics are 
represented in a) and the gametocyte dynamics in b). Model results were calculated from 
equations 2.55b) and 2.56b) using MATHEMATICA® (v. 4.1.2.0, Wolfram Research) to find 
the eigenvalues of S. Parameter values are n = 5, a1 = 1.96, a2 = 3.78, a3 = 2.86, 
a4 = 1.76, a 5 = 3.26, m = 16 and T = 2. The correct values were calculated from 
equations 2.1) and 2.2a) with m = 16. 
The cost of increased gametocyte investment is substantially too high for Gravenor 
and Kwiatkowski's (1998) model for investments less than 70% (Figure 2.14). But 
the cost is not as high over this range as for Gravenor et al.'s (1998) model. The 
benefit of increased gametocyte investment is considerably too low under Gravenor 
and Kwiatkowski's (1998) model for gametocyte investment between 30% and 95% 
(Figure 2.14). Again, however the discrepancy is not as big as for Gravenor et al.'s 
(1998) model. There is a negative benefit of increased investment when investment is 
over 75% but not quite 100%. The optimum gametocyte investment is too low for 








Gravenor and Kwiatkowski's (1998) model, although not as low as for Gravenor et 
al. 's (1998) model. The optimum gametocyte investment is 14%. 
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Figure 2.14. Fitness cost and benefit of increased gametocyte investment for Gravenor and 
Kwiatkowski's (1998) model. Fitness is defined as the number of gametocytes produced in 
the fourth cycle period. Arrows indicate optimum gametocyte investment. Model results were 
calculated using MATHEMATICA® (v. 4.1.2.0, Wolfram Research), equation 2.57b) and 
equation 2.58b) multiplied by 3. Parameter values are n = 5, a1 = 1.96, a2 = 3.78 
a3 = 2.86, a4 =1.76, a5 = 3.26, m = 16 and T= 2. The correct values were calculated 
from equation 2.9), and equation 2.10) multiplied by 3. 
2.5.3. 	Gravenor et A's (2002) model 
In Gravenor et al. 's (2002) model, n =48 and a =24. Gravenor et al. (2002) 
examined their model for values of m from 10 to 12, but as previously, I use m =16 
here. As before, T = 2. The asexual multiplication factor for Gravenor et al. 's (2002) 
model is close to the correct value (Figure 2.15a)). Gravenor et al. 's (2002) model 
reproduces asexual multiplication much better than any of the other models 
investigated, although asexual multiplication is slightly too high when gametocyte 
investment is small. The number of gametocytes produced for Gravenor et al. 's 
(2002) model is very close to the correct value (Figure 2.1 5b)). Gravenor et al. 's 
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(2002) model also provides a better description of gametocyte production than any of 
the other models examined. 






Figure 2.15. Parasite dynamics for Gravenor et al.'s (2002) model. Gametocyte production is 
given per asexual at the start of the cycle period. The asexual dynamics are represented in 
a) and the gametocyte dynamics in b). Model results were calculated from equations 2.55a) 
and 2.56a) with n = 48, a = 24, m = 16 and T = 2. The correct values were calculated 
from equations 2.1) and 2.2a) with m = 16. 
The cost of increased gametocyte investment for Gravenor et al. 's (2002) model is 
close to the correct cost (Figure 2.16). The cost is slightly higher than the correct 
value except when gametocyte investment is very high. Gravenor et al. 's (2002) 
model reproduces the fitness cost of increased gametocyte investment considerably 
better than any of the other models investigated. The benefit of increased gametocyte 
investment is very similar to the correct benefit except when investment is very high 
(Figure 2.16). Except when gametocyte investment is very high, the benefit of 
increased investment is slightly less than the correct value for Gravenor et al. 's 
(2002) model. Gravenor et al. 's (2002) model describes the fitness benefit of 
increased gametocyte investment much better than any of the other models 
considered. As the costs and benefits of gametocyte investment are accurately 
represented by Gravenor et al. 's (2002) model, the optimum gametocyte investment 
is very close to the correct value. The optimum gametocyte investment for Gravenor 
et al. 's (2002) model is 24%. 
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Figure 2.16. Fitness cost and benefit of increased gametocyte investment for Gravenor et 
aL's (2002) model. Fitness is defined as the number of gametocytes produced in the fourth 
cycle period. Arrows indicate optimum gametocyte investment. Model results were calculated 
from equation 2.57a), and equation 2.58a) multiplied by 3, with n =48, a = 24, m = 16 and 
T = 2. The correct values were calculated from equation 2.9), and equation 2.10) multiplied 
by3. 
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2.6. Discussion 
I explored the dynamics of continuous malaria models and what consequences these 
might have for determining optimum gametocyte investment. In all but one case, the 
basic forms of the models (excluding immunity or red blood cell limitation) failed to 
reproduce the number of asexuals and gametocytes produced each cycle period when 
gametocyte investment was incorporated. The increase in number of asexuals per 
cycle period was substantially too low in about half of the models and considerably 
too high in the others. Only Gravenor et al.'s (2002) model accurately described the 
parasite dynamics. The number of gametocytes produced per asexual each cycle 
period was substantially too high in the other models except for McKenzie and 
Bossert's (1997) model (and similar models). Gametocyte production was 
considerably too low in McKenzie and Bossert's (1997) model (and similar models). 
Using a simple approximation of fitness, the basic forms of the models failed to 
predict the optimum gametocyte investment, except in two cases. The optimum was 
substantially too low. This was because the cost of increased gametocyte investment 
was much too high and the benefit was considerably too low. Optimum gametocyte 
investment was close to the correct value for Hellriegel's (1992) model and Gravenor 
et al.'s (2002) model. However in Heliriegel's (1992) model this was only a result of 
too low a fitness benefit being offset by too low a fitness cost. Therefore it is likely 
that Hellriegel's (1992) model would not correctly predict the optimum gametocyte 
investment were another criterion for fitness used. In contrast, Gravenor et al.'s 
(2002) model correctly represented the cost and benefits of increased gametocyte 
investment. 
A fourth type of continuous model has been proposed by Gravenor and Lloyd 
(1998), but without presenting any analysis. Gravenor and Lloyd's (1998) model 
combines a type 3 (compartmentalised) model with an equation for merozoite 
dynamics. The difference between Gravenor and Lloyd's (1998) model and type 3 
models is analogous to the difference between type 1 and type 2 models. Comparison 
of McKenzie and Bossert's (1997) model to Anderson et al.'s (1989) model therefore 
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suggests that asexual multiplication will be similar for Gravenor and Lloyd's (1998) 
model to an equivalent (same number of compartments) type 3 model, but that 
gametocyte production will be considerably higher for Gravenor and Lloyd's (1998) 
model. By the same reasoning, the benefit of increased gametocyte investment may 
be similar for Gravenor and Lloyd's (1998) model to an equivalent type 3 model, and 
the cost is likely to be substantially higher. I anticipate that the optimum gametocyte 
investment would be slightly lower for Gravenor and Lloyd's (1998) model than for 
an equivalent type 3 model. 
Hoshen et al. (2002) constructed a continuous malaria model that incorporated a 
fixed time period between a parasite invading a red blood cell and releasing 
merozoites. They demonstrate that this model generates an abrupt increase in parasite 
numbers at intervals of one cycle period. Hoshen et al.'s (2002) model will not, 
therefore, suffer from the same errors as the continuous models that I have discussed 
here. 
My results show that, in general, continuous within-host malaria models have 
substantial failings when gametocyte production is included. I examined the models 
under very simple conditions, but the errors in the models may be magnified when 
complexities, such as a developing immune response, are added. A good 
approximation of malaria infections can be realised by a continuous model split into 
many compartments, as in Gravenor et al.'s (2002) model. Hoshen et al.'s (2002) 
model shows that malaria infections can also be realistically modelled in continuous 
time when a fixed time lag is included. But both Gravenor et al.'s (2002) model and 
Hoshen et al.'s (2002) model increase realism at the expense of a considerable 
increase in computational difficulty. Modelling infections discretely is a much 
simpler way to emulate the inherently discrete biology of the parasite. It is also a 
sensible approach for testing models with data, as typically parasites are only 
sampled from infections once a day. 
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3. Low gametocyte investment in malaria is predicted from 
the trade-off between gametocyte production and within-
host parasite growth 
3.1. Introduction 
Blood stage malaria parasites can develop as either asexuals or gametocytes. Only 
asexuals replicate. Therefore gametocyte production reduces the within-host growth 
rate of the parasite population. Gametocyte investment consequently decreases the 
number of parasites that can develop into gametocytes later in infections. I used an 
optimality approach (Parker and Maynard Smith, 1990) to investigate whether this 
effect could explain low gametocyte investment in malaria. To determine the fitness 
outcomes of different amounts of gametocyte investment, I modelled the within-host 
dynamics of malaria. I then found the level of gametocyte investment that maximised 
transmission to new hosts. 
Two previous optimality analyses of transmission investment have been published 
(Koella and Antia, 1995; McKenzie and Bossert, 1998b). Both were based on 
continuous within-host models. As I demonstrated in chapter 1, gametocyte 
production mostly reduces the within-host parasite growth rate too much in these 
models. As a result, these models can represent the cost of gametocyte investment as 
higher than it actually is and the benefit as lower. I also showed that these 
discrepancies could considerably lower the optimum gametocyte investment. I 
modelled the parasite dynamics discretely. Molineaux and Dietz (1999) 
recommended discrete modelling of malaria infections and this is reflected in recent 
models (Hoshen et al., 2000b; Molineaux etal., 2001; Haydon etal., 2003). 
Koella and Antia's (1995) and McKenzie and Bossert's (1998b) within-host models 
incorporate immune responses against asexuals. Immune-mediated killing of 
asexuals reduces the cost of gametocyte investment by curtailing the potential for 
within-host parasite growth. Both Koella and Antia (1995) and McKenzie and 
Bossert (1998b) modelled the size of the immune response as increasing with asexual 
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density (although in Koella and Antia's (1995) model, this only applied at low 
parasite densities and at higher densities the immune response was independent of 
asexual density). When the immune response increases with asexual density, 
gametocyte investment has an additional benefit of reducing the immune response. 
The appropriateness of Koella and Antia's (1995) and McKenzie and Bossert's 
(1998b) representations of immunity is not known. Almost no theoretical studies 
have compared functions used to describe immunity with the dynamics observed 
during malaria infections (a notable exception is Haydon et al., 2003; see also 
McKenzie and Bossert, 1997). Therefore, it is difficult to judge how relevant Koella 
and Antia's (1995) and McKenzie and Bossert's (1998b) results are without knowing 
how much they depend on the immune functions chosen. Here, I investigate the 
trade-off between gametocyte production and within-host parasite growth under the 
assumption that the size of the immune response does not depend on the parasite 
growth rate. One established characteristic of immune responses that is missing from 
Koella and Antia's (1995) and McKenzie and Bossert's (1998b) functions is the 
delay between the initiation of an adaptive immune response and the release of 
effectors (T cells and antibodies) able to clear parasites (Janeway et al., 2001). 
Therefore I assumed that parasite clearance occurs a fixed time after the start of 
infection. Koella and Antia (1995) and McKenzie and Bossert (1998b) did not find 
general analytic results for their models. Under my within-host model, I derive 
analytic results for how the optimum gametocyte investment changes with the time 
to parasite clearance and with parasite fecundity. 
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3.2. Methods 
	
3.2.1. 	Key to symbols 
A key to the symbols used in this chapter is given in Table 3.1. 
A[t] 	number of asexuals at time t 
M 	number of merozoites produced per asexual 
g gametocyte investment (proportion of merozoites that are gametocytes) 
I 	time to maximum asexual density (time to parasite clearance) 
G[t] number of gametocytes produced at time t 
CO 	parasite fitness 
W , Y, Z components of the differential of fitness with respect to g 
B 	fitness benefit of increased gametocyte investment 
C fitness cost of increased gametocyte investment 
g 	optimum gametocyte investment 
optimum gametocyte investment for 1 and ifi 
1, ñi 	particular values for the parameters 1 and m 
Table 3.1. Key to symbols 
3.2.2. 	Within-host model 
Time is measured discretely. It seems likely that successful malaria transmission 
depends on producing gametocytes throughout infections; therefore I assume that 
investment into gametocytes is constant. Each time step, asexuals replicate to 
produce m merozoites. A proportion g of merozoites develop as gametocytes. I 
assume that infections last for I replication cycles, with asexuals increasing 
exponentially to a maximum at time 1, followed by rapid drop in asexual numbers to 
zero at time 1+ 1. Host immunity is implicit in the termination of infection, with 1 
also being the time to parasite clearance. The effect of immunity is represented by a 
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step function, with no parasites being killed up to time 1 and all asexuals killed 
thereafter. The behaviour of the model is described by the following equations: 
A[t] = m(1—g)A[t-1] 	t:51 	 3.1) 
G[t]=mgA[t—l] 	 tl 	 3.2) 
where A[t] is the number of asexuals at time t and G[t] is the number of 
gametocytes produced at time t. 
3.2.3. 	Fitness 
Fitness for microparasites (parasites that replicate extensively within their host 
(Anderson and May, 1979)) is usually taken to be the number of secondary infections 
generated by an infected host in a susceptible population (Anderson and May, 1982 
(fitness was not explicitly defined in this way but selection was assumed to maximise 
the number of secondary infections); May and Anderson, 1990; Antia et al., 1994; 
Koella and Antia, 1995; Frank, 1996; Moore, 2002). Transmission of malaria 
parasites to the blood of new hosts involves a series of processes: infection of 
mosquitoes, development of parasites to the infectious stage, inoculation of 
infectious stages into new hosts and invasion of liver cells. An approximation of 
fitness for malaria parasites should therefore take into account the probability of each 
event in transmission and the numbers of parasites at each stage. 
The percentage of mosquitoes that develop oocysts after feeding on P. falciparum-
infected blood increases with gametocyte density (Boudin et al., 1993; Tchuinkam et 
al., 1993; Mulder et al., 1994; Robert et al., 1996). The relationship between 
infectivity and gametocyte density was linear in two of these studies (Tchuinkam et 
al., 1993; Mulder et al., 1994). For P. chabaudi, the proportion of mosquitoes that 
developed oocysts increased linearly with gametocytaemia (Buckling and Read, 
2001). The number of oocysts per mosquito has been found to increase with the 
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density of P. falciparum gametocytes (Tchuinkam et al., 1993; Robert et al., 1996) 
but not always (Boudin et al., 1993). The number of oocysts was also independent of 
gametocytaemia when mosquitoes were fed on cultures of P. falciparum (Ponnudurai 
et al., 1989). However oocyst number did increase with gametocyte density or 
gametocytaemia for infections of P. vivax (Sattabongkot et al., 1991), P. chabaudi 
(Taylor et al., 1997) and P. gallinaceum (Eyles, 1951). Furthermore, other studies 
have demonstrated positive associations between the number of oocysts per mosquito 
and the proportion of mosquitoes infected for P. falciparum (Gamage-Mendis et al., 
1993; Billingsley et al., 1994; Vaughan et al., 1994). Taken together, these results do 
suggest that oocyst number increases with gametocyte density for P. falciparum. But 
it is not clear what shape this relationship takes. Robert et al. (1996) and Tchuinkam 
et al. (1993) both tested linear relationships between oocyst number and gametocyte 
density for P. falciparum but Robert et al. 's, (1996) used transformed data and 
neither study discussed alternative relationships or illustrated the data. The 
association between oocyst number and the proportion of mosquitoes infected has 
been characterised as saturating at high oócyst numbers for several Plasmodium 
species (Eyles, 1951; Medley et al., 1993; Billingsley etal., 1994; Taylor et al., 
1997) indicating that oocyst number may increase exponentially with gametocyte 
density. 
The proportion of mosquitoes that develop sporozoites has been positively linearly 
associated with the proportion that develops oocysts for P. vivax (Gamage-Mendis et 
al., 1993). A similar pattern appeared to exist for mosquitoes infected with P. 
falciparum, but this was not tested (Gamage-Mendis et al., 1993). The proportion of 
mosquitoes that developed P. falciparum sporozoites did not differ from the 
proportion that developed oocysts in another study (Vaughan et al., 1992). The 
number of P. falciparum sporozoites per mosquito has been positively linearly 
associated with the number of oocysts per mosquito (Vaughan et al., 1992). A linear 
relationship between numbers of sporozoites and oocysts has also been found for 
mosquitoes infected with P. vivax (Sattabongkot et al., 1991; Gamage-Mendis et al., 
1993). 
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Some studies suggest that the probability of mosquitoes transmitting P. falciparum 
increases with their number of sporozoites. Naturally infected mosquitoes that 
ejected parasites in their saliva were found to have greater numbers of sporozoites 
than those that did not (Beier et al., 1991 a). For Anopheles stephensi infected with P. 
falciparum, a higher proportion of mosquitoes with large numbers of sporozoites 
ejected parasites than those with low numbers of sporozoites (Beier et al., 199 lb). 
However the level of P. falciparum sporozoite infection did not affect the proportion 
of A. gambiae that ejected sporozoites (Beier etal., 1991b). Furthermore, the results 
of Beier et al. (1991 a, b) may not demonstrate natural relationships because the 
methods were very artificial. Beier etal. (1991a) also found a positive relationship 
between the number of parasites ejected and the number of sporozoites. However 
when mosquitoes were allowed to feed on blood through mouse skin in another 
study, the number of parasites they inoculated into the skin and blood did not relate 
to their number of P. falciparum sporozoites (Ponnudurai et al., 1991). Therefore it is 
unclear whether the number of parasites transmitted by a mosquito or the likelihood 
of transmission from a mosquito depends on the number of sporozoites it has. 
Artificial infections of mice with P. yoelii indicate that the number of parasites 
reaching the liver increases with the number of parasites inoculated (Bruña-Romero 
etal., 2001). 
On the basis of these results, the number of new infections arising from an infected 
host may increase linearly with the number of gametocytes. This is likely to be the 
case if the probability of a mosquito ejecting sporozoites does not depend on the 
number of sporozoites it has. But if mosquitoes are more likely to transmit parasites 
when they have high numbers of sporozoites, the probability of new infections may 
increase non-linearly, possibly exponentially, with gametocyte numbers. The number 
of parasites transmitted to each new host may have an even more complex 
relationship with gametocyte density if the number of sporozoites transmitted by a 
mosquito depends on the number of sporozoites it has. Here, I assume that at any 
time, malaria parasite fitness is linearly proportional to the number of gametocytes 
and hence that the total fitness of malaria parasites is linearly proportional to the 
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integral of gametocyte numbers over time. I also assume that the lifespan of 
gametocytes is fixed and therefore equate fitness with the total number of 
gametocytes produced over an infection. 
3.2.4. 	Finding the optimal gametocyte investment 
Equating fitness with the total number of gametocytes produced over an infection, 
from equations 3.1) and 3.2), parasite fitness is given by: 
2 / 	\ 	/ 	\2 	 \I-I w=mgA{O]+mgIl—g)A[O]+m 3  g1—g) A[O]+...+m ,g 'l—g) A[O] 	3.3) 






The value of g that maximises fitness can be determined by differentiating equation 
3.4) with respect to g. A (local) maximum occurs at a particular value of g when 
this differential is positive for (a range of) lower values of g and negative for (a 
range of) higher values of g. The differential of fitness with respect to g is given by: 




A[O]—m2gl  m(1—g)-1 A[O]+m2g 
(m(1—g)-1)2 A[O] 
	3.5) 
To find the optimum value of g, it is helpful to rearrange equation 3.5) so that the 
differential of fitness equals the sum of two functions that have different signs. The 
positive function can be considered the benefit of increased gametocyte investment 
and the negative function the cost of increased investment. A value of g that 
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maximises fitness can then be identified by the benefit being greater than the cost for 
lower values of g and less than the cost for higher values of g. 
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W is a common factor of both functions on the right hand side of equation 3.6). W 
is positive when g < 1-1/rn and negative when g > 1-1/rn. Y is always positive (g 
has the range 0 .!-. g --s 1). Therefore WY is positive for g <1 - 11rn whilst —WZ is 
negative or zero. In contrast, for g > 1 - 1/m, WY is negative and —WZ is positive. 
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Hence the fitness benefit of increased gametocyte investment is given by: 
B=WY 	 g<1-11m 	 3.11 a) 
B=—WZ 	 g>1-1/m 	 3.1 lb) 
The fitness cost of increased gametocyte investment is given by: 
C=WZ 	 g.<1-11rn 	 3.12a) 
C=—WY 	 g>1-1/rn 	 3.12b) 
A consequence of equations 3.11) and 3.12) is that if Y 2- Z for all g, there will be a 
single maximum in fitness at g = 1-1/rn. It also follows from equations 3.11) and 
3.12) that the value of g which maximises fitness can be found by comparing the 
behaviour of Y and Z. 
Y can be rewritten as the sum of a geometric series: 
m_1( 	1 	I 	 1 
Y= 	11+ + +... 	1_il 
M1 m(1 - g) (m(1 
- g))2 	
(rn(1 - g)) ) 
3.13) 
From equation 3.13) it can be seen that Y is always positive (for m > 1) and increases 
with g at an ever-increasing rate (for I > 1), becoming infinite as g approaches 1. 
When g=1-1/m (for rn>1), Y=Z(Y=(m-1)/m=mg). Therefore (for m>1 and 
1>1), either Y = Z at g = 1— 1/rn and Y> Z for all other values of g, or Y = Z at 
g = 1 - 11rn and one other value of g that is less than 1, with which of Y and Z is 
bigger differing either side of these points (Figure 3.1). In the first case there is a 
single maximum in fitness at g = 1-1/rn. In the second case, because Y switches 
from determining the fitness benefit for g <1-1/rn to determining the fitness cost for 
g > 1 - 1/rn (and vice versa for Z), whichever of the benefit or cost is bigger remains 
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the same either side of g = 1-1/rn (Figure 3.2). Hence in this second case there is no 
turning point in fitness at g = 1 - 1/rn. Instead there is a single maximum in fitness at 
the value of g ;e 1-1/rn for which Y = Z. This value of g is less than 1. 
Y -z 
31 
Figure 3.1. Behaviour of Yand Z. Arrows indicate g = 1-1/rn. In a) Y = Z at g = 1 - 1/rn 
and Y > Z for all other values of g. Note that the gradients of V and Z are the same at 
Y = Z. In b) V = Z at g = 1- 1/rn and a lower value of g (g*)• V > Z for 0 :r. g < g ° , 
Y<Zfor g*<g<1_1/rn  and Y>Zfor g>1-1/rn. Inc) Y=Zat g=1-1/m and  
higher value of g (g)• Y > Z for 0 ~ g <1- 1/rn, V <Z for 1-11rn < g 
< g* and Y> Z 
for g> g$ Y was calculated from equation 3.9) and Z from equation 3.10) with in a) I = 8, 
m=1.3,inb) 1=8, rn=6andinc) 1=8, m=1.1. 
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Figure 3.2. Fitness benefits and costs of increased gametocyte investment. Arrows indicate 
g = 1-1/rn, stars indicate the optimum gametocyte investment 
(g*)• 
 The benefits and costs 
correspond to the values of Y and Z in Figure 3.1. In a) the benefit of increased gametocyte 
investment is greater than the cost for g <g* = 1 - 1/rn and the cost is greater than the 
benefit for 
g*  <g < 1. In b) the benefit of increased gametocyte investment is greater than 
the cost for 
g < g*, 
the cost is greater than the benefit for g <g < 1 - 1/rn and for 
1— 1/rn <g < 1 (shown in insert). In c) the benefit is greater than the cost for g <1-1/rn 
and 1 - 1/rn < g < g* but the cost is greater than the benefit for g* <g < 1. Fitness benefits 
were calculated from equations 3.11 a) and 3.11 b) and fitness costs from equations 3.12a) 
and 3.12b) within a) 1=8, m =1.3,  in b) 1=8, m = 6  and in c) 1=8, m =1.1. 
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The two cases outlined can be distinguished by the differential of Y with respect to g at 
g = 1 - 1/m. As illustrated by Figure 3.1 
Figure 3. 1, when (for 1>1) Y = Z only at g = 1-1/rn, the gradients of Z and Y are 
the same at g = 1 - 1/m. The differential of Z with respect to g, from equation 3.10), 
is 1. From equation 3.9), the differential of Y with respect to g is given by: 
dy = —l(m(1-9))' (rn(1—g)-1)+ 1 —(m(1-9))' rn—i 	
3.14) 
dg 	 (M(1 - g)— 1) 2 	 1 





Therefore the differentials of Z and Y with respect to g are equal at g = I - 1/rn and 





Whether the optimum gametocyte investment is less than 1-1/rn or greater than 
1-1/rn can also be determined by comparing the differentials of Z and Y at 
g = 1-1/rn. As shown in Figure 3. lb), when the optimum investment is less than 
1—i/rn, the gradient of Y is greater than the gradient of Z at g = 1 - 1/m. As shown 
in Figure 3. ic), however, when (for m > 1) the optimum investment is more than 
1-1/rn, the gradient of Y is less than the gradient of Z at g = 1-1/rn. Investments 
less than 1-1/rn correspond to infections where the number of asexuals is able to 
increase within the host, whereas investments greater than 1 - 1/rn cause the number 
of asexuals to decrease within the host. 
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Hence optimum gametocyte investment is less than 1-1/rn when: 
1+1 
rn>— 	 3.17) 
1-1 
Optimum investment (for rn > 1) is greater than 1 - 1/rn when: 
1+1 
rn<— 	 3.18) 
i—i 
Hence (for m >1, 1>1), optimum gametocyte investment can be found as the 
solution to: 
1_(rn(i_g*)) rn—i 	* 	 * 
1 	 g ~ 1—l/m 	 3.19) 
1_(rn(1_9)) ml 
provided m ;e (1 + i)/(i —1). If rn = (1 + 1)/(1 - 1) the optimal investment is I. - 1/m. 
When m >1 and 1>1, optimum investment is less than 1. When rn = 1 or 1=1, 
fitness is highest when g = 1. There is no analytical solution to equation 3.19) but 
solutions can be found numerically. 
3.2.5. 	Determining the direction of change in optimum gametocyte 
investment with time to maximum asexual density and 
number of merozoites per asexual 
When 1=1 or rn =1, the optimum gametocyte investment is 1. When 1>1 and rn> 1, 
the optimum gametocyte investment is less than 1. Therefore, (for rn > 1) the 
optimum investment declines as I increases from 1 = 1 to 1> 1. Similarly, (for 1> 1) 
the optimum gametocyte investment declines as m increases from m = 1 to m > 1. 
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As illustrated by Figure 3. ic), when m <(1 + i)/(i -1) (or equivalently 
1<(m+1)/(m-1)),for m>1 and 1>1, Y=Z at g=1-1/m and a higher value of g 
(g*) which is the optimal investment, only. Hence when g >1-1/rn, for 













Figure 3.3. Behaviour of Y and Z for g > 1— 1/rn when rn < (1 + 1)/(1 —1) 
(l < (m + 1)/(rn —1)) and rn > 1 and 1> 1. Star indicates optimum gametocyte investment 
(g)• 
When g is greater than 
g*, 
 Y > Z. Y was calculated from equation 3.9) and Z from 
equation 3.10) with 1=8 and rn = 1.1. 
As illustrated by Figure 3. lb), when m > (1 + 1)/(1 -1), V = Z at g = 1 - 1/rn and a 
lower value of 
g (g*), 
which is the optimum investment, only. Hence when 
g <1-1/rn, for rn > (1+ i)/(i-i), Y < Z if that value of g is greater than g* (Figure 
3.5). 
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Figure 3.4. Behaviour of Y and Z for g <1 - 1/rn when rn > (1 + 1)/(1 -1). Star indicates 
optimum gametocyte investment (g) When g is greater than gt , Y < Z. Y was calculated 
from equation 3.9) and Z from equation 3.10) with 1 = 8 and rn = 6. 
It follows that the direction of change in optimum investment with 1 (or rn) within 
the ranges m<(l+1)/(1-1) (for m>l and 1>1) and rn>.(l+1)/(l-1) can be 
determined by which of Y and Z is bigger across 1 (or m) when g is the optimum 
investment for a given set of parameters (m > 1 and 1> 1), provided g > 1-1/rn when 
m.<(l+1)/(1-1) and g<1-1/rn when rn>(l+1)/(1-1). Z does not vary with 1 o 
m. By definition for (the optimum investment for I and in) (when th >1 and 
I > 1), Y = Z when I = 1 and rn = th. Therefore the value of Y across 1 (or rn) for 
g = (when in-  > 1 and I > 1), relative to when 1 = I and rn = ifi, is sufficient to 
determine the direction of change in optimum investment. When the value of Y is 
greater than for I = / (or rn = ñi), V > Z. 
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Direction of change in optimum investment with time to maximum asexual 
density 
When i<(th+l)/(n—i) (for ñz>1), >1-1/ni. If for g equal to a 	> 
(1>1 and nz>1), Y is greater for all l>.i than for 1=1, then Y > Z for all 1>1 and 
(as demonstrated by Figure 3.3), 	is higher than the optimum investment for all 
1> 1 (in the range 1 < (Fn + i)/(th —1)). Therefore optimum investment declines as 1 
increases over the range 1 < (m + l)/(m —1) (for 1> 1 and m > 1) if for g equal to any 
> 1— 1/ni (1 > 1 and Fn > 1), Y is greater for all 1> 1 than for I = 1. 
When I = (m + 1)/(rn - 1), 	= 1-11rn. Therefore optimum investment declines as I 
increases from 1 < (rn + 1)/(m - 1) to 1 = (rn + 1)/(rn - 1). 
When ñz > (1 + 1)1(1 —1), 	<1 - 11ni. Therefore optimum investment declines as 1 
increases from I = (m + 1)/(rn —1) to 1< (m + 1)1(rn —1). If for g equal to a 
<1-1/ni, Y is less for all 1> 1 than for 1 = 1, then Y < Z for all 1> 1 and (as 
demonstrated by Figure 3.5), f is higher than the optimum investment for all 1> 1. 
Therefore optimum investment declines as 1 increases over the range 
l<(m+l)/(rn-1) if for g equal toany 	<1-1/ni, Y is less for all 1>1 than for 
= 7. 
Hence, optimum gametocyte investment declines as I increases (for m > 1) if for g 
equal to any *>1_1/i(1>1and  nz>1), Y is greater for all 1>1 than for 1=1 
and for g equal toany 	<1-1/ni, Y is less for all 1>! than 1=1. The value ofY 
across / can be determined from the differential of V with respect to 1. 
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Direction of change in optimum investment with number of merozoites per 
asexual 
When g is equal to a >1- 11nt (1 >1 and iii > 1), 	is higher than the optimum 
investment for all m > ñi in the range rn <(7 + 	- i) if Y is greater for all rn> th 
than for m = th and 	> 1- 1/rn for all m <(7 + 1)/(7 - i). As 1- 1/rn increases with 
m, it is necessary to prove that 	> 1 - 1/rn for all rn <(7 + i)/(i - i). Therefore, 
optimum investment declines as m increases over the range m <(1+ i)/(i -1) (for 
1>1 and rn> 1) if for g equal to any 	>1-1/ni (1>1 and ñz>1), Y is greater for 
all rn> ni that are less than (7 + i)/(i - i) than for m = ni and 	> 1- 1/rn for all 
m<(7+i)/(7-i). 
Optimum gametocyte investment declines as rn increases from rn < (1+ 1)/(l -1) to 
m =(1+ i)/(i-i) if for g equal to any 	> 1-1/nt, 	>1-1/rn when 
m = (7+ i)/(i - i). Similarly, optimum gametocyte investment declines as m 
increases from rn = (1 + i)/(i -1) to rn> (1 + i)/(l -1) if for g equal to any 
*<1_1/j,*<1_1/m when rn=(l+1)/(1_1). 
When g is equal toa 	<1-1/nt, 	<1-1/rn for all rn>nt and therefore 	is 
higher than the optimum investment for all rn> ñi if Y is less for all rn > ifi than for 
m = in- . Therefore optimum gametocyte investment declines as rn increases over the 
range m > (1+ i)/(i -1) if for g equal to any <1 - 1/nt, Y is less for all rn > fit 
than for rn=Fn. 
Hence, optimum gametocyte investment declines as m increases (for 1> 1) if for g 
equal to any 	>1-1/nt (where 7>1 and nt>.1), 	>1-1/rn when 
rn = (7 + 1)/(7 - i) and Y is greater for all rn > fit that are less than (7 + 1)/(7 - i) than 
for rn = in- , and for g equal to any 	<1- 1/nt, 	<1- 1/rn when rn= (7 + 1)/(7 - i) 
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3.3. Results 
The number of merozoites per asexual and the time to maximum asexual density are 
known for a variety of malaria species. Hence gametocyte investment can be 
predicted for these species from equation 3.19) (Table 3.2). 




number of replication 







P. berghei(mouse) 8 a 7 b 13 
P. brasillanum (spider monkey)' 10 5 21 
P. chabaudi(mouse) 6 a 8d 13 
P. coatneyi (rhesus monkey)c 20 4 25 
P. cynomolgi (rhesus monkey) C 16 4 26 
P. falciparum (man) 16e W 26 
P. fleldi (rhesus monkey)' 12 3 35 
Pinui(rhesus monkey)C 12 4 26 
P. knowlesi (man)C 10 8 13 
P. ma!ariae (man)c 8 6 17 
P. ovale (man)c 8 4 26 
P. schwetzi(man)c 14 4 26 
P. vivax(man)C 16 4 26 
Table 3.2. Predicted gametocyte investment for a range of malaria infections. Host listed is 
that for which data were collected. Parameter values were obtained from: a  Landau and 
Boulard, 1978, b  Dearsly etal., 1990, C  Coatney etal., 1971, d  Mackinnon and Read, 2003, 
Garnham, 1966, f average of data presented in Collins and Jeffery, 1999. m > (1+ 1)/(l-1) 
in every case. Predicted investment was found by numerical solution of equation 3.19) using 
MATH EMATICA® (v. 4.1.2.0, Wolfram Research). 
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3.3.1. 	Direction of change in optimum gametocyte investment with 
time to maximum asexual density 






dl  \ 1 - (rn(1 - g))' rn!2 
)11n[m(1 - g)] - ((m(1 - g))' - i)) 	 3.20) 
When rn > 1, this differential is positive for g > 1 - 1/rn and negative for g <1 - i/rn. 
Therefore for g equal to any > 1— 1/n (where 1 > 1 and ñz > 1), Y increases with 
1. For g equal to any <1— 1/ni, Y decreases as 1 rises. Hence, for g equal to any 
>1-1/ni (where 1>1 and ni>1), V is greater for all 1>1 than for 1=1 (Figure 
3.5). Also for g equal toany 	<1-1/ni, Y is less for all 1>1 than for 1=1 (Figure 	- 
3.6). 
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Figure 3.5. Behaviour of Y and Z across 1 when g is the optimum investment for 1 = 1 and 
m= ñi (1>1 and ñi>1)'and 	>1-1/ni. Diamond indicates i — i. By definition, Y  
when 1 = 1. Y > Z for all 1> 1. Therefore, the optimum investment for I = I is higher than 
the optimum investment for all 1> 1 (in the range 1 < (in- + i)/(ñi —1)). Y was calculated 
from equation 3.9) and Z from equation 3.10) with g =0.33 and m = 1.1. The value of g 
was found by numerical solution of equation 3.19) using MATH EMATICA® (v. 4.1.2.0, 
Wolfram Research). 
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Figure 3.6. Behaviour of Y and Z across 1 when g is the optimum investment for I = I and 
m = ffz and 	<1— 1/ni. Diamond indicates I = I. Y <Z for all 1> 1. Therefore, the 
optimum investment for 1 = I is higher than the optimum investment for all 1> 1. Y was 
calculated from equation 3.9) and Z from equation 3.10) with g =0.13 and m = 6. The 
value of g was found by numerical solution of equation 3.19) using MATHEMATICA® (v. 
4.1.2.0, Wolfram Research). 
Therefore, optimal gametocyte investment declines as time to maximum asexual 
















1 2 3 4 5 6 7 8 9 1011 12 13 14 15 16 17 18 19 20 
number of replication cycles to maximum asexual density 
Figure 3.7. Effect of time to maximum asexual density on optimum gametocyte investment. 
Optimum gametocyte investment was found by numerical solution of equation 3.19) with 
m = 6 using MATHEMATICA® (v. 4.1.2.0, Wolfram Research). 
3.3.2. 	Direction of change in optimum gametocyte investment with 
number of merozoites per asexual 
The differential of Y with respect to m, from equation 3.9), is: 
dY ((m(1 - g) ' i _L)[i(i - I) - 1(m(1 - 9))' - i 
dm 	1-(m(1-g))'  ml 	m 	(m(lg)_l)f) 	
3.21) 
By logic similar to that used to determine how fitness changes with g, when 1> 1 
and g > 0, this differential changes from being positive to being negative either side 
of a single value of m. Hence (for 1> 1 and g > 0), there is a single turning point in 
Y across m and it is a maximum. When m<(l+1)/(l-1) for g=1-1/m, the 
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maximum is avalue of m>1/(l-g). When m=(1+l)/(1-1) for g=1-1/m, the 
maximum is at m=1/(l-g), and when m>.(1+1)/(l-1) for g=1-1/rn, the 
maximum is a value of rn <l/(1 - g). 
For g equal toany >1-1/th (>1, ñz>1),bydefinition, Y = Z when rn=th. Y 
will also equal Z at a higher value of m equal to i/(i - *). Therefore, the maximum 
in Y must occur at a value of m < i/(i - 	Hence m > ( 1 + 	- i) when 
= 1-1/rn. It follows that when rn =(i + 1)1(7 - i), .r > 1-1/rn. It also follows that 
Y is greater for rn > ñz in the range m < ( 7 + 	- i) than for rn = in-  (Figure 3.8). 
For g equal to any <1- 1/ffi, Y = Z when rn = ñz and at a lower value of rn equal 
to i/(i - 	The maximum in Y must occur at a value of rn > i/(i - i). Therefore, 
Y is less for all m > ñi than for m = ñz (Figure 3.9) and rn < ( 7 + 1)1(7 - i) when 
-* =1-1/rn. It follows that when m =(7+i)/(7_i), 	<1-1/rn. 











number of merozoites per schizont 
(m) 
Figure 3.8. Behaviour of Y and Z across rn when g is the optimum investment for I = 1 
and m = ñz (1 >1, ñz >1) and 	> 1— 1/ni. Diamond indicates m = ni. Vertical dashed 
line indicates value of m for which r = 1-1/rn. V = Z when m = ni and when 
M = i/(i - ). As described in the text, when rn = (7 + 1)1(7 - i), k * > 1 - 1/M. Therefore 
the optimum investment is higher for m = ñz (ñz <(7 + i)/(i —1)) than for 
m = ( 7 + 	- i). Additionally, Y> Z for all m > ni in the range m < ( 7 + 
Therefore the optimum investment for m = ni is higher than the optimum investment for all 
rn > ñi in the range rn 	+ i)/(i - i). V was calculated from equation 3.9) and Z from 
equation 3.10) with g = 0.33 and 1 = 8. The value of g was found by numerical solution of 
equation 3.19) using MATH EMATICA® (v. 4.1.2.0, Wolfram Research). 
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Figure 3.9. Behaviour of Y and Z across rn when g is the optimum investment for I = I 
and rn = ñz and 	<1-1/th. Diamond indicates m = in- . Y = Z when m = 1/(1_,*) and 
when m = in- .   Y <Z for all m > ñ1 > i/(i_ *). Therefore the optimum investment is higher 
for rn = th than for all m > ñz. As described in the text, when m = (7 + 	- 
, <1-1/rn. Therefore the optimum investment for m = (7 + i)/(i - i) is higher than the 
optimum investment for m = th (in-  > ( 7 + i)/(i —1)). Y was calculated from equation 3.9) 
and Z from equation 3.10) with g = 0.13 and 1 = 8. The value of g was found by numerical 
solution of equation 3.19) using MATHEMATICA® (v. 4.1.2.0, Wolfram Research). 
Therefore, optimal gametocyte investment declines as the number of merozoites per 
asexual increases (Figure 3.10). 
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Figure 3.10. Effect of the number of merozoites per asexual on optimum gametocyte 
investment. Optimum gametocyte investment was found by numerical solution of equation 
3.19) with / = 8 using MATHEMATICA® (v. 4.1.2.0, Wolfram Research). 
The impact of the number of merozoites per asexual on optimum gametocyte 
investment is small when schizonts produce at least four merozoites. 
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34. Discussion 
I have shown that low gametocyte investment in malaria can be expected to evolve 
because of the trade-off between gametocyte production and within-host growth. I 
assumed that fitness could be equated with the total number of gametocytes produced 
over an infection and modelled parasite dynamics discretely, to reflect malaria 
biology. My results do not depend on an immune function of the sort common in 
malaria models, which have little empirical support. Instead I assumed that infections 
were cleared after a fixed time. I predicted that gametocyte investment should 
decline with increasing time to maximum asexual density and increasing numbers of 
merozoites per schizont. I found that the time of maximum asexual density was 
likely to have considerably more impact on the level of gametocyte investment than 
the number of merozoites per schizont would. The number of merozoites per 
schizont only had a noticeable effect on optimum gametocyte investment when there 
were less than four merozoites per schizont. 
Koella and Antia (1995) optimised the integral of gametocyte density over time. 
They predicted that when gametocyte investment is constant, investment should 
decrease as the parasite growth rate rises. This is similar to my finding that 
gametocyte investment should decline as the number of merozoites per schizont 
increases. However if parasites grow quickly enough that they can reach a density 
that would kill the host, Koella and Antia (1995) found that gametocyte investment 
should increase with growth rate. Optimum investment values can be read from their 
Fig. 2, with the growth rate calculated as ln[m] divided by the cycle period (time 
from an asexual invading a red blood cell to producing new parasites). Hence they 
predicted 3% gametocyte investment for P. falciparum, 5% investment for P. 
chabaudi and 10% for P. berghei. The values for P. chabaudi and P. berghei depend 
on the assumption that these parasites can kill their hosts. Koella and Antia' s (1995) 
predictions are all lower than mine, mostly considerably so. On the basis of my 
findings in chapter 1 (see section 2.3.1, page 23), this is probably a consequence of 
Koella and Antia (1995) using a continuous malaria model. 
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McKenzie and Bossert (1998b) optimised the integral of (i - e2)2 (where G is the 
gametocyte density) over the first 50 days of infection. This measure emphasises the 
time for which gametocytes are present rather than just gametocyte numbers. 
McKenzie and Bossert (1998b) predicted that gametocyte investment should be 
between 5% and 76% for P. falciparum (calculated from the g values given in their 
Fig. 1 divided by m In[m] /(2 x (m - 1)) to make them directly comparable to my 
values). The low investment values probably result from McKenzie and Bossert's 
(1 998b) continuous formulation of parasite dynamics. The higher predictions are for 
more rapid immune responses, and may be a consequence of McKenzie and 
Bossert's (1998b) fitness parameter. However, McKenzie and Bossert (1998b) also 
found that high gametocyte investment was disadvantageous in double infections 
when there is a common immune response to both parasite strains. In such infections 
a high gametocyte investor is suppressed by a greater immune response than it would 
elicit alone, which is driven by the higher asexual densities of the low gametocyte 
investor. 
To evaluate how well my analysis describes the nature of selection on gametocyte 
investment, my predictions need to be tested against data. However there are 
problems with published estimates of gametocyte investment that mean they may be 
inaccurate (see sections 6.1.1, page 160 and 6.1.2, page 164). Some estimates are 
reasonably similar to my predictions. In P. falciparum up to about 20% gametocyte 
investment was measured in culture (Carter and Miller, 1979). For P.chabaudi 
infections in mice, maximum gametocyte investment was estimated at around 10% 
(Buckling et al., 1999b; Mackinnon et al., 2002; Mackinnon and Read, 2003). But an 
estimate of 45% for P. berghei infections in mice (Dearsly et al., 1990) is much 
higher than my prediction. Estimates that address the particular difficulties associated 
with measuring gametocyte investment (which are detailed in chapter 1) are needed 
to fully test my results. I present such data in chapter 1. Longitudinal data over the 
course of infection are also required to assess my assumption of constant investment. 
Specific predictions could be tested for particular parasite species and clones, hosts 
and populations. However a more rigorous test of my results would be to look at the 
relationships between gametocyte investment and both timing of maximum asexual 
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density and number of merozoites per schizont, under experimental manipulation or 
artificial selection. The time of maximum asexual density can be altered by adjusting 
parasite dose (Timms et al., 2001; also see chapter 1). Drug treatment could be used. 
to clear parasites earlier (Buckling et al., 1997, 1999b). Manipulation of the host 
immune system, for example through adoptive transfer of immune components or 
using nude mice (Janeway et al., 2001), might also affect the time of maximum 
asexual density. Vaccination could be used to reduce parasite growth rates and 
hence, effectively, the number of merozoites per schizont (Mackinnon and Read, 
2003). 
My analysis suggests that widespread treatment of malaria infections with 
antimalarial drugs would select for increased gametocyte investment through 
shortening the average time to maximum asexual density. Such an increase would, at 
least partly, counter the reduction in transmission achieved by treatment. However, 
increased gametocyte investment would also have the favourable outcome of 
reducing parasite growth rates, provided higher parasite fecundity did not evolve. 
Therefore consideration of the fitness consequences of gametocyte investment 
suggests that over time, drug-treatment could lead to decreased community levels of 
malaria virulence. In contrast, vaccination that reduces parasite growth rates, but has 
little effect on clearance times, would be expected to have little effect on gametocyte 
investment unless a very considerable suppression of growth was achieved 
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4. Estimating parasitaemias and gametocytaemias from thin 
blood smears; comparing a new method of counting 
parasites with traditional methods 
4.1. Introduction 
Malaria parasitaemias are the proportion of red blood cells that are infected with 
asexuals (which includes indistinguishable young gametocytes). Gametocytaemias 
are the proportion of red blood cells infected with mature gametocytes. Parasitaemias 
are measured in studies of malaria parasite virulence and dynamics, immunity, drug 
efficacy and vaccination. Accurate determination of parasitaemia is important in 
cloning. In the field, both parasitaemia and gametocytaemia measurements are used 
to assess the intensity of malaria infections within communities. Measurement of 
gametocytaemia is important in investigations relating to mosquito infections and 
parasite transmission. Parasitaemias and gametocytaemias are commonly estimated 
from thin red blood smears. Suggested methods for counting parasitised cells (either 
those infected with asexuals or those infected with mature gametocytes) in thin blood 
smears are to count the number of parasitised cells in a fixed number of microscopic 
fields and to count the number in relation to total red blood cells (Cove!l et al., 1953; 
Field and Shute, 1956; Garnham, 1966). The current recommendation from the 
Centres for Disease Control and Prevention is to count the number of parasitised 
cells in 500-2000 red blood cells, 500 red blood cells if parasitaemia is above 10% 
and 2000 or more if parasitaemia is less than 1% (http://www.dpd.cdc.gov/dpdxl  
HTML/DiagnosticProcedures.htm). 
In this chapter, I examine estimates of parasitaemia and gametocytaemia from three 
methods of counting parasitised red blood cells in smears. The first two are 
traditional methods. The third has not previously been used in malaria research, as 
far as I am aware. Method I is to examine a fixed number of red blood cells and 
count how many are parasitised. Method 2 is to count parasitised cells in a fixed 
number of microscopic fields and the number of red blood cells in a fixed part of this 
area. The proportion of red blood cells that are parasitised is then estimated from the 
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two counts. Method 3 is to measure the area that has to be examined to count a fixed 
number of parasitised cells and, from a different part of the smear, the area that has 
to be examined to count a fixed number of red blood cells. Similarly to method 2, the 
proportion of red blood cells that are parasitised is then estimated from the two 
measurements. Method 3 is a form of inverse sampling (Tweedie, 1945). Originally 
applied to estimating the frequency of abnormal red blood cells (Haldane, 1945), 
inverse sampling has been used for estimating bacterial density (Sandelius, 1950) 
and is successfully used in crop pest management (Pedigo and Zeiss, 1996). 
Both accuracy and precision should be considered in evaluating the methods. 
Accuracy relates to how close estimates are to the actual value. Precision indicates 
the similarity between estimates from repeated counts. An important determinant of 
accuracy is whether the estimator is biased. Estimates from a biased estimator will be 
consistently too high or too low. The precision of an estimator can be quantified by 
the standard error of estimates, which determines the size of the 95% confidence 
interval, whatever the distribution of the estimates (Lynch and Walsh, 1997). Bias 
can sometimes be ignored if the standard error is sufficiently high. A working rule is 
that the inaccuracy due to bias is negligible if the standard error is at least 10 times 
the bias, or equivalently, the bias is less than 0.1 times the standard error (Cochran, 
1977). 
Here, I derive expressions for the bias in the parasitaemia and gametocytaemia 
estimator and the standard error of estimates, using the delta method (Lynch and 
Walsh, 1997), which is based on the Taylor series expansion. I consider each method 
in turn. I determine the size of the bias and standard error and under what conditions 
they will be large. I explore how the bias and standard error change with sample size 
and how best to increase sample size in order to reduce them. I also compare the size 
of the bias to the size of the standard error. I conclude with an overall comparison of 
the three methods. 
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4.2. Methods 
I present the results with reference to parasitaemia estimates but they apply equally 
to estimating gametocytaemia. I define the bias in an estimator as the difference 
between the average of estimates and the actual value. I report the bias and the 
standard error of estimates as percentages of the actual values. These give a better 
indication of the importance of bias and standard error than the absolute values, and 
facilitate comparisons between the methods. I use the term parasites to mean red 
blood cells infected with asexuals. I consider sample sizes of 200-2000 red blood 
cells, 10-100 fields for parasites and 0.05-3 fields for red blood cells and 5-50 
parasites. I evaluate the methods for parasitaemias of 0.02-70% and red blood cell 
densities of 400-1000 per field. 
4.2.1. 	Assumptions 
I make the following assumptions: 
a smear is a random sample of host blood 
parasites (and red blood cells infected with mature gametocytes) are 
binomially distributed amongst red blood cells on a smear 
red blood cells are Poisson distributed across a smear 
parasites (and red blood cells infected with mature gametocytes) are Poisson 
distributed across a smear. 
Red blood cells are usually either very concentrated or very sparse at the edges of 
smears and these areas are excluded in counts. Therefore the assumptions apply to 
the main area of a smear, excluding the edges. In particular an implicit assumption is 
that parasites (and red blood cells infected with mature gametocytes) do not tend to 
be clustered at, or be absent from, the edges of smears. Counts of red blood cells in 
the central 1122nd  (4 squares from a grid of 88 squares) of at least 40 fields showed 
that the distribution of red blood cells was not significantly different from Poisson. 
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Counts of parasites in at least 30 fields and of red blood cells infected with mature 
gametocytes in at least 60 fields showed that their distributions were not significantly 
different from Poisson. 
4.2.2. 	Key to symbols 
A key to the symbols used in this chapter is given in Table 4.1. 
P 	parasitaemia estimator 
n, number of parasites counted 
nc 	number of red blood cells sampled 
[I parasitaemia 
P. 	average value of x over all possible non-overlapping counts 
E[A] average value of function A over all possible non-overlapping counts 
cr2 (x) 	variance of x 
fC 	number of fields sampled for red blood cells 
l/d fraction of a field sampled for red blood cells 
fp 	number of fields sampled for parasites 
u(x,y) covariance of x and y 
b(P) 	bias in estimator P 
ci,j 	number of red blood cells in the 
1th  sub-area of the i h  field 
Pij 	proportion of red blood cells infected with asexuals in the 
11hz  sub-area of 
the i h  field 
average number of red blood cells per field 
ac 	area sampled for red blood cells 
a area sampled for parasites 
Table 4.1. Key to symbols. 
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4.3. Method 1: sampling a fixed number of red blood cells 
A fixed number of red blood cells are examined for parasites. The parasitaemia 
estimator is: 




where n,, is the number of parasites counted and n is the number of red blood cells 




4.3.1. 	Bias in method 1 estimator 
Expanding equation 4.1) by a Taylor series about ,i, gives: 
P !iP- + 
(
np — An p  
nc 	 nc 
Hence: 
E[P]=fl 
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4.3.2. 	Standard error of method 1 estimates 
From the definition of variance and equations 4.3) and 4.4): 
21 
[(un 	 a2(n) 
4.5) or 	
E[I__&+ ¼ flC  
Under assumptions 1) and 2): 
a2(n) nH(1—H) 	 4.6) 
Hence the standard error of method 1 parasitaemia estimates is given by: 
U(P) I 1 (i 	 4.7) 
H 
The standard error of method 1 estimates can be very small to very large. The 
standard error considerably increases when parasitaemia is low (Figure 4.1). As 
shown in Figure 4. 1, the standard error can be considerably decreased by sampling 
more red blood cells for parasites. As more red blood cells are sampled for parasites, 
each further increase has successively less effect on the standard error. 










200 	500 	800 1100 1400 1700 2000 
number of red blood cells sampled 
Figure 4.1. Predicted standard error of parasitaemia estimates. The standard error is given 
as a percentage of the actual value. The standard error was calculated from equation 4.7). 
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4.4. Method 2: sampling a fixed number of fields 
A fixed number of fields are examined for parasites. Red blood cells are counted in a 




where fc is the number of fields sampled for red blood cells, l/d is the fraction of a 
field sampled for red blood cells and f, is the number of fields sampled for 
parasites. n,, and n are Poisson distributed and fc , d and f are constants. nP and 




4.4.1. 	Bias in method 2 estimator 
Expanding equation 4.8) by a Taylor series about 	and 	up to second order 
gives the approximation: 













df 	 dfpPnc  
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Therefore the method 2 parasitaemia estimator is biased and: 
b(P) u2(n) - +, , n , ) 
H 
4.12) 
Under assumptions 1) and 3): 
a2(n)i 
4.13) 
12& - J1, 
An expression for 	can be derived by treating each field as consisting of d 
sub-areas and writing n, and n as functions of the number of red blood cells in 
each sub-area. Hence: 
nc =cii +c21 ±.+c11 
	 4.14) 
where c, is the number of red blood cells in the 1th  sub-area of the ith  field and the 
1t  sub-area is taken to be the part of a field that is sampled for red blood cells. Also: 
fp d 
fl = C11 f3 + C2,IP2,1  + + c 1fJ 1  + ...+ C1 lPf +I I  C jJPjJ 	 4.15) 
i-I j-2 
where pi, j is the proportion of red blood cells infected with asexuals in the 
Jth  sub- 
area of the i th field. Under assumptions 1) and 3), equation 4.14) can be expanded by 
a Taylor series about pc, , /, , ... 	 as: 
( 
nc = 	+ C11 --) + c 21 - 	+ ...+ 	
----1 	 4.16) 
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c - —s- 
) 
2 
H + C 2 - —i-  
2 	 2 
( 11+... + C 	- 	fl 
fc fc fc 
fc 
+2 ~Ckj  !!nc ~( fp +  (Ck,I 	2S-)(CII 
- 
 
k>i i- I c C k- I i- f+1 C C 




ku 	lj 	2 C 
L f P 	d 
(p1 —ri) 
fp kI f 
ffpd 
+2 11 Cki 	 ! nc  ( 
c,, _!- (p 	—H)  An. 
kI 	ii 	jI Jc f p 
= 4.19) 
Under assumptions 2) and 3), equation 4.15) can be expanded by a Taylor series 




+ ( ,i 	'.r 	 ( 1 - c2--I+...+ fl = f2 + C11 
- 	 f i f) 
fpd( 
+ ... + 
(,, 
- _)n + 	cii  - iH 	 4.17) 
i=1 j-2 	f) 
fp d 	 fp dl 'In 'In 
+ 	
(p,, - n) + 	
( 
c, - -- 	- n) 
C i=I jI 	 i1 jI\ 	JC , 
Therefore from the definition of covariance: 
+ (1, - + (C2,1 P- 1  )ri + ... + Cf 
- 
- — 
f) L... + 	 ) 	i-I E 	, d f d/ !H+1cjj -71' 
+ - 	(p _ri)+ 
	




( 	 ( \ 
('Ia. + ( 11 - 	+ I C21 
IIn 
- — + ... + 	- 
un 
- ) 'Ia fp f 	 ) - ) 7 
4.18) 
which multiplies out to: 
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As functions of different variables where the variables are independent are also 
independent (Cramer, 1946) and the average value of a product of independent 
functions is equal to the product of the average values of the individual functions 
(Cramer, 1946), under assumptions 2) and 3), equation 4.19) simplifies to: 
cr(n,n) = 	+ a2 (c 21 )H + ...+ 
	
4.20) 
As the sum of the variances of uncorrelated variables is equal to the variance of the 
sum of the variables (Lynch and Walsh, 1997), under assumption 3): 
cy( np , nc )=cy2 (n)n 	 4.21) 
and therefore under assumptions 1) and 3): 
ci(n,n) = 	 4.22) 
Substituting equations 4.13) and 4.22) into equation 4.12) gives the approximation: 
b(P) 	1 	lI 4.23) 
H !1n 	/2, ,, 
Equation 4.23) can be written as: 
b(P) 1 1 d 	i 4.24) 
H  
where ó is the average number of red blood cells per field. Therefore the 
parasitaemia estimator overestimates parasitaemia. The bias is small (Figure 4.2). 
The bias considerably increases when there are few red blood cells per field (Figure 
4.2). It does not vary with parasitaemia. The bias can be decreased by sampling a 
larger area for red blood cells, either by examining a larger area within each field or 
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by examining more fields (Figure 4.2). As the area sampled for red blood cells is 
increased, each further increase has successively less effect on the bias. As shown in 
Figure 4.2, the bias very slightly increases with the number of fields sampled for 








0 1 	 2 	 3 
total field area sampled for red blood cells 
5 fields sampled for parasites 
400 red blood cells per field 
100 fields sampled for parasites 
400 red blood cells per field 
5 fields sampled for parasites 
1000 red blood cells per field 
100 fields sampled for parasites 
1000 red blood cells per field 
Figure 4.2. Predicted upward bias in the parasitaemiä estimator. Bias is given as a 
percentage of the actual value. Bias was calculated from equation 4.24). 
4.4.2. 	Standard error of method 2 estimates 




1(fc or 2(P) 
E 	
4u 




un 	 un 
Under assumptions 1) and 4): 
o2(n)u 	 4.26) 
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Therefore, substituting from equations 4.26), 4.22) and 4.13), the standard error of 
parasitaemia estimates is approximately given by: 
o-(P)
_~T"
1H 1 4.27) 
H i1 	ILn 
Equation 4.27) can be written as: 






1-I 5f\l 	) f 
4.28) 
The standard error can be small to large. The standard error considerably increases 
when there are few red blood cells per field (Figure 4.3 and Figure 4.4) and when 
parasitaemia is low (Figure 4.4). 
When parasitaemia is moderate to high, the standard error can be considerably 
decreased by sampling a larger area for red blood cells (Figure 4.3 and Figure 4.4a)). 
But, sampling a larger area for red blood cells has little effect on the standard error 
when parasitaemia is low (Figure 4.4b)). The standard error can be considerably 
decreased when parasitaemia is low to moderate by sampling more fields for 
parasites (Figure 4.3b) and Figure 4.4). When parasitaemia is high, sampling more 
fields for parasites has little effect on the standard error and when parasitaemia 
exceeds 50%, the standard error actually slightly increases with the number of fields 
sampled for parasites (Figure 4.3a)). As the area sampled for red blood cells and the 
number of fields sampled for parasites is increased, each further increase has 
successively less effect on the standard error. 
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5 fields sampled for parasites 
400 red blood cells per field 
100 fields sampled for parasites 
400 red blood cells per field 
a) 	 70% parasitaemia 	 b) 
5 fields sampled for parasites 
1000 red blood cells per field 
100 fields sampled for parasites 






0 	1 	2 	3 
total field area sampled for 





0 	1 	2 	3 
total field area sampled for 
red blood cells 
Figure 4.3. Predicted standard error of parasitaemia estimates. The standard error is given 
as a percentage of the actual value. In a) the parasitaemia is 70% and in b) the parasitaemia 
is 2%. The standard error was calculated from equation 4.28). 
0.05 of a field sampled for red blood cells ------0.05 of a field sampled for red blood cells 
400 red blood cells per field 	 1000 red blood cells per field 
1 field sampled for red blood cells 	 1 field sampled for red blood cells 
400 red blood cells per field 	 1000 red blood cells per field 
a) 	 0.2% parasitaemia 	 b) 	 0.02% parasitaemia 
	
100% 	 100% 
standard 	 standard 
error 50% 	 error 50% 
0% 	 0% 1. 
10 40 	70 	100 	 10 	40 	70 	100 
number of fields sampled for number of fields sampled for 
parasites 	 parasites 
Figure 4.4. Predicted standard error of parasitaemia estimates. The standard error is given 
as a percentage of the actual value. In a) the parasitaemia is 0.2% and in b) the 
parasitaemia is 0.02%. The standard error was calculated from equation 4.28). 
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The standard error can be less than 10 times the bias. The standard error considerably 
decreases compared to the bias when parasitaemia is high (Figure 4.5). The standard 
error also considerably decreases relative to the bias when there are few red blood 
cells per field (Figure 4.5). 
The bias can be considerably reduced relative to the standard error by sampling a 
larger area for red blood cells (Figure 4.5). When parasitaemia is low, the relative 
bias considerably increases with the number of fields sampled for parasites (Figure 
4.5a)). But when parasitaemia is high, the number of fields sampled for parasites has 
little effect on the relative bias, for the cases where the standard error is less than 10 
times the bias (Figure 4.5b). 
0.2 of a field sampled for red blood cells 
400 red blood cells per field 
0.05 of a field sampled for red blood cells 
400 red blood cells per field 
0.05 of a field sampled for red blood cells 
1000 red blood cells per field 
	





to bias 2 
0 
10 	40 	70 	100 
number of fields sampled for 
parasites 









10 	40 	70 	100 
number of fields sampled for 
parasites 
Figure 4.5. Predicted size of the standard error of parasitaemia estimates relative to the bias 
in the estimator. In a) the parasitaemia is 0.02% and in b) the parasitaemia is 2%. The 
standard error was calculated from equation 4.28) and the bias from equation 4.24). 
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4.5. Method 3: sampling a fixed number of parasites 
Fields are sampled until a fixed number of parasites have been counted and the total 
area examined is recorded. From a different part of the smear, fields are sampled 
until a fixed number of red blood cells have been counted and again the area 




where ac is the area examined for red blood cells and a,, is the area examined for 
parasites. ac and a are Erlang distributed (Knight, 1965) and are independent and 
n,, and n are constants. n,, —1 appears in the numerator of equation 4.29) because 
under assumptions 1) and 4) and inverse sampling, (n - 1)/a,, is an unbiased 
estimator of flp/Iap , provided n,, > 1 (Sandelius, 1950; Anscombe, 1953). 




4.5.1. 	Bias in method 3 estimator 
The Taylor series expansion of equation 4.29) about flp//a  and Mac can be written 
as: 
p = 
flp 	 p 	- 	n  IA, + ((np - i) - 
Ma,n 
+ i) nP 
+ (a -  / iI(a 	aj Map flc 	 a,, Pa ) nc 
4.31) 
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Hence, as (n - 1)/a, is an unbiased estimator of flp14Ua  and as parasites and red 




Therefore the method 3 parasitaemia estimator is unbiased. 
4.5.2. 	Standard error of method 3 estimates 
From equations 4.31) and 4.32): 
a2 (P) = E 
	
 
((ne_i) 	,p 	 fl _l2!( 
-)2  ap iiap ) 
(na _i) n 	 2 1 	"(n _i) n 	 pIa + ___?_I (ac —u a ) ---i-2l " 	---- I(ac-4ua) 	2  pap n 
( a 
	nap) 	 !Lap) 
1"(n _i) 	 (( 	—1' 	 2 fl ___ _ _____  " ---s- (ac 	 I1a ----+2l " ° '------ I(ac—a) 	p +21 	 2
pap n a 	J gap) 
- i) 	11 2 	 112 	
2((np 	
G2(ac) 
a 	Fnpltt.p) 	 ap ) 	(p/ap ) 2 





provided n,, > 2 (Sandelius, 1950; Anscombe, 1953). 
4.33) 
4.34) 
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As a is Erlang distributed: 
22 (a)= 14 c 
nc 
4.35) 
(Hastings and Peacock, 1975). Hence, substituting from equations 4.34) and 4.35), 
the standard error of parasitaemia estimates is given by: 
cj(P) 	Ii 	1 	1 
H 4.36) 
The standard error is moderate (Figure 4.6 and Figure 4.7). It does not vary with 
parasitaemia. The standard error can be considerably decreased by sampling more 
parasites (Figure 4.6). The standard error can also be considerably decreased by 
sampling more red blood cells (Figure 4.7). The effects of sampling more parasites 
and sampling more red blood cells are similar, although increasing the number of 
parasites sampled has a considerably bigger effect when very few parasites and red 
blood cells are sampled. As more parasites and more red blood cells are sampled, 
each further increase in the number sampled has successively less effect on the 
standard error. 








5 red blood cells sampled 
20 red blood cells sampled 
50 red blood cells sampled 
20 	 35 	 50 
number of parasites sampled 
Figure 4.6. Predicted standard error of parasitaemia estimates. The standard error is given 








5 parasites sampled 
20 parasites sampled 
50 parasites sampled 
20 	 35 	 50 
number of red blood cells sampled 
Figure 4.7. Predicted standard error of parasitaemia estimates. The standard error is given 
as a percentage of the actual value. The standard error was calculated from equation 4.36). 
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4.6. Discussion 
I have evaluated the merits of three different counting methods for estimating 
parasitaemias from thin blood smears. Method 1 is to count the number of parasitised 
cells in a fixed number of red blood cells. Method 2 is to count the number of 
parasitised cells in a fixed number of fields and to estimate the number of red blood 
cells in those fields from a small sample in the same area. Method 3 is an inverse 
sampling technique. For method 3, sampling is continued until a predetermined 
number of parasites are observed. The number, of red blood cells examined is then 
estimated from sampling a fixed number of red blood cells in a separate area. Method 
1 and 2 are routinely used for counting malaria parasites in smears. As far as I am 
aware, this is the first time that inverse sampling has been considered in this context. 
I determined the bias in the estimators for each method and the standard error of 
estimates. A summary of the results is presented in Table 4.2. 
The parasitaemia estimators for methods 1 and 3 are unbiased. Therefore, for these 
methods, provided the estimates are fairly precise, they will be accurate. The 
parasitaemia estimator for method 2, however, is biased. Estimates of parasitaemia 
from method 2 will tend to be too high. Despite this, the effect of the bias will 
sometimes be negligible. Inaccuracy is only likely to be a problem with method 2 
when fairly small areas are sampled for red blood cells. The importance of bias 
increases with parasitaemia. When 0.05 of a field is sampled for red blood cells, 
parasitaemia will probably be overestimated when it is above 0.02%. When 0.2 of a 
field is sampled for red blood cells, parasitaemias over 2% are likely to be 
overestimated (see Figure 4.5). However, when the mean of several parasitaemia 
estimates is taken, inaccuracy may be more of a problem. If most of the variation 
between estimates is sampling variation, the standard error will decrease as the 
number of estimates rises, and therefore the bias in the mean will be relatively larger 
than the bias in any one estimate. But if individual variation is high, bias may not 
have a significant effect on the mean. 
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Method 1 Method 2 Method 3 
0.02-5% upwards 
size none 0.0003-0.2 times none 
size of standard 
error 
main 
m 	conditions few red blood cells 
causing per field 
increase 
main sampling a larger 
methods of -: area for red blood 
reducing - cells 
size 1-500% 3-114% 20-77% 
main low parasitaemia 
conditions 
low parasitaemia 
causing few red blood cells 
increase per field 
when parasitaemia 
is moderate to high: 
CO sampling a larger 
area for red blood sampling more CO 	
main 




reducing when parasitaemia sampling more red 
is low to moderate: 
blood cells 
sampling more fields 
for parasites 
Table 4.2. Summary of the biases in parasitaemia estimators and the standard errors of the 
estimates from them for parasitaemias from 70-0.02%. Biases and standard errors are 
reported as percentages of the actual values. For method 1, values are for samples of 200-
2000 red blood cells and were calculated from equation 4.7). For method 2, values are for 
samples of 10-100 fields for parasites and 0.05-3 fields for red blood cells at densities of 
400-1000 red blood cells per field and biases were calculated from equation 4.24) and 
standard errors from equation 4.28). Values for method 3 are for samples of 5-50 parasites 
and 5-50 red blood cells and were calculated from equation 4.36). 
The level of precision that is acceptable for estimates will depend on the particular 
application. It will also depend on the level of discrimination that is required, that is, 
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what size of effect would be considered to be biologically interesting or important. 
For a given level of precision, the permissible standard error will depend on the exact 
distribution of the estimates. If the estimates are approximately normally distributed, 
a standard error that is half the size of the required 95% confidence interval either 
side of the estimate, is sufficiently low. But if the estimates are not normally 
distributed, only a standard error of 1/4.5 times the size of the required 95% 
confidence interval either side of the estimate may be sufficiently low (Lynch and 
Walsh, 1997). When the mean of several estimates is taken, the standard error of 
each estimate can be larger for the same level of precision. If the variation between 
estimates is low, this is because the standard error of the mean is lower than that of 
each estimate, as discussed previously. If there is considerable variation between 
estimates, this variation and not the precision of estimates, dominates the precision of 
the mean. As a guideline, a standard error of 50% will probably give sufficient 
precision for many purposes. For estimates with a standard error of 50%, the mean of 
five estimates will have a 95% confidence interval of approximately 45% of the 
estimate each side of the mean, if estimates are approximately normally distributed. 
Using this guideline, method 1 is suitable for parasitaemias over 2% and method 2 
for parasitaemias over 0.2%. For sufficiently large sample sizes method 1 could be 
used for parasitaemias above 0.2% and method 2 for parasitaemias as low as 0.02%. 
By the same guideline, method 3 is precise when at least 10 parasites and red blood 
cells are sampled. If greater precision were required, the minimum parasitaemias for 
which methods 1 and 2 are acceptable would be higher. 
For each method, the standard error of estimates can be reduced by increasing the 
sample size as indicated in Table 4.2. However, in each case the reduction in the 
standard error is successively less the more sample size is increased. Therefore, for 
most purposes, it is not worth increasing the sample size beyond a certain point, 
given the increased sampling time required. From this perspective, I suggest that 
when estimating parasitaemias by method 1, 1200 red blood cells should be sampled 
(Figure 4. 1, page 95). Similarly for method 2, I suggest that 1 field should be 
sampled for red blood cells (Figure 4.3, page 102) and 60 fields should be sampled 
for parasites (Figure 4.4, page 102) when estimating parasitaemias. For this sample 
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size, bias should not affect the accuracy of estimates. However when the mean of 
several estimates is going to be taken, I would recommend sampling a larger area for 
red blood cells in order to eliminate the effects of bias. When the mean of five 
estimates is going to be taken, I suggest sampling 1 + fields for red blood cells. For 
method 3, the time required for sampling depends on the parasitaemia as well as the 
sample size. The extra time needed for large samples is much smaller when 
parasitaemia is high than when it is low. Therefore the sampling time for the lowest 
parasitaemias should influence the choice of sample size for method 3. A quick 
approach is to choose the number of parasites expected to occur within the maximum 
acceptable sample area for the lowest parasitaemia of interest. The number of red 
blood cells sampled should be the same as the number of parasites sampled, because 
the number of parasites sampled and the number of red blood cells sampled have 
similar effects on the standard error of estimates. I suggest that 20 parasites (Figure 
4.6, page 107) and 20 red blood cells (Figure 4.7, page 107) should be sampled for 
method 3. Twenty parasites can, on average, be sampled from 150 fields with an 
average density of 700 red blood cells per field when parasitaemia is 0.02%. Table 
4.3 gives the standard errors of parasitaemia estimates for these sample sizes. 
Which method produces parasitaemia estimates with the lowest standard error 
depends on the parasitaemia being measured (Table 4.3). When parasitaemia is 70%, 
estimates from method 1 usually have a smaller standard error than method 2 
estimates, if there is a low density of red blood cells per field and a small area is 
sampled for red blood cells. But the standard errors are quite similar when there is a 
high density of red blood cells per field and more than I a field is sampled for red 
blood cells. When parasitaemia is 20%, estimates from method 1 and 2 have similar 
standard errors although method 2 estimates have a smaller standard error when there 
is a high density of red blood cells per field and more than I a field is sampled for 
red blood cells. Parasitaemia estimates from method 3 have a much larger standard 
error than estimates from the other two methods when parasitaemia is 70% or 20%. 
For a 2% parasitaemia, method 2 nearly always produces estimates with the smallest 
error, and method 1 estimates usually have a smaller standard error than estimates 
from method 3. However, the standard errors of estimates from methods 1 and 3 are 
Estimating parasitaemias 	 111 
similar for a 2% parasitaemia when 50 parasites and red blood cells are sampled. 
Method 2 estimates also nearly always have the smallest standard error when 
parasitaemia is 0.2%, although the standard error of estimates from method 3 are 
similar when 0.05 of a field is sampled for red blood cells under method 2 and 50 
parasites and 50 red blood cells are sampled for method 3. Estimates from method 1 
nearly always have the largest standard error when parasitaemia is 0.2%. For a 
0.02% parasitaemia, methods 2 and 3 produce parasitaemia estimates with a similar 
standard error, and estimates from method 1 have much larger standard errors. 











0.2% 64% 10-15% 33% 
0.02% 204% 29-46% 33% 
Table 4.3. Example standard errors of parasitaemia estimates. Standard errors are reported 
as percentages of the actual values. Values for method 1 are for samples of 1200 red blood 
cells and were calculated from equation 4.7). For method 2, values are for samples of 60 
fields for parasites and 1 fields for red blood cells at densities of 400-1000 red blood cells per 
field and were calculated from equation 4.28). Values in brackets are corresponding errors 
for sampling 1 - fields for red blood cells, where these are different. Values for method 3 are 
for samples of 20 parasites and 20 red blood cells and were calculated from equation 4.36). 
The advantage of method 3 is when parasitaemias vary considerably, which is typical 
for in vivo infections. Method 3 standardises the error of parasitaemia estimates such 
that the standard error is a fixed proportion of the estimate irrespective of the actual 
parasitaemia. Although the standard error of estimates for low parasitaemias can be 
decreased for method 2 by increasing the sample size, this requires preliminary 
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counting to first assess parasitaemia and is unwieldy when parasitaemia is very 
variable. Method 3 inherently adjusts the sampling effort to suit the level of 
parasitaemia as the sample is taken. It would not be practical to use method 1 to 
estimate parasitaemia when it is low. Method 3 is a very efficient way of sampling 
when parasitaemias appreciably vary. The increased time spent on sampling at low 
parasitaemias is offset by considerably shorter sampling times when parasitaemia is 
high. In contrast, sampling time for methods 1 and 2 will tend to be insufficient when 
parasitaemia is low, and longer than necessary when parasitaemia is high. Sampling 
using the same principles as method 3 has been demonstrated to reduce sampling 
effort by 50% or more in crop pest management (Pedigo and Zeiss, 1996). 
When parasitaemias are fairly constant, the discussion on the relative size of the 
standard errors of estimates suggests that methods 1 or 2 are preferable to method 3 
for parasitaemias over 0.2%. However, when parasitaemia is limited to these levels, 
the number of parasites and red blood cells sampled under method 3 can always be 
increased, without the sampling time becoming too long, to make the precision of 
estimates more comparable to the other two methods. I would recommend using 
method 1 when parasitaemias are particularly high, in the order of 20%. However I 
would suggest method 3, with a suitable number of parasites and red blood cells 
sampled, in preference to method 2 for all lower parasitaemias, because it is 
unbiased. To conclude, I suggest that estimates of malaria parasitaemia from smears 
should be made by sampling a fixed number of parasites and a fixed number of red 
blood cells, except when parasitaemia is very high. 
Estimating parasitaemias 	 113 
5. Estimating gametocyte investment from thin blood 
smears; comparing a new method of counting parasites 
with traditional methods 
5.1. Introduction 
Gametocyte investment can be assessed from two blood smears taken an appropriate 
interval apart (Carter and Miller, 1979; Mons, 1986; Buckling et al., 1999b). 
Asexuals and indistinguishable young gametocytes are sampled in the first smear. 
Mature gametocytes that have developed from the same cohort of parasites are 
sampled in a second, later smear. Gametocyte investment can then be estimated as 
the proportion of asexuals (which includes indistinguishable young gametocytes) that 
became mature gametocytes. Gametocyte investment cannot, in general, be measured 
by the proportion of parasites that are gametocytes in any one smear because usually 
a smear will not contain distinguishable asexuals and gametocytes from the same 
parasite cohort. In many cases, this is because gametocytes cannot be identified by 
light microscopy until after the age when asexual parasites have replicated 
(Gamham, 1966; Mons, 1986; Gautret eta!, 1996a, b, c). First stage Plasmodium 
falciparum gametocytes can be identified at about the age that asexuals become 
schizonts (Day et al., 1998), but at this age parasites of both types are not 
representatively sampled in smears from in vivo infections, because they sequester 
from the peripheral blood (Garnham, 1966). In P. falciparum cultures, gametocyte 
investment can only be accurately measured from asexual and gametocyte numbers 
in the same smear if cultures are synchronised and smears taken just before schizont 
rupture. Only when cultures are synchronised will the first stage gametocytes in the 
smear be about the same age as the schizonts, because P. falciparum gametocytes 
remain in this stage for 24 hours (Day etal., 1998) whereas schizonts persist a much 
shorter time (Gravenor and Kwiatkowski, 1998). 
For synchronous infections, gametocytes should be sampled when they are at a stage 
that lasts less than the asexual cycle period, to ensure that they belong to a single 
parasite cohort. When infections are asynchronous, gametocytes and asexuals should 
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be sampled at stages of equal duration. For asynchronous infections, the time interval 
between the two smears must also exactly equal the time it takes parasites to develop 
from one stage to the next. The timing of the smears does not have to be as precise 
when infections are synchronous. 
Parasite counts from smears are measured relative to red blood cell numbers. 
Therefore, to estimate gametocyte investment from smears taken at different times, 
changes in red blood cell density between these times needs to be taken into account. 
Gametocyte investment can then be measured by (Buckling et al., 1999b): 
gametocyte conversion ratio = 
ratio of gametocytes to red blood cells at time of 2 n smear 
ratio of asexuals to red blood cells at time ofF' smear 
red blood cell density at time of 2u11  smear 
red blood cells density at time of is  smear 
Similar measures, but which omitted the effect of red blood cell densities, have been 
previously defined and called gametocyte conversion rates (Carter and Miller, 1979; 
Mons, 1986). 
Here I investigate the accuracy and precision of estimates of the gametocyte 
conversion ratio from the three counting methods that I considered in chapter 4. 
Following the same approach as in chapter 4, I determine the bias in estimators, the 
standard error of estimates and the relative size of any bias compared to the standard 
error. I establish when the bias and standard error will be large and how they can be 
most efficiently reduced by increasing sample size. The results are much more 
complex than for estimating parasitaemia or gametocytaemia. I conclude with an 
overall comparison of the three sampling methods. 
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5.2. Methods 
I examine estimates of the gametocyte conversion function, which I define as: 
gametocyte conversion function = 
ratio of gametocytes to red blood cells at time 0f 2nd smear 
ratio of asexuals to red blood cells at time off' smear 
The gametocyte conversion function multiplied by the ratio of red blood cell 
densities at the time the two smears were taken gives the gametocyte conversion 
ratio. As in chapter 4, I report the bias in estimators and the standard error of 
estimates as percentages of the actual values. I assume that bias has a negligible 
effect on accuracy if the standard error is at least 10 times the bias, or equivalently, 
the bias is less than 0.1 times the standard error (Cochran, 1977). As it is unlikely 
that more than one parasite develops to maturity in cells that are multiply infected, 
parasites in multiply-infected cells should be treated as a single parasite. I use the 
term ring stages to mean cells infected with asexuals and indistinguishable young 
gametocytes, and the term gametocytes to mean cells infected with mature 
gametocytes. I call the smear sampled for gametocytes, the gametocyte smear, and 
the smear sampled for ring stages, the ring stage smear. I investigate sample sizes of 
200-2000 red blood cells, 10-100 fields for parasites and 0.05-3 fields for red blood 
cells and 5-50 parasites. I concentrate my analysis on gametocytaemias in the range 
2-0.02% and ring stage parasitaemias in the range 20-0.2% and at least 10 times the 
gametocytaemia, based on the typical values that occur during P. chabaudi infections 
in mice. I consider red blood cell densities of 400-1000 per field. I make the same 
assumptions as in chapter 4 (page 91). 
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5.2.1. 	Key to symbols 
A key to the symbols used in this chapter is given in Table 5.1. 
F 	gametocyte conversion function estimator 
S 	 number of gametocytes counted 
C r number of red blood cells sampled in ring stage smear 
C , 	number of red blood cells sampled in gametocyte smear 
r number of ring stages counted 
gametocyte conversion function 
average value of x over all possible non-overlapping counts 
E[A] 	average value of function A over all possible non-overlapping counts 
a2 (x) 	variance of x 
b(F) bias in estimator F 
A 	actual ring stage parasitaemia 
F actual gametocytaemia 
fc 	number of fields sampled for red blood cells in gametocyte smear 
1/dy fraction of a field sampled for red blood cells in gametocyte smear 
fr 	 number of fields sampled for ring stages 
number of fields sampled for gametocytes 
fIr 	
number of fields sampled for red blood cells in ring stage smear 
1/dr fraction of a field sampled for red blood cells in ring stage smear 
c(x,y) covariance of x and y 
61 	average number of red blood cells per field in gametocyte smear 
average number of red blood cells per field in ring stage smear 
a 	area sampled for red blood cells in gametocyte smear 
a,. 	area sampled for ring stages 
as area sampled for gametocytes 
a,. 	area sampled for red blood cells in ring stage smear 
Table 5.1. Key to symbols. 
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5.3. Method 1: sampling a fixed number of red blood cells 
Parasites are counted in a fixed number of red blood cells. The gametocyte 




where s is the number of gametocytes counted, Cr  is the number of red blood cells 
sampled in the ring stage smear, C  is the number of red blood cells sampled in 
gametocyte smear and r is the number of ring stages counted. s and r are 
binomially distributed and are independent and Cr  and C  are constants. The actual 
gametocyte conversion function is given by: 
5.2) 
C siUr 
5.3.1. 	Bias in method 1 estimator 
Expanding equation 5.1) by a Taylor series about M, and /r  up to second order, 
gives the approximation: 
F-t-+(s-ii)--r---(r 	
C,. 	 C )2 
14 	5.3) 
C s/2r 	 CjAr 	 C s/hr 	 CJLT 
Hence: 
E[F]I+cy2  (r) -T 	 5.4) 
IAr 
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The expected value of (s - 	- r) is zero. Equation 5.4) shows that the method 1 
gametocyte conversion function estimator is biased. Substituting from equation 4.6) 
(page 94): 
b[F] 	i/i _' 
	 5.5) 
CA 
where A is the actual ring stage parasitaemia. Hence the method 1 gametocyte 
conversion function estimator overestimates the gametocyte conversion function. 
The bias can be very small to very large. The bias considerably increases when ring 
stage parasitaemia is low (Figure 5.1) but does not vary with gametocytaemia. 
The bias can be considerably decreased by sampling more red blood cells for ring 
stages (Figure 5.1). As more red blood cells are sampled for ring stages, each further 
increase in the number sampled has successively less effect on the bias. The bias is 







- - - - 0.2% ring stage parasitaemia 
—2% ring stage parasitaemia 
—20% ring stage parasitaemia 
0% F-rn 
200 	500 	800 	1100 1400 1700 2000 
number of red blood cells sampled for ring stages 
Figure 5.1. Predicted upward bias in the gametocyte conversion function estimator. Bias is 
given as a percentage of the actual value. Bias was calculated from equation 5.5). 
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5.3.2. 	Standard error of method 1 estimates 






CsI.2r 	 C s/lr 	 CsIlr 	Cj2,.) ] 	 5.6) 
= a2 (s)—+ cj 2 (r) 11S2 	 2 
Pr 
Therefore substituting from equation 4.6) (page 94), the standard error of method 1 
gametocyte conversion function estimates is given by: 
cr(F) _Vc, 11   +i) c r 	 5.7) 
where F is the actual gametocytaemia. The standard error can be small to very large. 
The standard error considerably increases when gametocytaemia is low (Figure 5.2). 
The standard error generally slightly increases when ring stage parasitaemia is low, 
although the effect can be considerable when very few red blood cells are sampled 
for ring stages and at least a moderate number of red blood cells are sampled for 
gametocytes (Figure 5.3). 
The standard error can be considerably decreased by sampling more red blood cells 
for gametocytes (Figure 5.2, Figure 5.3 and Figure 5.4). In general the standard error 
can only be slightly decreased by sampling more red blood cells for ring stages 
(Figure 5.2b) and Figure 5.3a)). However, when ring stage parasitaemia is not much 
higher than gametocytaemia, the standard error can be considerably decreased by 
sampling more red blood cells for ring stages if at least a moderate number of red 
blood cells are sampled for gametocytes (Figure 5.3b) and Figure 5.4). As more red 
blood cells are sampled for gametocytes and more red blood cells are sampled for 
ring stages, each further increase has successively less effect on the standard error. 
Estimating gametocyte investment 	 121 
200 red blood cells sampled for gametocytes ------500 red blood cells sampled for gametocytes 
1200 red blood cells sampled for gametocytes 2000 red blood cells sampled for gametocytes 
a) 	






200 	800 	1400 	2000 
number of red blood cells sampled for 
ring stages 
20% ring stage parasitaemia 
0.2% gametocytaemia 
150% . 




200 	800 	1400 	2000 
number of red blood cells sampled for 
ring stages 
Figure 5.2. Predicted standard error of gametocyte conversion function estimates. The 
standard error is given as a percentage of the actual value. In a) the ring stage parasitaemia 
is 20% and the gametocytaemia is 2% and in b) the ring stage parasitaemia is also 20% and 
the gametocytaemia is 0.2%. The standard error was calculated from equation 5.7). 
200 red blood cells sampled for ring stages 
1200 red blood cells sampled for ring stages 
500 red blood cells sampled for ring stages 
2000 red blood cells sampled for ring stages 
a) 	







200 	800 	1400 	2000 
number of red blood cells sampled for 
gametocytes 
0.2% ring stage parasitaemia 
0.02% gametocytaemia 
450% 
error standard :: 	 ::.........:.:::.... 
0% 
200 	800 	1400 	2000 
number of red blood cells sampled for 
gametocytes 
Figure 5.3. Predicted standard error of gametocyte conversion function estimates. The 
standard error is given as a percentage of the actual value. In a) the ring stage parasitaemia 
is 2% and the gametocytaemia is 0.02% and in b) the ring stage parasitaemia is 0.2% and 
the gametocytaemia is also 0.02%. The standard error was calculated from equation 5.7). 
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2% ring stage parasitaemia 
0.2% gametocytaemia 






200 	800 	1400 	2000 
number of red blood cells sampled for 
ring stages 
1200 red blood cells sampled for 
gametocytes 
2000 red blood cells sampled for 
gametocytes 
Figure 5.4. Predicted standard error of gametocyte conversion estimates. The standard error 
is given as a percentage of the actual value. The ring stage parasitaemia is 2% and the 
gametocytaemia is 0.2%. The standard error was calculated from equation 5.7). 
The standard error can be less than 10 times the bias. For a given ring stage 
parasitaemia, the standard error considerably decreases compared to the bias when 
the ratio of ring stage parasitaemia to gametocytaemia is low (Figure 5.5). For a 
given ratio of ring stage parasitaemia to gametocytaemia, the bias considerably 
increases compared to the standard error when ring stage parasitaemia is low (Figure 
5.6). 
The bias can be considerably reduced relative to the standard error by sampling more 
red blood cells for ring stages (Figure 5.6 and Figure 5.5). The standard error 
considerably decreases relative to the bias when more red blood cells are sampled for 
gametocytes (Figure 5.5 and Figure 5.6). 
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200 red blood cells sampled for ring stages ------500 red blood cells sampled for ring stages 
1200 red blood cells sampled for ring stages 2000 red blood cells sampled for ring stages 
	
a) 	










200 	800 	1400 	2000 
number of red blood cells sampled for 
gametocytes 
b) 	








200 	800 	1400 	2000 
number of red blood cells sampled for 
gametocytes 
Figure 5.5. Predicted size of the standard error of gametocyte conversion function estimates 
relative to the bias in the estimator. In a) the ring stage parasitaemia is 2% and is 100 times 
the gametocytaemia and in b) the ring stage parasitaemia is also 2% and is 10 times the 
gametocytaemia. The standard error was calculated from equation 5.7) and the bias from 
equation 5.5). 
200 red blood cells sampled for gametocytes ------500 red blood cells sampled for gametocytes 
1200 red blood cells sampled for gametocytes 2000 red blood cells sampled for gametocytes 
a) 	








200 	800 	1400 	2000 
number of red blood cells sampled for 
ring stages 
0.2% ring stage parasitaemia 
0.02% gametocytaemia 
bias 	0.8 relative 
standard 0.4 
error 	0.2 	 . 
0 
- ....V: 
200 	800 	1400 	2000 
number of red blood cells sampled for 
ring stages 
Figure 5.6. Predicted size of the bias in the gametocyte conversion function estimator 
relative to the standard error of estimates. In a) the ring stage parasitaemia is 2% and is 10 
times the gametocytaemia and in b) the ring stage parasitaemia is 0.2% and is also 10 times 
the gametocytaemia. The bias was calculated from equation 5.5) and the standard error from 
equation 5.7). 
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5.4. Method 2: sampling a fixed number of fields 
Parasites are counted in a fixed number of fields and red blood cells are counted in a 






where fc, is the number of fields sampled for red blood cells in the gametocyte 
smear and 1/d5 is the fraction of each of those fields that is examined for red blood 
cells, fr is the number of fields sampled for ring stages, f is the number of fields 
sampled for gametocytes, fCr is the number of fields sampled for red blood cells in 
the ring stage smear and 1/dr  is the fraction of each of those fields that is examined 
for red blood cells. s, CrI c5 and r are Poisson distributed and fc,, fr' dr d5 , f5 and 
are constants. s and c are not independent, but are independent of Cr  and r. 
Similarly, Cr  and r are not independent, but are independent of s and c5 . The actual 
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5.4.1. 	Bias in method 2 estimator 
Expanding equation 5.8) by a Taylor series about M, ik,' itt. and I2r  up to second 
order, gives the approximation: 
/1f fr/icr dr 	fc, fr/Ac, d r  F= 	+(s—u5 ) 	 +( 	- r ,) 
_ikf fd  




(r - /Ar) 
!.2f fr/Ac, d r  
It, f" 
	df/A 
+ (s - /As)(Cr - i,)_
f, f rdr  
- (s - /AXc3 - 	) 
fc, fr/Ac, d r  
dsfs/Ac/Arfc df 	/Arfc, 
-  - (s - /A3)(r - /Ar) 	
f, fr/Ac, dr 	
(Cr - c, )(c - 
fr2!r 
d5f,/if 
- (Cr - 	)(r - /r) 	
/A.fc, f rdr  
+ (c - 	)(r - /Ar ) dfji 
/Af fr/Ac,'r 
d5fji,uf 
+ (c - /A, 
)2 ikf, fr/Ac, dr
.  + (r - Mr 





E[F]cI—U(S,C) 	— a(C r ,r) 	+a (c)---+a (r)-- 
/Ac, Pr 	/k 	/Ar 
5.10) 
5.11) 
Therefore the method 2 gametocyte conversion function estimator is biased. 
Substituting from equations 4.22) (age 99), 4.13) (page 97) and 4.26) (page 100): 
b(F) 	F A 	1 	1 
5.12) 
Its Pr 	/Ac, 	Pr 
Equation 5.12) can also be written as: 
b[F] _ I ds 	1 	1 	
5.13) - I 
ôsfc f) rfrL 
- - +  
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where ô is the average number of red blood cells per field in the gametocyte smear 
and or  is the average number of red blood cells per field in the ring stage smear. 
Therefore the method 2 gametocyte conversion function estimator overestimates the 
gametocyte conversion function. The bias is fairly small. The bias considerably 
increases when ring stage parasitaemia is low (compare Figure 5.7 with Figure 5.8). 
When ring stage parasitaemia is high, the bias considerably increases when there are 
few red blood cells per field in the gametocyte smear (Figure 5.7a)). When ring stage 
parasitaemia is moderately high, the bias also usually considerably increases when 
there are few red blood cells per field in the gametocyte smear, although this effect is 
small when a large area is sampled for red blood cells in the gametocyte smear and 
few fields are sampled for ring stages (Figure 5.7b)). But when ring stage 
parasitaemia is low, there is little increase in bias when there are few red blood cells 
per field in the gametocyte smear, except when a very small area is sampled for red 
blood cells in the gametocyte smear. 
10 fields sampled for ring stages 	------10 fields sampled for ring stages 
400 red blood cells per field in both smears 	1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
100 fields sampled for ring stages 
400 red blood cells per field in both smears 
100 fields sampled for ring stages 
1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 





0 	 1 	 2 	3 
total area sampled for red blood cells on 




0 	1 	2 	3 
total area sampled for red blood cells on 
smear sampled for gametocytes 
Figure 5.7. Predicted upward bias in the gametocyte conversion function estimator when 60 
fields are sampled for gametocytes. Bias is given as a percentage of the actual value. In a) 
the ring stage parasitaemiais 20% and in b) the ring stage parasitaemia is 2%. Bias was 
calculated from equation 5.13). 
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When ring stage parasitaemia is low, the bias usually considerably increases when 
there are few red blood cells per field in the ring stage smear (Figure 5.8). When ring 
stage parasitaemia is moderately high, the bias also considerably increases when 
there are few red blood cells per field in the ring stage smear if a large area is 
sampled for red blood cells in the gametocyte smear or when a smaller area is 
sampled for red blood cells in the gametocyte smear if few fields are sampled for 
ring stages. The number of red blood cells per field in the ring stage smear generally 
has little effect on bias when ring stage parasitaemia is high. 
0.05 of a field sampled for red blood cells 
in gametocyte smear 
400 red blood cells per field in both smears 
0.2% ring stage parasitaemia 
1 field sampled for red blood cells 
in gametocyte smear 





0.05 of a field sampled for red blood cells 
in gametocyte smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
1 field sampled for red blood cells 
in gametocyte smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
 
10 	40 	70 	100 
number of fields sampled for ring stages 
Figure 5.8. Predicted upward bias in the gametocyte conversion function estimator when 60 
fields are sampled for gametocytes. Bias is given as a percentage of the actual value. The 
ring stage parasitaemia is 0.2%. Bias was calculated from equation 5.13). 
The bias can be considerably reduced by sampling a larger area for red blood cells in 
the gametocyte smear (Figure 5.7 and Figure 5.8). When ring stage parasitaemia is 
low, the bias can be considerably decreased by sampling more fields for ring stages 
(Figure 5.8). When ring stage parasitaemia is moderately high, the bias can also 
usually be considerably reduced by sampling more fields for ring stages (Figure 
5.7b)). But when ring stage parasitaemia is high, the bias cannot usually be 
significantly reduced by sampling more fields for ring stages, except when a large 
area is sampled for red blood cells in the gametocyte smear (Figure 5.7a)). As the 
area sampled for red blood cells in the gametocyte smear and the number of fields 
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sampled for ring stages is increased, each further increase has successively less effect 
on the bias. The bias very slightly increases with the number of fields sampled for 
gametocytes. Sampling a larger area for red blood cells in the ring stage smear has no 
effect on bias 
5.4.2. 	Standard error of method 2 estimates 
From equations 5.10) and 5.11), ignoring second order differentials: 
((s - IL) 
df/I/If + 	' df4f 
fc,fr/c,r (c/I  )_
/Isfc, fr'r 1 
a2 (F)E 	 2 1 
(c5
' 
) 	- (r - /IPrfc,
fr/Ic, d r 	/If fr/Ic, d r I 
r) df/I /Ifc,)] 
- -  
= cr2 (:)20(sc) 
+u (c)--+a (r)-- 
Pr  
+ U2 (C r ) 	- 2cr(r,cr ) 
lIc, 	 /Ic, Pr 
5.14) 
Therefore substituting from equations 4.26) (page 100), 4.22) (page 99) and 4.13) 
(page 97), the standard error of method 2 gametocyte conversion function estimates 
is approximately given by: 
0(F) 	1 	F 	1 	A 	1 	1 
	
-2—+--2—+—+— 	 5.15) 
1j 10, /Is 	/Ic, /Ir 	Pc, 	Pr 
Equation 5.15) can also be written as: 
a(F) Il 1 1 	d ' 	 1(1 fi 	 5.16) 2 +--I ~ (D 	y( ( - 	
fe,) ôrJ'r( A 	) fe,) 
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The standard error can be small to large. The standard error considerably increases 
when gametocytaemia is low (Figure 5.9). The standard error also nearly always 
considerably increases when there are few red blood cells per field in the gametocyte 
smear (Figure 5.10). But the number of red blood cells per field in the gametocyte 
smear has only a small effect on the standard error when gametocytaemia is high and 
a small area is sampled for red blood cells in the ring stage smear, or when 
gametocytaemia is moderately high, a small area is sampled for red blood cells in the 
ring stage smear and many fields are sampled for gametocytes (Figure 5.11). 
0.05 of a field sampled for red blood cells 
in ring stage smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
1 field sampled for red blood cells 
in ring stage smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
0.05 of a field sampled for red blood cells 
in ring stage smear 
400 red blood cells per field in both smears 
1 field sampled for red blood cells 
in ring stage smear 
400 red blood cells per field in both smears 
20% ring stage parasitaemia 	 20% ring stage parasitaemia 





10 	40 	70 	100 






10 	40 	70 	100 
number of fields sampled for 
gametocytes 
Figure 5.9. Predicted standard error of gametocyte conversion function estimates when 60 
fields are sampled for ring stages and 1 field is sampled for red blood cells in the gametocyte 
smear. The standard error is given as a percentage of the actual value. In a) the ring stage 
parasitaemia is 20% and the gametocytaemia is 0.2% and in b) the ring stage parasitaemia 
is also 20% and the gametocytaemia is 0.02%. The standard error was calculated from 
equation 5.16). 
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0.05 of a field sampled for red blood cells ------0.05 of a field sampled for red blood cells 
in gametocyte smear 	 in gametocyte smear 
400 red blood cells per field in both smears 	1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
1 field sampled for red blood cells 
in gametocyte smear 
400 red blood cells per field in both smears 
1 field sampled for red blood cells 
in gametocyte smear 
1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
2% ring stage parasitaemia 






10 	40 	70 	100 
number of fields sampled for ring 
stages 
0.2% ring stage parasitaemia 




0% . . 
10 	40 	70 	100 
number of fields sampled for ring 
stages 
Figure 5.10. Predicted standard error of gametocyte conversion function estimates when 60 
fields are sampled for gametocytes and I a field is sampled for red blood cells in the ring 
stage smear. The standard error is given as a percentage of the actual value. In a) the ring 
stage parasitaemia is 2% and the gametocytaemia is 0.02% and in b) the ring stage 
parasitaemia is 0.2% and the gametocytaemia is also 0.02%. The standard error was 
calculated from equation 5.16). 
The standard error generally slightly increases when ring stage parasitaemia is low. 
But the standard error considerably increases when ring stage parasitaemia is low if 
few fields are sampled for ring stages, gametocytaemia is low, the density of red 
blood cells in the gametocyte smear is similar or higher than the density of red blood 
cells in the ring stage smear and at least a moderate number of fields are sampled for 
gametocytes (Figure 5.10). The standard error also considerably increases when ring 
stage parasitaemia is low if gametocytaemia is moderately high, few fields are 
sampled for ring stages, the density of red blood cells in the gametoáyte smear is 
similar or higher than the density of red blood cells in the ring stage smear, at least a 
moderate number of fields are sampled for gametocytes and the area sampled for red 
blood cells in each smear is not very small. 
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0 	1 	2 	3 
number of fields sampled for red blood 
cells in ring stage smear 
10 fields sampled for gametocytes 
400 red blood cells per field in both smears 
100 fields sampled for gametocytes 
400 red blood cells per field in both smears 
10 fields sampled for gametocytes 
1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
100 fields sampled for gametocytes 
1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
Figure 5.11. Predicted standard error of gametocyte conversion function estimates when 60 
fields are sampled for ring stages and 1 field is sampled for red blood cells in the gametocyte 
smear. The standard error is given as a percentage of the actual value. The ring stage 
parasitaemia is 2% and the gametocytaemia is 0.2%. The standard error was calculated 
from equation 5.16). 
In general, the standard error slightly increases when there are few red blood cells 
per field in the ring stage smear. However the standard error considerably increases 
when there are fewer red blood cells per field in the ring stage smear if 
gametocytaemia is high and a small area is sampled for red blood cells in the ring 
stage smear (Figure 5.12), or if gametocytaemia is moderately high, a very small area 
is sampled for red blood cells in the ring stage smear and at least a moderate number 
of fields are sampled for gametocytes (Figure 5.9a)). The standard error also 
considerably increases when there are few red blood cells per field in the ring stage 
smear if ring stage parasitaemia is low, gametocytaemia is not much less, many 
fields are sampled for gametocytes and few fields are sampled for ring stages. 
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- 0.05 of a field sampled for red blood cells 
in ring stage smear 
20% ring stage parasitaemia 	400 red blood cells per field in both smears 
2% gametocytaemia 
1 field sampled for red blood cells 
in ring stage smear 
30% 	 400 red blood cells per field in both smears 
standard 20% 0.05 of a field sampled for red blood cells 
error 10% in ring stage smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
0% 
0 	1 	2 	3 -1 field sampled for red blood cells 
in ring stage smear 
number of fields sampled for red blood 	1000 red blood cells per field in ring stage smear 
cells in gametocyte smear 	 400 red blood cells per field in gametocyte smear 
Figure 5.12. Predicted standard error of gametocyte conversion function estimates when 60 
fields are sampled for ring stages and gametocytes. The standard error is given as a 
percentage of the actual values. The ring stage parasitaemia is 20% and the 
gametocytaemia is 2%. The standard error was calculated from equation 5.16). 
The standard error can nearly always be considerably reduced by sampling more 
fields for gametocytes (Figure 5.9 and Figure 5.11). However sampling more fields 
for gametocytes only has a small effect on the standard error when gametocytaemia 
is high and a very small area is sampled for red blood cells in either or both smears. 
In the extremely unlikely case that gametocytaemia exceeded 50%, the standard error 
would very slightly increase with the number of fields sampled for gametocytes. 
When gametocytaemia is high, the standard error can be considerably reduced by 
sampling a larger area for red blood cells in either smear (Figure 5.12). The size of 
the effects is approximately the same (Figure 5.12). When gametocytaemia is 
moderately high, the standard error can also be considerably reduced by sampling a 
larger area for red blood cells in the gametocyte smear and usually can be reduced by 
sampling a larger area for red blood cells in the ring stage smear (Figure 5.11). 
However, sampling a larger area for red blood cells in the ring stage smear has only a 
small effect on the standard error when gametocytaemia is moderately high if few 
fields are sampled for gametocytes and the density of red blood cells is much higher 
in the ring stage smear than in the gametocyte smear (Figure 5.9a)). When 
gametocytaemia is low, sampling a larger area for red blood cells in either smear 
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generally has only a small to moderate effect on the standard error (Figure 5.9b) and 
Figure 5.10). However, sampling a larger area for red blood cells in the ring stage 
smear can considerably reduce the standard error when gametocytaemia is low if 
there is a much higher density of red blood cells in the gametocyte smear than the 
ring stage smear, many fields are sampled for gametocytes and at least a moderate 
number of fields are sampled for ring stages. 
Increasing the number of fields sampled for ring stages usually has only a small 
effect on the standard error. But the standard error can be considerably reduced by 
increasing the number of fields sampled for ring stages when ring stage parasitaemia 
is low, gametocytaemia is not much less, the density of red blood cells in the 
gametocyte smear is similar or higher than the density of red blood cells in the ring 
stage smear and at least a moderate number of fields are sampled for gametocytes 
(Figure 5.1Ob)). The standard error can also be considerably reduced by increasing 
the number of fields sampled for ring stages when ring stage parasitaemia is 
moderately high and gametocytaemia is not much less, the density of red blood cells 
in the gametocyte smear is similar or higher than the density of red blood cells in the 
ring stage smear, at least a moderate number of fields are sampled for gametocytes 
and the area sampled for red blood cells in each smear is not very small. When ring 
stage parasitaemia exceeds 50% the standard error very slightly increases with the 
number of fields sampled for ring stages. 
As the number of fields sampled for gametocytes and the number of fields sampled 
for ring stages is increased, each - further increase has successively less effect on the 
standard error. In probably all cases of interest, each successive increase in the area 
sampled for red blood cells in each smear has a smaller effect on the standard error. 
In particular, each successive increase in the area sampled for red blood cells in the 
gametocyte smear has a smaller effect on the standard error when either 
gametocytaemia is less than 50% or the area sampled for red blood cells in the 
gametocyte smear is less than of the area sampled for gametocytes. Similarly, each 
successive increase in the area sampled for red blood cells in the ring stage smear has 
a smaller effect on the standard error when either ring stage parasitaemia is less than 
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50% or the area sampled for red blood cells in the ring stage smear is less than - of 
the area sampled for ring stages. 
The standard error can be less than 10 times the bias. For a given ring stage 
parasitaemia, the standard error considerably decreases compared to the bias when 
the ratio of ring stage parasitaemia to gametocytaemia is low (Figure 5.13). 
0.05 of a field sampled for red blood cells ------0.05 of a field sampled for red blood cells 
in gametocyte smear 	 in gametocyte smear 
400 red blood cells per field in both smears 	1000 red blood cells per field in ring stage smear 400 red blood cells per field in gametocyte smear 
0.1 of a field sampled for red blood cells 
in gametocyte smear 
400 red blood cells per field in both smears 
0.1 of a field sampled for red blood cells 
in gametocyte smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
20% ring stage parasitaemia 
	





















0 	1 	2 	3 	 0 	1 	2 	3 
total field area sampled for red blood total field area sampled for red blood 
cells in ring stage smear 	 cells in ring stage smear 
Figure 5.13. Predicted size of the standard error of gametocyte conversion function 
estimates relative to the bias in the estimator when 60 fields are sampled for ring stages and 
100 fields are sampled for gametocytes. In a) the ring stage parasitaemia is 20% and is 1000 
times the gametocytaemia and in b) the ring stage parasitaemia is also 20% and is 100 
times the gametocytaemia. The standard error was calculated from equation 5.16) and the 
bias from equation 5.13). 
For the cases that are of interest, which are those where the standard error is about 10 
times the bias, the bias nearly always considerably increases relative to the standard 
error when there are few red blood cells per field in the gametocyte smear (Figure 
5. 14a)). But when ring stage parasitaemia is low, the standard error considerably 
decreases relative to the bias when there are many red blood cells per field in the 
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gametocyte smear if the area sampled for red blood cells in the gametocyte smear is 
not very small and few fields are sampled for gametocytes. The standard error also 
considerably decreases relative to the bias when there are many red blood cells per 
field in the gametocyte smear if ring stage parasitaemia is low, the area sampled for 
red blood cells in the gametocyte smear is large and a moderate number of fields are 
sampled for gametocytes or a large number of fields are sampled for gametocytes but 
at least a moderate number of fields are sampled for ring stages (Figure 5. 14b)). 
0.05 of a field sampled for red blood cells ------.05 of a field sampled for red blood cells 
i in gametocyte smear 	 n gametocyte smear 
400 red blood cells per field in both smears 	1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
1 field sampled for red blood cells 
in gametocyte smear 
400 red blood cells per field in both smears 
1 field sampled for red blood cells 
in gametocyte smear 
1000 red blood cells per field in gametocyte smear 
400 red blood cells per field in ring stage smear 
a) 
2% ring stage parasitaemia 
0.2% gametocytaemia 
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number of fields sampled for 	 number of fields sampled for 
gametocytes 	 gametocytes 
Figure 5.14. Predicted size of the standard error of gametocyte conversion function 
estimates relative to the bias in the estimator when 30 fields are sampled for ring stages and 
a field is sampled for red blood cells in the ring stage smear. In a) the ring stage 
parasitaemia is 2% and is 10 times the gametocytaemia and in b) the ring stage 
parasitaemia is 0.2% and is also 10 times the gametocytaemia. The standard error was 
calculated from equation 5.16) and the bias from equation 5.13). 
For a given ratio of ring stage parasitaemia to gametocytaemia, the bias sometimes 
considerably increases relative to the standard error when ring stage parasitaemia is 
low, and sometimes the standard error considerably decreases relative to the bias 
when ring stage parasitaemia is high. In those cases of interest, for a given ratio of 
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ring stage parasitaemia to gametocytaemia, the bias considerably increases relative to 
the standard error when ring stage parasitaemia is low if a large area is sampled for 
red blood cells in the gametocyte smear (Figure 5.14). When a very small area is 
sampled for red blood cells in the gametocyte smear, for a given ratio of ring stage 
parasitaemia to gametocytaemia, the standard error usually considerably decreases 
relative to the bias when ring stage parasitaemia is high (Figure 5.14). However 
when a very small area is sampled for red blood cells in the gametocyte smear and 
the ring stage parasitaemia is 10 times the gametocytaemia, the bias considerably 
increases relative to the standard error when ring stage parasitaemia is low in a 
number of cases. These are firstly, when the density of red blood cells is much higher 
in the gametocyte smear than in the ring stage smear, a very small area is sampled for 
red blood cells in the ring stage smear, and the number of fields sampled for ring 
stages is similar or less than the number of fields sampled for gametocytes. Secondly, 
when the density of red blood cells is higher in the gametocyte smear than in the ring 
stage smear, a large area is sampled for red blood cells in the ring stage smear, at 
least a moderate number of fields are sampled for gametocytes and few fields are 
sampled for ring stages (Figure 5.14). Thirdly, when the densities of red blood cells 
are similar on both smears, few fields are sampled for ring stages and many fields are 
sampled for gametocytes. When the ring stage parasitaemia is 100 times the 
gametocytaemia and a very small area is sampled for red blood cells in the 
gametocyte smear, the bias also considerably increases relative to the standard error 
when ring stage parasitaemia is low if the density of red blood cells is much higher in 
the gametocyte smear then in the ring stage smear, few fields are sampled for ring 
stages, many fields are sampled for gametocytes and a very small area is sampled for 
red blood cells in the ring stage smear. 
The number of red blood cells per field in the ring stage smear usually has little 
effect on the relative sizes of the standard error and the bias. However when ring 
stage parasitaemia is low, the bias nearly always considerably increases relative to 
the standard error when there are few red blood cells per field in the ring stage smear 
if the number of fields sampled for ring stages is not high. The bias also considerably 
increases relative to the standard error when there are few red blood cells per field in 
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the ring stage smear if gametocytaemia is moderately high, a very small area is 
sampled for red blood cells in the ring stage smear and at least a moderate number of 
fields are sampled for gametocytes (Figure 5.13) and if ring stage parasitaemia is not 
much higher than gametocytaemia, the number of fields sampled for ring stages is 
not very small. But, the standard error considerably decreases relative to the bias 
when there are many red blood cells per field in the ring stage smear if 
gametocytaemia is high and a small area is sampled for red blood cells in the ring 
stage smear (Figure 5.15). 
0.05 of a field sampled for red blood cells in 
gametocyte smear 
400 red blood cells per field in both smears 
20% ring stage parasitaemia 
2% gametocytaemia 
...... 0.05 of a field sampled for red blood cells in 
gametocyte smear 
1000 red blood cells per field in ring stage smear 
0.2 i.......................................................... 400 red blood cells per field in gametocyte smear 
bias 
relative 	J 	 0.2 of a field sampled for red blood cells in to 0.1 gametocyte smear standard 	 400 red blood cells per field in both smears 
error Ii 
0 
0 	1 	2 	3 
total field area sampled for red blood 
cells in ring stage smear 
0.2 of a field sampled for red blood cells in 
gametocyte smear 
1000 red blood cells per field in ring stage smear 
400 red blood cells per field in gametocyte smear 
Figure 5.15. Predicted size of the bias in the gametocyte conversion function estimator 
relative to the standard error of estimates when 60 fields are sampled for ring stages and 
gametocytes. The ring stage parasitaemia is 20% and the gametocytaemia is 2%. The bias 
was calculated from equation 5.13) and the standard error from equation 5.16). 
The bias can nearly always be considerably reduced relative to the standard error by 
sampling a larger area for red blood cells in the gametocyte smear (Figure 5.14 and 
Figure 5.15). 
When ring stage parasitaemia is low, the bias can be considerably reduced relative to 
the standard error by sampling more fields for ring stages. The bias can also usually 
be considerably reduced relative to the standard error by sampling more fields for 
ring stages when ring stage parasitaemia is moderately high (Figure 5.16). But when 
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the density of red blood cells is much higher in the ring stage smear than in the 
gametocyte smear and a very small area is sampled for red blood cells in the 
gametocyte smear, increasing the number of fields sampled for ring stages has only a 
small effect on the size of the bias relative to the standard error for moderate ring 
stage parasitaemias. Sampling more fields for ring stages has very little effect on the 
size of the bias relative to the standard error, for the cases of interest, when ring stage 
parasitaemia is high. 
2% ring stage parasitaemia 
0.02% gametocytaemia 
0.05 of a field sampled for red blood cells in 
ring stage smear 












1 field sampled for red blood cells in 
ring stage smear 
10 fields sampled for gametocytes 
0.05 of a field sampled for red blood cells in 
ring stage smear 
100 fields sampled for gametocytes 
1 field sampled for red blood cells in 
ring stage smear 
100 fields sampled for gametocytes 
  
10 	40 	70 	100 
fields sampled for ring stages 
Figure 5.16. Predicted size of the bias in the gametocyte conversion function estimator 
relative to the standard error of estimates when 1 field is sampled for red blood cells in the 
gametocyte smear and there are 1000 red blood cells per field in the gametocyte smear and 
400 red blood cells per field in the ring stage smear. The ring stage parasitaemia is 2% and 
the gametocytaemia is 0.02%. The bias was calculated from equation 5.13) and the standard 
error from equation 5.16). 
The standard error nearly always considerably decreases relative to the bias when 
more fields are sampled for gametocytes (Figure 5.14 and Figure 5.16). But 
increasing the number of fields sampled for gametocytes has little effect on the size 
of the standard error relative to the bias, for the cases of interest, when ring stage 
parasitaemia is high and gametocytaemia is not much less. 
When gametocytaemia is high, the standard error considerably decreases relative to 
the bias when a larger area is sampled for red blood cells in the ring stage smear 
(Figure 5.15). The standard error usually also considerably decreases relative to the 
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bias when a larger area is sampled for red blood cells in the ring stage smear if 
gametocytaemia is moderately high (Figure 5. 13b)), although the effect is small 
when the density of red blood cells is much higher in the ring stage smear than in the 
gametocyte smear and few fields are sampled for gametocytes. When 
gametocytaemia is low, increasing the area sampled for red blood cells in the ring 
stage smear usually only slightly or moderately reduces the standard error relative to 
the bias. However the standard error considerably decreases relative to the bias when 
a larger area is sampled for red blood cells in the ring stage smear, for low 
gametocytaemias, if the density of red blood cells is higher on the gametocyte smear 
than the ring stage smear and a moderate or large number of fields are sampled for 
gametocytes (Figure 5.16) and if ring stage parasitaemia is not much higher than 
gametocytaemia, a moderate or large number of fields are sampled for ring stages. 
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5.5. Method 3: sampling a fixed number of parasites 
Fields are sampled until a fixed number of parasites are counted. From a different 
part of the smear, fields are sampled until a fixed number of red blood cells have 
been counted. The gametocyte conversion function estimator is: 
F= (s-1)ac ar (c r  —1) 	
5.17) 
a5c5ra 
where ac, is the area sampled for red blood cells in the gametocyte smear, ar  is the 
area sampled for ring stages, a  is the area sampled for gametocytes and a c , is the 
area sampled for red blood cells in the ring stage smear. a,  a,.,  a  and ac, are 
Erlang distributed (Knight, 1965) and are independent and s, C,., c and r are 




!2a, C sr/.La 
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5.5.1. 	Bias in method 3 estimator 
The Taylor series expansion of equation 5.17) about S//ia , /ia ' /ia, and c,  /M.,  can 
be written as: 
F= 
S/ia/ia,Cr __________ ((s—I) 	s _____ -- /ia, /ia,C r 	 \ 	S/ia  C r 
/ia,CsT/ia,, as 	pa, ) 
/ia, 
) Cf/i a, 	 /ia,Cf/ia, 
+(ar 	/iar 
s/ia, Cr 	+ ((Cr - i) :ri. S/ia 	/ia, 











/ia, ' Cf/it, a5 	pa, ) Cf/ia 
(S - 1) . (Cr - i) Cr_  /ia, /iar SC 
a3 
+ ' 
/ia, a  /ia,, ) 




• ac, 	/ia 
)((C r -1)_ 	j _S/ia, 	+ (ar - /ia, )1 - 	 Cr pa,  C 5 a a 	/ia,, ) Ma ,  Cf 
• 
( (s—i) 	s 	 )( I - - (ac, - /ia, ar - /ia,)a5 	/ia, C5T/ia 
+1 	 (ac, /ia,
- 1) 	. (Cr 	
) 
/ia,
a3 	/ia ' 	 a P., Cf 
((s—i) 	 (C r i) 	c 	/ia, ~ 1 a5 	/ia,) 	 a 	/ia,, 
) 
Cf 
-- I(ar — /ia ,)I 
 
+ (a 	/ia,, )(ar - /ia, 
)((Cr  —1) 	S 
a Cr /ia,, ) /ia, C3T 
( (s—i) 	 (( _ —i) 	Cr 	i 1 s (a,, /ia )(ar /ia,)a3 	/ia 	 a 	/ia,, ) Cf 
5. 19) 
Under assumptions i), 3) and 4) (page 91) and inverse sampling, (s - Was is an 
unbiased estimator of S//ia  and (Cr - I)lac, is an unbiased estimator of Crly"
cr 
 
(Sandelius, 1950; Anscombe, 1953). Hence: 
E[F]=J? 	 5.20) 
142 	 Chapter 5 
Therefore the method 3 gametocyte conversion function estimator is unbiased. 
5.5.2. 	Standard error of method 3 estimates 
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Under assumptions 1) and 3) (page 91): 
Or 
2(Cr 
ac, I(Crlya_ )2 = C
r  —2 
provided C r  > 2 (Sandelius, 1950; Anscombe, 1953). 
5.21) 
5.22) 
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As ar is Erlang distributed: 
a2 (ar) = 
	
5.23) 
(Hastings and Peacock, 1975). Hence, substituting from equations 4.34) (page 105), 
4.35) (page 106), 5.22) and 5.23): 
	
Ii 	1 	1 	1 	1 	1 	1 
+ 	+ 	+ 
Is_2 C 5 r Cr  -2 c5 (s-2) r(s_2) (S2)(C r _2) 
or(F) 	1 	1 	1 	1 	 1 
= + 	+ 	+ 	 5.24) 
J cr C s (C r  -2) r(Cr  -2) c 5r(s-2) Cs (S 2)(C r 2) 
1 	 1 1 
r(s - 2)(C r 
 -2) + _______ + 
Csr(cr - 2) c5r(s - 2)(C r -2) 
The standard error can be moderate to large. The standard error does not vary with 
gametocytaemia or ring stage parasitaemia. The standard error can be considerably 
decreased by sampling more gametocytes (Figure 5.17), red blood cells in the ring 
stage smear (Figure 5.18), ring stages (Figure 5.19), or red blood cells in the 
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Figure 5.17. Predicted standard error of gametocyte conversion function estimates. The 
standard error is given as a percentage of the actual value. The standard error was 
calculated from equation 5.24). 
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Figure 5.18. Predicted standard error of gametocyte conversion function estimates. The 
standard error is given as a percentage of the actual value. The standard error was 
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Figure 5.19. Predicted standard error of gametocyte conversion function estimates. The 
standard error is given as a percentage of the actual value. The standard error was 
calculated from equation 5.24). 
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Figure 5.20. Predicted standard error of gametocyte conversion function estimates. The 
standard error is given as a percentage of the actual value. The standard error was 
calculated from equation 5.24). 
The effects on the standard error of sampling more gametocytes and sampling more 
red blood cells in the ring stage smear are the same (compare Figure 5.17 to Figure 
5.18). The effect of sampling more ring stages is the same as the effect of sampling 
more red blood cells in the gametocyte smear (compare Figure 5.19 to Figure 5.20). 
In general sampling more ring stages or red blood cells in the gametocyte smear has 
a similar effect on the standard error to sampling more gametocytes or more red 
blood cells in the ring stage smear. However, when few gametocytes and ring stages 
are sampled, increasing the number of gametocytes sampled decreases the standard 
error considerably more than increasing the number of ring stages sampled (compare 
dotted grey lines in Figure 5.17 and Figure 5.19). Similarly, when few red blood cells 
are sampled in both smears, increasing the number sampled in the ring stage smear 
decreases the standard error considerably more than increasing the number sampled 
in the gametocyte smear. 
146 	 Chapter 5 
5.6. Discussion 
I have evaluated the merits of the three counting methods described in chapter 4 for 
estimating gametocyte conversion functions from thin blood smears. Multiplying the 
gametocyte conversion function by the ratio of the red blood cell densities at the time 
the smears were taken provides an estimate of gametocyte investment. Of the three 
methods investigated, methods 1 and 2 are commonly used for sampling from thin 
smears but method 3 is, as far as I am aware, a novel approach in malaria research. 
Method 1 is to count the number of parasitised cells in a fixed number of red blood 
cells. Method 2 is to count the number of parasites in a fixed number of fields and to 
count the number of red blood cells in a small part of this area. Method 3 is to 
measure the area sampled until a fixed number of parasites are observed and to 
independently measure the area sampled until a fixed number of red blood cells are 
observed. I calculated the bias in the gametocyte conversion function estimators for 
the three methods and the standard error of estimates as well as considering the size 
of any bias relative to the size of the standard error. Summaries of the main results 
are provided in Table 5.2, Table 5.3 and Table 5.4. 
Method 3 is the only method that has an unbiased gametocyte conversion function 
estimator. Therefore provided estimates from method 3 are fairly precise, they will 
also be accurate. The gametocyte conversion function estimators for methods 1 and 2 
will tend to overestimate the conversion function. In both cases, inaccuracy is most 
likely to be a problem when gametocytaemia is high relative to ring stage 
parasitaemia. Hence the bias in methods 1 and 2 could generate misleading results 
when gametocyte conversion changes. In P. chabaudi, gametocyte conversion was 
found to increase over the course of infection (Buckling et al., 1999b). Such a pattern 
could have been exaggerated by bias in the gametocyte conversion estimator. 
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Method 1 Method 2 Method 3 
0.2-250% upwards 0.03-17% upwards 
size 0.0004-1 times size 0.0004-0.3 times none 
of standard error size of standard 
error 
low ring stage 
parasitaemia 
when ring stage 
parasitaemia is 
moderate to high: main 
few red blood cells 
conditions low ring stage 
causing parasitaemia 




in when ring stage 
parasitaemia is low: 
few red blood cells 
per field in ring 
stage smear 
- sampling a larger 
area for red blood 
cells in gametocyte 
main sampling more red 
smear 
methods of blood cells for ring 
reducing stages 
when ring stage 
parasitaemia is low 
to moderate: 
sampling more fields 
for ring stages  
Table 5.2. Summary of the biases in gametocyte conversion function estimators for 
gametocytaemias from 2-0.02% and ring stage parasitaemias from 20-0.2% and at least 10 
times the gametocytaemia. Biases are reported as percentages of the actual values. For 
method 1, values are for samples of 200-2000 red blood cells and were calculated from 
equation 5.5). For method 2, values are for samples of 10-100 fields for parasites and 0.05-3 
fields for red blood cells at densities of 400-1000 red blood cells per field and were 
calculated from equation 5.13). 
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Method 1 Method 2 Method 3 




low gametocytaemia few red blood cells - 
causing 




sampling more fields 
gametocytes 
for gametocytes 
CZ sampling more red 
CO blood cells in ring when 
main sampling more red stage smear 
gametocytaemia is 
methods of blood cells for 
reducing gametocytes 
moderate to high: 
sampling more ring 
sampling a larger 
stages 
area for red blood 
cells in either smear 
sampling more red 
blood cells in 
gametocyte smear 
Table 5.3. Summary of the standard errors of gametocyte conversion estimates for 
gametocytaemias from 2-0.02% and ring stage parasitaemias from 20-0.2% and at least 10 
times the gametocytaemia. Standard errors are reported as percentages of the actual 
values. For method 1, values are for samples of 200-2000 red blood cells and were 
calculated from equation 5.7). For method 2, values are for samples of 10-100 fields for 
parasites and 0.05-3 fields for red blood cells at densities of 400-1000 red blood cells per 
field and were calculated from equation 5.16). Values for method 3 are for samples of 5-50 
parasites and 5-50 red blood cells and were calculated from equation 5.24) 
Using the guideline that the effect of bias on estimate accuracy can be ignored if the 
standard error is more than 10 times the bias (Cochran, 1977), when 500 red blood 
cells are sampled for ring stages and gametocytes, estimates of the gametocyte 
conversion function from method 1 should be accurate when ring stage parasitaemia 
is more than 2%. If 1000 red blood cells are sampled for gametocytes, estimates from 
method 1 should be accurate when ring stage parasitaemia is more than 2% provided 
at least 650 red blood cells are sampled for ring stages. Method 1 estimates of the 
gametocyte conversion function should be accurate for ring stage parasitaemias as 
low as 0.2% if only 500 red blood cells are sampled for gametocytes and at least 
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1600 red blood cells are sampled for ring stages. When the mean of several estimates 
is taken, inaccuracy will be a problem over a wider range of ring stage parasitaemias 
and sample sizes if most of the variation between estimates is sampling variation. 
This is a consequence of the reduced standard error of the mean. 
Method 1 Method 2 
low ratio of ring stage parasitaemia to 
gametocytaemia 
low ratio of ring few red blood cells per field in gametocyte 
main stage parasitaemia 
smear 
conditions to gametocytaemia 
when a large area is sampled for red blood causing 
P 	increase low ring stage 
cells in gametocyte smear: 
Q) parasitaemia 
low ring stage parasitaemia 
ca 
when a very small area is sampled for red 
blood cells in gametocyte smear: 
high ring stage parasitaemia 
a, 
sampling a larger area for red blood cells in 
main sampling more red 
gametocyte smear 
methods of blood cells for ring 
o 
a, 	reducing stages when ring stage parasitaemia is low to 
moderate: 
sampling more fields for ring stages 
except when ring stage parasitaemia is high 
and gametocytaemia is not much less: 
main sampling more red sampling more fields for gametocytes 
methods blood cells for 
increasing gametocytes when gametocytaemia is moderate to high: 
sampling a larger area for red blood cells in 
ring stage smear 
Table 5.4. Summary of the size of the bias in gametocyte conversion function estimators 
compared to the standard error of estimates for gametocytaemias from 2-0.02% and ring 
stage parasitaemias from 20-0.2% and at least 10 times the gametocytaemia. For method 1, 
values are for samples of 200-2000 red blood cells and the standard error was calculated 
from equation 5.7) and the bias from equation 5.5). For method 2, values are for samples of 
10-100 fields for parasites and 0.05-3 fields for red blood cells at densities of 400-1000 red 
blood cells per field and the bias was calculated from equation 5.13) and the standard error 
form equation 5.16). 
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With sampling method 2, when 0.05 of a field is sampled for red blood cells in each 
smear and 20 fields are sampled for gametocytes and ring stages, using the same 
guideline, estimates of the gametocyte conversion function are unlikely to be 
accurate unless gametocytaemia is less than 0.05%. However, when 0.2 of a field is 
sampled for red blood cells in each smear and 50 fields are sampled for gametocytes 
and ring stages, estimates from method 2 should be accurate for gametocytaemias 
down to 0.02%. As discussed for method 1, accuracy is likely to be limited to a 
smaller range of gametocytaemias, ring stage parasitaemias and sample sizes when 
the means of several estimates are taken. 
Which of methods 1 and 2 produces least biased gametocyte conversion function 
estimates depends on the ring stage parasitaemia and to a lesser extent on the 
gametocytaemia. When ring stage parasitaemia is 20% and gametocytaemia is 2%, 
the size of the bias relative to the standard error is mostly comparable for the two 
methods. However, the bias can be smaller relative to the standard error for method 1 
if a small area is sampled for red blood cells in the gametocyte smear under method 
2. 
When ring stage parasitaemia is 20% and gametocytaemia is less than 0.2%, the size 
of the bias relative to the standard error is comparable for the two methods over 
approximately half of the sample sizes considered. But the bias is smaller relative to 
the standard error for method 1 when either a small area is sampled for red blood 
cells in the gametocyte smear under method 2 or a moderate to large number of red 
blood cells are sampled for ring stages under method 1. 
When ring stage parasitaemia is 2%, the size of the bias relative to the standard error 
of estimates is similar for method 1 and method 2 over most of the sample sizes 
considered. However, the bias can be smaller relative to the standard error for 
method 2 in two cases. These are firstly, if many fields are sampled for ring stages 
and a large area is sampled for red blood cells in the gametocyte smear under method 
2. Secondly, when gametocytaemia is 0.2% and few red blood cells are sampled for 
ring stages under method 1. 
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For ring stage parasitaemias of 0.2%, over the range of gametocytaemias considered, 
the bias is smaller relative to the standard error for method 2 than method 1 if few 
red blood cells are sampled for ring stages under method 1 or if many fields are 
sampled for ring stages and a large area is sampled for red blood cells in the 
gametocyte smear under method 2. Over the rest of the sample sizes investigated, the 
size of the bias relative to the standard error is comparable for the two methods. 
The acceptable level of precision in estimates of the gametocyte conversion function 
will depend on the particular application and on the distribution of estimates. As 
discussed in chapter 4, a standard error of 50% is probably a sufficient criterion in 
most instances. When estimates are approximately normally distributed with a 
standard error of 50%, the 95% confidence interval for the mean of five estimates is 
approximately 45% of the estimate each side of the mean. With this guideline, when 
500 red blood cells are sampled for gametocytes and ring stages, method 1 is precise 
for gametocytaemias over 1%. If 2000 red blood cells are sampled for ring stages and 
gametocytes, then method 1 is precise for gametocytaemias over 0.3%. Method 2 is 
precise when gametocytaemia is over 0.2%. If 100 fields are sampled for ring stages 
and gametocytes, method 2 is precise for gametocytaemias down to 0.02%. Method 3 
is precise when 20 or more ring stages, gametocytes and red blood cells in each 
smear are sampled. If greater precision were required, the minimum 
gametocytaemias for which methods 1 and 2 would be suitable would be higher. 
Which method produces gametocyte conversion function estimates with the lowest 
standard error depends on the gametocytaemia. When gametocytaemia is 2%, 
method 1 and method 2 estimates generally have similar standard errors. However, 
estimates from method 2 have a considerably smaller standard error than estimates 
from method 1 when very few red blood cells are sampled for gametocytes under 
method 1 and a large area is sampled for red blood cells in each smear under method 
2. Estimates from method 3 nearly always have a considerably higher standard error 
than estimates from the other two methods when gametocytaemia is 2%. However, 
method 3 estimates have a comparable standard error to estimates from method 1 
when few red blood cells are sampled for gametocytes under method 1 and at least a 
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moderate number of gametocytes, ring stages and red blood cells in each smear are 
sampled for method 3. 
When gametocytaemia is 0.2%, method 2 estimates have considerably smaller 
standard errors than estimates from method 1 and usually considerably smaller 
standard errors than method 3 estimates. But estimates from method 3 can have 
comparable standard errors to method 2 estimates for 0.2% gametocytaemia when at 
least a moderate number of gametocytes, ring stages and red blood cells in each 
smear are sampled under method 3 and few fields are sampled for gametocytes under 
method 2. The standard error of estimates from methods 1 and 3 are mostly 
comparable when gametocytaemia is 0.2% but method 3 estimates have a 
considerably lower standard error when few fields are sampled for gametocytes 
under method 1 and at least a moderate number of gametocytes, ring stages and red 
blood cells in each smear are sampled under method 3. 
For gametocytaemias of 0.02%, estimates from methods 2 and 3 have considerably 
smaller standard errors than estimates from method 1. Method 2 and 3 estimates 
generally have comparable standard errors when gametocytaemia is 0.02%, although 
method 2 estimates can have smaller standard errors when many fields are sampled 
for gametocytes and a large area is sampled for red blood cells in each smear under 
method 2 
The standard error of gametocyte conversion estimates from any method can be 
reduced by increasing the sample size. Bias in the gametocyte conversion function 
estimator can also be reduced by increasing particular aspects of sample size. 
However, the reduction in the standard error from increasing sample size is 
successively less the more sample size is increased in probably all cases of interest. 
The same also appears to be true for reducing the size of the bias relative to the 
standard error. Therefore, for most purposes, it will not be beneficial to increase the 
sample size beyond a particular point, because of the extra time required for 
sampling. Components of sample size that do not have much influence on the 
standard error of estimates, or influence it only in specific conditions, can be 
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important determinants of the size of the bias relative to the standard error (compare 
Table 5.4 with Table 5.3). Therefore when deciding on a sample size, both the 
standard error of estimates and the size of any estimator bias relative to the standard 
error should be considered. 
For sampling method 1, from consideration of the standard error of estimates, I 
suggest that 1200 red blood cells should be sampled for gametocytes when 
estimating gametocyte conversion functions (Figure 5.3, page 122). Based on the 
size of the bias in the estimator relative to the standard error of estimates, I 
recommend also sampling 1200 red blood cells for ring stages (Figure 5.6 page 124). 
These recommendations are the same as those I suggested for estimating 
parasitaemias and gametocytaemias in chapter 4. Bias should have negligible effect 
for this sample size when ring stage parasitaemia is at least 0.7%. When the mean of 
five estimates is taken, there should be negligible effect of bias for this sample size if 
ring stage parasitaemia is at least 4%. 
For sampling method 2, based on the standard error of estimates, I recommend that 
60 fields should be sampled for gametocytes when estimating gametocyte conversion 
functions (Figure 5.9, page 130). Based on the size of estimator bias relative to the 
standard error, I suggest that 60 fields should be sampled for ring stages (Figure 5.16, 
page 139) and I a field should be sampled for red blood cells in the ring stage smear 
(Figure 5.15, page 138). On the basis of both the standard error and the size of the 
bias relative to the standard error, I suggest that 1 field should be sampled for red 
blood cells in the gametocyte smear. These recommendations are similar to those I 
proposed for estimating parasitaemias and gametocytaemias in chapter 4, except that 
I suggest sampling half as much area for red blood cells in the ring stage smear when 
estimating conversion. For this sample size, bias should have negligible effect on the 
accuracy of estimates for gametocytaemias down to 0.02% and when the means of 
five estimates are taken, bias should be negligible when ring stage parasitaemias are 
over 0.5%. When gametocyte conversion is estimated over consecutive days, the 
gametocyte smear for one day will become the ring stage smear for the next day. In 
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this instance, to reduce sampling time I suggest sampling 1 field for red blood cells 
in each smear. 
For method 3 of sampling, I suggest that 20 gametocytes (Figure 5.17, page 144), 
ring stages (Figure 5.19, page 145) and red blood cells on each smear (Figure 5.18, 
page 145 and Figure 5.20, page 146) should be sampled for estimating the 
gametocyte conversion function. When 15 of each cell type are sampled, increasing 
the number of any one sampled from 15 to 20 only slightly reduces the standard 
error. However increasing the number of each cell type counted from 15 to 20 
considerably reduces the standard error to below the 50% guideline. The same 
number of gametocytes, ring stages and red blood cells from each smear should be 
sampled because the number of each have similar effects on the standard error. These 
sample size recommendations are the same as those I suggested for estimating 
parasitaemias and gametocytaemias in chapter 4. Twenty gametocytes can on 
average be sampled from 150 fields with an average density of 700 red blood cells 
per field when gametocytaemia is 0.02%. 
The predicted standard errors and size of biases relative to the standard error for the 
sample sizes that I recommend are given in Table 5.5. 
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Method Method Method 
1 2 3 
Bias I Bias / 
Standard Standard Standard 
Gametocytaemia standard standard 
error error error 
error error 
0.01 
2% 21% 0.02 6-10% 48% 
-0.03 
0.01 
















0.02% 205% 0.02 30-47% 48% 
-0.01 
0.02 
0.2% 0.02% 214% 0.2 31-499/6 48% 
-0.07 
Table 5.5. Predicted standard errors in gametocyte conversion function estimates and size of 
biases relative to the 8tandard error for recommended sample sizes. Standard errors are 
reported as percentages of the actual value. Values for method 1 are for samples of 1200 
red blood cells for gametocytes and for ring stages and the standard error was calculated 
from equation 5.7) and the bias from equation 5.5). Values for method 2 are for samples of 
60 fields for gametocytes and for ring stages, 1 field for red blood cells in gametocyte smear 
and I a field for red blood cells in ring stage smear at densities of 400-1000 red blood cells 
per field and the standard error was calculated from equation 5.16) and the bias from 
equation 5.13). Method 3 values are for samples of 20 gametocytes, ring stages and red 
blood cells in both smears and were calculated from equation 5.24). 
Method 3 has two advantages over the other sampling methods for estimating 
gametocyte conversion functions. It has an unbiased estimator and the standard error 
of estimates is a fixed proportion of the actual value regardless of the 
gametocytaemia and ring stage parasitaemia. With appropriate sample sizes, the bias 
in sampling methods 1 and 2 can be small enough to have negligible effect on the 
accuracy of individual estimates. But to reduce the bias to a level where it should not 
affect accuracy requires larger sample sizes, and therefore sampling effort, than 
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would otherwise be necessary. The bias in methods 1 and 2 is particularly likely to 
be a problem when the mean of several estimates is taken, in which case it may not 
be possible to prevent bias influencing accuracy. An important characteristic of the 
biases is that they increase when gametocytaemia is high relative to ring stage 
parasitaemia, so using sampling methods 1 and 2 could exaggerate changes in 
gametocyte conversion. 
The constant standard error of method 3 estimates is an advantage when gametocyte 
conversion is being compared for different gametocytaemias and ring stage 
parasitaemias, as occurs over the course of infections. With method 3, precision is 
ensured even for low gametocytaemias and ring stage parasitaemias. Furthermore, as 
discussed in chapter 4, method 3 minimises sampling time. Method 3 is much more 
efficient than the other two when gametocytaemias vary. When gametocytaemias and 
ring stage parasitaemias are fairly constant, it would seem from the previous 
discussion that method 2 should be preferred to method 3, at least for individual 
estimates, when gametocytaemia is over 0.2% and that similarly method 1 should be 
preferred to method 3 when gametocytaemia is over 2%. However, in these 
situations, the sample size could be increased for method 3, without the sampling 
time becoming too long, to improve precision to a level comparable with the other 
methods. Therefore, to conclude, I suggest that gametocyte conversion should be 
estimated from smears by sampling a fixed number of gametocytes, ring stages and 
red blood cells from each smear. This method will provide accurate and precise 
estimates of the gametocyte conversion function across a wide range of 
gametocytaemias and ring stage parasitaemias. 
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6. Empirical estimates of gametocyte investment by malaria 
parasites 
6.1. Introduction 
In chapter 2, I proposed a theoretical model of malaria parasite investment into 
gametocytes. In this model, investment was fixed over an infection and higher 
proportions of asexuals producing gametocytes were traded-off against lower 
numbers of asexuals. The cost of gametocyte production was reduced asexual 
multiplication, which resulted in the lower asexual densities. I predicted that 
investment into gametocytes should be lower when maximum asexual density occurs 
later in infections, because the cost of investment accumulates for longer. I made 
quantitative predictions of investment. Two other models of transmission investment 
have been proposed. McKenzie and Bossert (1998b) also considered fixed 
gametocyte investment and they modelled asexuals being killed by an immune 
response that increased with asexual density. They predicted between 5% and 76% of 
merozoites should be gametocytes, dependent on the speed at which the immune 
system responds to parasites, for the range of responses expected in clinical 
infections. In contrast, Koella and Antia (1995) investigated variable investment into 
transmission. For the results that they present, they assumed that immune cells 
increase exponentially over an infection. They found that parasites should delay 
producing transmission stages until just before the immune-induced decrease in 
parasite density. Parasites should then produce entirely transmission stages, hence 
avoiding the cost of transmission investment on parasite growth. This type of 
outcome is common in life history theory and is known as a bang-bang strategy 
(Bulmer, 1994). 
To date, there are no good data to test these models against. Although there have 
been a large number of studies on gametocyte production, there are problems with 
the method used to estimate gametocyte investment in nearly all of them. 
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6.1.1. 	Studies of gametocyte investment in P. falciparum 
Probably the best estimate of P. falciparum behaviour in vivo is that 1% of parasites 
develop as gametocytes early in infections and 8% later (Smalley et al., 1981), based 
on the assumption that early in infections no mature gametocytes are present. As 
there are many studies of gametocyte investment in P. falciparum, I begin by briefly 
listing those that are most relevant here. Gametocyte investment was estimated to 
increase in response to immune factors (Smalley and Brown, 1981). Investment was 
reported as decreasing when cultures were diluted and parasitaemia rose and then 
increasing rapidly to 10% when parasitaemia declined from a peak (Carter and 
Miller, 1979). Gametocyte investment increased with parasitaemia (Bruce et al., 
1990; Buckling et al., 1999a) and with inhibition of asexual growth (Buckling et al., 
1999a) and decreased with soluble factors from cultures in which parasitaemia was 
increasing (Dyer and Day, 2003). Finally, gametocyte investment was found to 
decrease when the maximum asexual density was higher (Eichner et al., 2001). 
The majority of studies of gametocyte production in P. falciparum did not actually 
assess investment into gametocytes because gametocyte numbers were not related to 
the number of parasites from which they developed. Instead gametocytaemias 
(Phillips et al., 1978; Brockelman, 1982; Ponnudurai etal., 1983; Maswoswe et al., 
1985; Read and Mikkelsen, 1991; Schneweis etal., 1991; Lingnau et al., 1993; 
Ohnishi et al., 2001) gametocyte density (Trager and Gill, 1989) and the proportion 
of parasites that were gametocytes (Jensen, 1979; Trager et al., 1981; Ono et al., 
1986; Freese etal., 1988; Ono and Nakabayashi, 1989; Ono and Nakabayashi, 1990; 
Trager and Gill, 1992; Ono et al., 1993; Mann et al., 1996; Mehra and Bhasin, 1996; 
Trager et al., 1999) were reported. The proportion of parasites that were gametocytes 
does not measure investment into gametocytes, because asexuals present at the same 
time as gametocytes would have been from an earlier parasite cohort. 
One parameter used to measure gametocyte investment has been the conversion rate, 
which is the ratio of the number of gametocytes in a given number of red blood cells 
to the number of young parasites in the same number of red cells an appropriate time 
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earlier (Carter and Miller, 1979). In P.falciparum cultures under normal conditions, 
conversion rates of 0-20% (Carter and Miller, 1979), 3-6% (Kaushal et al., 1980) and 
1% (Smalley and Brown, 198 1) have been reported. In another culturing system the 
conversion rate was estimated as 17-25% (Ponnudurai et al., 1986), but N-acetyl 
glucosamine was added to kill trophozoites and schizonts and this may have affected 
gametocyte investment. Conversion rates were higher, at 11-71%, when 1 mM of 
cyclic AMP was added to cultures on day four and nearly 100% when the cyclic 
AMP was added on day six (Kaushal et al., 1980). The conversion rate was also 
higher, calculated as 6%, when serum and lymphocytes from infected children were 
added to cultures (Smalley and Brown, 1981). Over the course of culturing, the 
conversion rate decreased to zero when parasitaemia increased from a low level 
following dilution with red blood cells, then rapidly increased to about 10% as 
parasitaemia fell because of the degeneration of schizonts (Carter and Miller, 1979). 
Thereafter parasitaemia increased slowly again then gradually decreased and the 
conversion rate fluctuated between 5% and 20%. 
There are some problems with these conversion rate data. As they are ratios of 
measured values they will tend to be overestimates (see chapter 5). They also do not 
take account of changing red blood cell densities (see chapter 5) and therefore will 
overestimate gametocyte conversion when red blood cell density is decreasing. Bias 
is particularly likely to be a problem in the studies by Carter and Miller (1979), 
Kaushal etal. (1980) and Ponnudurai et al. (1986) because only 100 red blood cells 
were sampled for parasites. Red blood cell density probably changes most at high 
parasitaemias; therefore changing red blood cell density is especially an issue in 
Carter and Miller's (1979) study. In fact, they report that the red blood cell density 
dropped by about 90% over the course of the study (Carter and Miller, 1979). The 
results from Carter and Miller (1979), Kaushal et al. (1980) and Smalley and Brown 
(198 1) may also overestimate gametocyte conversion because cultures were 
asynchronous and gametocytes were counted at stage II, which persist for two days 
(Day et al., 1998) whilst young parasites persist for one day (see chapter 5). 
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These problems can be avoided by using monoclonal antibodies to distinguish 
gametocytes from asexuals before the age when asexuals rupture, provided the 
asexual and gametocyte stages identified are the same age. The proportion of 
parasites of the same cohort that are gametocytes can then be measured directly. 
Several studies on P. falciparum in culture have used monoclonal antibodies on 
parasites that had invaded a monolayer of red blood cells as merozoites (Bruce et al., 
1990; Buckling et al., 1999a; Dyer and Day, -.2000; Dyer and Day, 2003). When the 
inoculating culture was at low parasitaemia, under normal conditions, 7% (Bruce et 
al., 1990, average of data in their Table 4 for parasitaemias <5%), and 3-4% 
(Buckling et al., 1999a) of parasites in the monolayer were gametocytes. For 
moderate parasitaemias, the proportion of gametocytes was 8% (Bruce et al., 1990, 
average of data in their Table 4 for parasitaemias between 5% and 14%) and 13% 
(Dyer and Day, 2000). At high parasitaemias, 60% of parasites in the monolayer 
were gametocytes (Bruce et al., 1990, average of data in their Table 4 for 
parasitaemias >14%). The proportion of parasites that were gametocytes increased 
with the parasitaemia of the inoculating culture (Buckling et al., 1999a). The 
proportion of parasites that were gametocytes was approximately five times higher 
when cultures were treated with chioroquine (Buckling et al., 1999a) and twice as 
high when cholera toxin was added to cultures (Dyer and Day, 2000). The effect of 
chioroquine increased with the level of asexual growth inhibition of treatment 
(Buckling et al., 1999a). The number of parasite developing into gametocytes 
dropped to about a third when they were exposed to soluble factors from cultures in 
which parasitaemia was increasing (Dyer and Day, 2003). Two earlier studies of P. 
falciparum also used monolayers, but parasites were left to develop for longer so that 
stage II gametocytes could be identified (Inselburg, 1983; Williams, 1999). In these 
studies, parasites at the start had to be counted separately from the gametocytes and 
therefore, as before, these estimates will be biased upwards. 0.4% of synchronised 
parasites were estimated to be gametocytes (Inselburg, 1983) and 2% of parasites in 
an asynchronous culture (Williams, 1999). As discussed previously, this second 
value is likely to overestimate investment because the cultures were asynchronous. 
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The behaviour of P. falciparum in vitro may not reflect gametocyte investment 
during P. falciparum infections. Two studies have measured gametocyte investment 
by P. falciparum parasites in natural infections (Smalley et al., 1981; Mohapatra et 
al., 1992) and a third provides data from which the conversion rate can be calculated 
(Smalley, 1976). Smalley et al. (198 1) took blood from infected children and 
cultured it to allow gametocytes to be identified at stage II. From the initial asexual 
parasitaemia, the gametocyte conversion rate was estimated as 1% in parasites from 
infections without mature gametocytes and 8% in parasites from infections with 
mature gametocytes. In an earlier investigation carried out in the same way, the 
results indicate a conversion rate of 7% (Smalley, 1976, average of conversion rates 
calculated from data in his Table 2). These conversion rates, as before, will be biased 
upwards and may overestimate investment because of decreasing red blood cell 
densities in culture. However these effects are likely to be small, as the number of 
asexuals sampled was large and asexual parasitaemia was low. Mohapatra et al. 
(1992) estimated gametocyte investment from the density of mature gametocytes that 
appeared in the blood of asymptomatically infected individuals, divided by the initial 
parasite density. Values of 0.8% for infections of children and 2% for infections of 
adults were found. A problem with these estimates is that in a number of cases the 
gametocytes detected could not have developed from the initial parasite population 
because the timings of gametocyte appearance are given as three to twenty-eight 
days after parasites were counted. These figures are also likely to underestimate 
investment because of gametocyte mortality during the eight to ten days of 
development before they appear in the peripheral blood. 
For ethical reasons, gametocyte investment cannot be followed over the course of a 
P. falciparum infection; infections should be drug-treated when they are detected. 
Therefore gametocyte investment can only be estimated for one day and the point at 
which infections are sampled is unknown and probably quite variable. In these 
circumstances it is not clear whether averaging measures of investment across 
infections is appropriate, nor is it possible to determine whether investment varies 
over the course of infection. However some valuable data sets exist of daily parasite 
counts over the duration of P. falciparum infections from the early part of the 20th 
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Century, collected during the routine treatment of neurosyphilis with malaria (Collins 
and Jeffery, 1999; Weijer, 1999). One analysis of gametocyte investment has been 
performed on such data (Diebner et al., 2000; Eichner et al., 2001). Diebner et al. 
(2000) developed several models to predict mature gametocyte densities from daily 
counts of young parasites and then fitted them to the recorded gametocyte densities 
of individual infections. The model that gave the best fit to the data incorporated a 
time lag between gametocyte production and the appearance of mature gametocytes 
in the blood, gametocyte mortality exponentially increasing age, increased 
gametocyte mortality at high asexual densities and variable investment into 
gametocytes between successive waves in infection (one wave being an increase in 
parasitaemia followed by a decrease in parasitaemia). From their model, they 
estimated 0.3% of young parasites became mature gametocytes in one set of 
infections (Diebner et al., 2000) and in another that 0.5% of young parasites became 
gametocytes in infections initiated with sporozoites and 0.9% in infections initiated 
with parasitised blood (Eichner et al., 2001). They also found that the mean 
proportion of parasites that became gametocytes over an infection negatively 
correlated with maximum asexual density (Eichner et al., 2001). A problem with 
their approach is that they assumed that investment into gametocytes is fixed within a 
wave of parasitaemia. If they had considered variable gametocyte investment they 
may have obtained different parameter values and found that a different model gave 
the best fit to the data. Obviously, they were also unable to determine whether 
gametocyte conversion did vary within a wave of the infection. Diebner et al.'s 
(2000) and Eichner et al.'s (200 1) values probably underestimate gametocyte 
investment because of gametocyte mortality before maturity. 
6.1.2. 	Studies of gametocyte investment in rodent models 
Gametocyte investment has been measured in two malaria parasites of rodents. In P. 
berghei, several methods have been used to estimate investment. The conversion rate 
has been measured by the number of gametocytes in 105  red blood cells during stable 
gametocytaemia divided by the number of trophozoites in 10 5 red blood cells during 
the preceding stable parasitaemia (Mons, 1986, chapter 4). Periods of stable 
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parasitaemia and gametocytaemia only occur in P. berghei if a technique for 
synchronising parasites is applied. The normal conversion rate of P. berghei in mice 
was calculated as 3% for the first day of infection (Mons, 1986, chapter 6). This 
conversion rate was increased to 13% when mice were pre-treated with 
phenythydrazine (PHZ), a haemolytic drug with the effect of rapidly reducing red 
blood cell density and enhancing production of new red blood cells. Investment was 
only measured on the first day of infection because red blood cells quickly became 
multiply infected, which appeared to prevent parasite development, and the author 
judged that this would severely compromise the results. A serious problem with these 
data is that the strain of parasites used was a mixture of clones, some of which were 
found to differ substantially in their level of gametocyte investment. This 
complication could be expected to obscure any relationship between gametocyte 
investment and aspects of infection that exists within clones. Furthermore, the 
theoretical models that I am testing are for infections by a single clone. Another 
problem is that changing red blood cell densities were not taken into account and 
therefore the conversion rate may overestimate investment when red blood cell 
density is decreasing. These estimates will also tend to overestimate conversion 
because they are a ratio of measured values. 
In a study with a clone of P. berghei, gametocyte investment was reported as the 
density of gametocytes divided by the density of trophozoites the day before. 
Investment was approximately 45% in the first two days of infection, decreased to 
20% on day three and continued to decline with time (Dearsly et al., 1990). The 
estimates from this study may be higher than the actual investment because the 
parasites were not synchronised and gametocytes persist for longer than trophozoites 
(Mons, 1986, chapter 3). Consequently the observed gametocytes would have come 
from a larger population than was sampled as trophozoites. Additionally the decline 
in investment over time may be a consequence of many young parasites failing to 
reach maturity, as observed by Mons (1986), rather than an actual decrease in 
investment. By the same logic as before, the estimates will be biased upwards. 
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Two techniques have been applied to P. berghei to generate unbiased estimates of 
gametocyte investment. The techniques enable mature gametocytes and schizonts 
from the same parasite cohort to be sampled at the same time by preventing schizont 
rupture. The proportion of parasites that are gametocytes can then be measured 
directly. One method was to attach cells from infected rats to a Petri dish in a 
monolayer and culture them until gametocytes matured. Under these conditions 
schizonts did not rupture (Mons, 1986, chapter 6). The proportion of parasites that 
were gametocytes on the first day of infection was 16%. Unfortunately, these 
parasites were a mixture of clones and there is the same difficulty in interpreting this 
result as before. Investment was measured for one rat infected with a P. berghei 
clone and 45% of parasites were found to be gametocytes. However, with no 
replication, it is difficult to know how meaningful this result is. The other method 
used was to add rat anti-P. berghei IgG to cultures of parasites from infected rats just 
before schizonts would have ruptured (Mons, 1986, chapter 6). The number of 
gametocytes relative to schizonts was then determined by flow cytometry based on 
differences in fluorescence intensity between the two parasite types. 30% of parasites 
were gametocytes (calculated from values for control at 16 hpi in his Table 2). 
However, as before this result is from just one infection. Although there have been 
some very promising experiments on gametocyte investment in P. berghei, the 
problem remains that because of multiple infection of red blood cells, it is difficult to 
determine investment over the course of an infection. 
I have proposed that gametocyte investment should be measured by the gametocyte 
conversion ratio (see chapter 1). I define the gametocyte conversion ratio as the 
density of gametocytes at a given time divided by the density of asexuals (which 
included indistinguishable young gametocytes) an appropriate time earlier. This 
measure therefore takes into account changes in red blood cell density between the 
two sample times, unlike the conversion rate. P. chabaudi is an ideal species for 
investigating gametocyte investment because infections are synchronous and 
gametocytes are short-lived (Gautret et al., 1996a). Therefore, as with infections of 
P. berghei that have been synchronised, it is possible to sample only gametocytes 
and young parasites from a single generation. Unlike P. berghei however, multiple 
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infection of red blood cells is rare in P. chabaudi, so gametocyte investment can be 
measured with confidence throughout an infection. Previously in P. chabaudi,the 
gametocyte conversion ratio has been found to rapidly increase after day eight to ten 
of infection with P. chabaudi (Buckling et al., 1999b; Buckling and Read, 2001; 
Mackinnon et al., 2002; Mackinnon and Read, 2003) up to about 10% (Buckling et 
al., 1999b; Mackinnon et al., 2002; Mackinnon and Read, 2003). At the start of 
infections the conversion ratio was about 0.1%-1% (Buckling et al., 1999b; 
Mackinnon et al., 2002; Mackinnon and Read, 2003). The increase in conversion 
was delayed when mice were pre-treated with low doses of anti-malarial drugs 
(Buckling et al., 1999b) and was also later in infections with a serially passaged 
parasite line (Mackinnon et al., 2002). Subcurative drug treatment of infections 
produced an immediate increase in the gametocyte conversion ratio (Buckling et al., 
1999b). In one study the conversion ratio was increased early in infection when mice 
were partially immune (Buckling and Read, 2001) and in another the maximum 
conversion ratio was lower during the later part of infection in partially immune mice 
(Mackinnon and Read, 2002). An abrupt drop in the gametocyte conversion ratio 
before the end of infection has been found in some, but not all cases (Mackinnon et 
al., 2002; Mackinnon and Read, 2003, but see also Buckling et al., 1999b). 
These earlier studies on P. chabaudi used the biased gametocyte conversion 
estimator. Therefore the gametocyte conversion ratio will have tended to be 
overestimated. Bias in this estimator is particularly likely to be important when 
gametocytaemia is high relative to asexual parasitaemia (chapter 5). Therefore it is 
possible that the apparent rise in gametocyte conversion is exaggerated by estimator 
bias. Another possible confounding factor in these studies is that parasites samples 
were not taken every day. The appropriate density of asexuals was therefore 
estimated from the density of asexuals the day before and the day after. The estimate 
was based on the assumption that the survival of asexuals and the gametocyte 
conversion ratio did not change between these days. These values will therefore 
overestimate the conversion ratio when asexual survival decreases over time or 
gametocyte investment increases over time. 
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6.1.3. 	Chapter outline 
Here, I present estimates of the gametocyte conversion ratio during P. chabaudi 
infections using a new counting method that produces unbiased estimates. The 
estimates are based on daily parasite samples. I determine whether the conversion 
ratio varies over time as suggested by previous P. chabaudi studies and studies of P. 
falciparum and P. berghei, and if so, if it varies in the manner predicted by Koella 
and Antia (1995). In P. chabaudi, the time when maximum asexual density occurs 
can be manipulated by altering the number of parasites used to initiate infection 
(Timms etal., 2001). Therefore I was able to investigate whether the gametocyte 
conversion ratio decreased when the maximum asexual density occurred later, as 
predicted from my theoretical model. The speed at which the immune system 
responds to infection is likely to vary with dose. Hence the data also provide a test of 
McKenzie and Bossert's (1998b) predictions. 
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6.2. Methods 
I counted parasites in Giemsa-stained thin blood smears prepared during a previous 
experiment (Timms et al., 2001). The experiment was designed to test the effect of 
parasite dose on disease severity in P. chabaudi infections of mice. The protocol was 
described in detail by Timms et al. (2001). Briefly, groups of five C57BL/6J mice 
were infected with clone CW at doses of 102,  10, 104, 106,  107 or 108  parasites and 
this was repeated in a second experimental block. The analyses reported here concern 
only the first block. Smears of tail blood were made daily between 15.00 and 19.00 
hours and the red blood cell density was estimated by flow cytometry (Coulter 
ElectronicsTM). Previously, asexual densities were reported from counts of asexuals 
in 500 red blood cells (Timms et al., 2001). Gametocyte densities had been measured 
by counting gametocytes in 50 fields with an estimated average of about 500 red 
blood cells per field (Timms, 2001, chapter 6). No previous attempt had been made 
to evaluate gametocyte investment during these infections. I use the term asexual to 
mean red blood cells infected with asexuals and indistinguishable young gametocytes 
and the term gametocytes to mean red blood cells infected with mature gametocytes. 
Estimates of the gametocyte conversion ratio made from the previous counts are 
likely to be biased upwards, especially when the gametocytaemia is high relative to 
the asexual parasitaemia (chapter 5). The estimates would also have a large standard 
error when gametocytaemia was low (chapter 5). Unbiased estimates of the 
gametocyte conversion ratio can be made if parasites and req blood cells are counted 
using a method of inverse sampling (chapter 5). Therefore I recounted smears using 
an inverse sampling technique. A second advantage of using a method of inverse 
sampling is that the standard error of estimates is constant (as a proportion of the 
actual value) across a wide range of parasite densities (chapter 5). 
I examined smears separately for asexual, gametocyte and red blood cell counts, 
starting from a different place each time. This was done to minimise the possibility 
of correlations between parasite and red blood cell counts as such correlations would 
introduce bias into estimates of gametocyte conversion and parasite density. For 
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parasite counts, I examined smears until I had observed 20 asexuals (or gametocytes) 
or looked at 100 fields and recorded the number of fields searched and the number of 
asexuals (or gametocytes) counted. For red blood cells, I used a grid of 88 squares 
per field and counted cells in the middle four grid squares. I determined the number 
of fields needed to observe at least 20 red blood cells and the number of red blood 
cells counted. Smears were available for up to day 26 of infection. I began counting 
in smears with high asexual densities and, for each infection, continued with smears 
from later days until I found only one or zero asexuals in 100 fields and with smears 
from earlier days until I only found one or zero asexuals in 100 fields. I counted the 
same range of smears for red blood cells and the same range excluding the first day 
for gametocytes. 
6.2.1. 	Key to symbols 
A key to the main symbols used in this chapter is given in Table 6.1. 
g[t] 	 gametocyte conversion ratio on day t 
hG[t + 2] 	estimate of number of gametocytes per field in day t + 2 smear 
kr[t + 2] estimate of the inverse of the red blood cells per field in day t + 2 smear 
kA  [t + 1] 	estimate of the inverse of the asexuals per field in day t + 1 smear 
hr [t + 1] 	estimate of the red blood cells per field in the day t + 1 smear 
d[t] 	 estimate of the ratio of red blood cell density on day t + 2 to day t + 1 
n 	 number of parasites or cells counted 
f 	 number of fields sampled 
4 t] mean estimated red blood cell density on day t 
s2 (c[t]) 	variance in estimates of red blood cell density on day t 
A[t] 	 asexual density on day t 
hA  [t] 	estimate of the number of asexuals per field in day t smear 
G[t] 	 gametocyte density on day t 
Table 6.1. Key to symbols 
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gametocytes 
HI 
6.2.2. 	Estimating gametocyte conversion 
I measured the gametocyte conversion ratio for day t of infection from the number 
of gametocytes on day t +2 divided by the number of asexuals on day t +1. For the 
times when smears were made, gametocytes on day t +2 should have developed 
entirely from the asexuals on day t + 1 (Figure 6.1). I ascribe the gametocyte 
conversion ratio to day t because in both P. chabaudi (Cornelissen and Walliker, 
198 5) and P.falciparum (Bruce etal., 1990; Dyer and Day, 2000; Silvestrini etal., 
2000; Smith et al., 2000) there is evidence that commitment to gametocyte 
production is made in the parental generation, before the merozoites that will become 
gametocytes are released (but for a different view in P. berghei see Mons, chapter 6). 
I 	 I 	I 
0 (36) 17 	 36 41 	 60 hours 
(60) 
Figure 6.1. Timing of gametocyte development relative to when smears were made. Flashes 
represent schizogony. The times when two consecutive smears were made are indicated by 
solid arrows. Gametocytes produced at time 0 are indistinguishable from asexuals when the 
first smear is made. P. chabaudi gametocytes can be identified 36 hours after they are 
produced (Gautret et al., 1996a). Therefore the second smear will contain recognisable 
gametocytes that were produced at time 0. Note that asexuals present in the second smear 
have come from a second round of replication and are therefore not the same generation as 
the identifiable gametocytes. Gametocytes have been reported to die at 60 hours (Gautret et 
al., 1996a) although investigation of their half-life indicates that their numbers decline by 70% 
over this time (calculated from half-life of 14 hours estimated in Reece etal., 2003). Hence I 
assume that a negligible number of gametocytes in the second smear will have come from 
previous schizogonies (time since their production shown prime and in brackets). 
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The gametocyte conversion ratio on day t can be estimated by: 
g[t] = hG{t + 2]kr[t + 2]kA It  + 1]hr[t + 1]d[t] 	 6.1) 
(chapter 5) where hG [t + 2] is an estimate of the number of gametocytes per field in 
the smear made on day t + 2, k,. It + 2] is an estimate of the inverse of the number of 
red blood cells per field in the day t + 2 smear, kA  It + 1] is an estimate of the inverse 
of the number of asexuals per field in the day t + 1 smear, hr[t + 1] is an estimate of 
the number of red blood cells per field in the day t + 1 smear and d[t] is an estimate 
of the ratio of red blood cell density on day t + 2 to day t + 1. When the area (a) 
needed to observe exactly 20 parasites or cells is measured, 191a  is an unbiased 
estimate of the number of parasites or cells per field and a120 is an unbiased 
estimate of its inverse (chapter 1). However I sometimes counted considerably more 
than 20 parasites or red blood cells and did not always observe 20 parasites when 
parasite density was very low. To determine the appropriate formulae under my 
sampling scheme, I simulated sets of 10,000 counts for between 0.001 and 250 
parasites or cells per field. As there were five mice per treatment, I assessed bias for 




0.2 <-- <26 	 6.2a) 
f 	 f 
h= - - 	 -~ 26 	 6.2b) 
f f 	f 
where n is the number of parasites or red blood cells counted and f is the number of 
fields sampled. In the simulations, bias was negligible when the number of parasites 
or cells per field (h) was estimated to be either -.-. 9 or 2-- 23. The mean values of hG 
and hr  across mice were within these ranges; therefore hG  and  hr  should be 
unbiased. 
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Also on the basis of the simulations, I calculated: 
k=L 	 n ~ 1 	 6.3a) 
k=''=f+1 	n=0 	 6.3b) 
In the simulations, bias was negligible when the inverse of the number of parasites or 
cells per field (k) was estimated to be between 0.14 and 3. However the mean values 
of k,, and kA  across mice were often outside this range. I therefore used the 
simulated data to correct for bias in the estimates of the gametocyte conversion ratio. 
The bias had very little effect on the results (see Appendix 6.7.1). 
Red blood cell density had been measured twice on each day, therefore I calculated: 
e[t+2]( s2 (c {t + 1]) 
d[t]= 	
1 
Eft +1] 	2e2[t+1] 	
6.4)
) 
which corrects for bias (proof not shown), where ë[t] is the mean estimated red 
blood cell density on day t and s2 (c[t]) is the variance in estimates of red blood cell 
density on day t . 
I estimated the asexual density on day t by: 
A[t] = hA [t]kr[t]4t] 
	
6.5) 
The mean value of hA  across mice was sometimes outside the range for which bias 
could be ignored. However bias in hA  and k,, had very little effect on estimates of 
asexual density (see Appendix 6.7.2). 
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I estimated the gametocyte density on day t by: 
G[t] = hG[t]kr[t]F[t] 
	
6.6) 
Bias in k, had very little effect on estimates of gametocyte density (see Appendix 
6.7.3). 
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6.3. Results (1): pattern of gametocyte conversion 















Figure 6.2. Gametocyte conversion during P. chabaudi infections in mice. Infections were 
initiated with a) 102,  b) iOn, c) iOn , d) 106,  e) iO and f) 108  asexuals. Values are the means 
of up to five mice (four in the case of infection with 104  asexuals) and error bars show 
standard errors of the means. Individual infections are shown in Appendix 6.7.4. 
There were two distinct peaks in the gametocyte conversion ratio during infections 
initiated with low numbers of parasites (Figure 6.2 a), b) and c)). It is unclear 
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whether there was a third conversion peak in infections with 102  and  103  parasites as 
indicated, because in each case this was due to a high value in one infection (see 
Appendix 6.7.4, Figure 6.13), based on a single gametocyte observation. The height 
of both conversion peaks was around 3-5%. In infections with high parasite doses, 
there was one dominant peak in gametocyte conversion and a small early conversion 
peak (Figure 6.2 d), e) and f)). The maximum conversion ratio in high dose 
infections was about 8%, although in individual infections the conversion could be as 
high as 18% (see Appendix 6.7.4). 
Gametocyte conversion rapidly decreased before the end of infection. In between the 
two conversion peaks in low dose infections and before the main conversion peak in 
high dose infections, the conversion ratio was very low, but not zero. 
On average, the second or main conversion peak occurred one to four days after the 
maximum asexual density (Figure 6.3). The first conversion peak in low dose 
infections occurred when the asexual density was very low. Maximum conversion in 
the second or main peak sometimes produced the maximum gametocyte density, 
observed two days later, (Figure 6.4 a), d) and f)) but not always (Figure 6.4 b), c) 
and e)). 
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Figure 6.3. Asexual densities (thin lines) and gametocyte conversion (thick lines, as in Figure 
6.2) during P. chabaudi infections in mice. Infections were initiated with a) 102,  b) iO, c) iOn , 
d) 106,  e) 107  and f) 108  asexuals. Values are the means of up to five mice (four in the case 
of infection with 104  parasites) and error bars show the standard errors for asexual densities. 
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Figure 6.4. Gametocyte conversion (thick lines, as in Figure 6.2)) and gametocyte densities 
(thin lines) during P. chabaudi infections in mice. Infections were initiated with a) 102,  b) iO, 
C) 104 ,  d) 106,  e) 10' and f) 108  asexuals. Values are the means of up to five mice (four in the 
case of infection with 104 parasites) and error bars show the standard errors for gametocyte 
densities. 
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6.4. Statistical analysis 
Analyses were carried out using MINITAB® (v. 13.30, Minitab Inc.). I considered 
two aspects of the pattern of gametocyte conversion. These were firstly, the 
maximum gametocyte conversion ratio or, in low dose infections with two 
conversion peaks, the maximum conversion ratio during the second peak. I used data 
from the second peaks because high dose infections apparently had an early 
conversion peak corresponding to the early peak in low dose infections. I refer to this 
measure as the maximum conversion ratio. Secondly, I examined the time between 
the day of maximum asexual density and the day of maximum conversion ratio, 
which I call the conversion time lag. 
The predictions from my theoretical model can be approximated by a linear 
relationship between the logarithm of gametocyte investment and log of day of 
maximum asexual density. Therefore I log transformed the day of maximum asexual 
density and maximum conversion ratio data. I then analysed the data by regression. 
As inoculating dose and magnitude of maximum asexual density might also affect 
the maximum conversion ratio, I started with the maximal statistical model: log 
maximum conversion ratio = log day of maximum asexual density + log dose + 
maximum asexual density. I treated dose as a covariate and log transformed it to 
reduce the influence of the highest dose. I then obtained a minimal statistical model 
by backwards elimination of variables with p> 0.05 (Sokal and Rohlf, 1995). 
To determine whether the data supported my predicted effect of day of maximum 
asexual density on gametocyte investment, I compared the regression coefficient of 
the data on the day of maximum asexual density to the regression coefficient of my 
theoretical predictions on the day of maximum asexual density. 
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I tested for a significant difference between the two regression coefficients by 
calculating: 
(bd _bP ) (SSXd)(SSIYP)(id + j —4) 	
6.7) 
(SSXd  + SSXP )(SSEd + SSE) 
(Sokal and Rohlf, 1995) where the subscript d relates to the regression of the data 
and the subscript p to the regression of the predictions and b is the regression 
coefficient, SSX is the sum of squared deviations of the x values from their mean, 
SSE is the error sum of squares and j is the number of distinct x values. I also 
evaluated whether the data were consistently higher or lower than the theoretical 
predictions by a sign test, which tests whether the number of deviations in one 
direction is significantly different from that expected under a binomial distribution 
(Sokal and Rohif, 1995). 
Koella and Antia (1995) predicted that there should be no conversion time lag, with 
maximum gametocyte investment occurring at maximum asexual density. I tested 
this prediction with a sign test on my data. I also analysed the time lag by regression 
to determine whether it varied with certain characteristics of infection. I started with 
the maximum statistical model: conversion time lag = log dose + maximum asexual 
density and used backwards elimination to obtain a minimal statistical model. 
The assumptions of homogeneity of variance and normality of residuals were upheld 
in all regression analyses. 
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6.5. Results (2): testing the models 
The maximum conversion ratio was lower in infections where maximum asexual 
density occurred later (Figure 6.5). The size of this effect was not significantly 
different from my theoretical prediction (F 1 , 21 = 0.35, p> 0.5). However the 
maximum conversion ratios were less than predicted (p <0.001), being on average 
half the predicted values. Dose had no effect on the maximum conversion ratio 
additional to the effect of day of maximum- asexual density (t25 = 0. 10, p> 0. 9), and 
neither did the magnitude of the maximum asexual density (t26 = 0.54, p> 0.5). 
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Figure 6.5. The effect of day of maximum asexual density on the maximum conversion ratio. 
Regression line is: log10 y = —0.526 - 0.759 log 10 x, t27 = -3.68, p = 0.001, R 2 = 31%. 
Theoretical line was determined by linear regression of predicted values against day of 
maximum asexual density and is: log10 y = 0.0510 —1 .041og 10 x. Predicted values were 
found by numerical solution of 1— (m(1 - g))'/l - (m(1 - g))' x (m - 1)/ml = g (see 
chapter 1) for m = 6 (Landau and Boulard, 1978), where 1 is the day of maximum asexual 
density, using MATH EMATICA® (v. 4.1.2.0, Wolfram Research). 
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The maximum gametocyte conversion ratio occurred after the maximum asexual 
density (p < 0.001). The conversion time lag was greater in infections with higher 
maximum asexual densities (Figure 6.6). There was no additional effect of dose on 
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Figure 6.6. The effect of maximum asexual density on the time lag between maximum 
asexual density and the maximum conversion ratio. Regression line is: y = 1.25 + 1.28x, 
t27 = 2.32, p = 0.028, R 2 = 14%. 
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6.6. Discussion 
Gametocyte conversion varied over the course of infection. There were two peaks in 
conversion. In high dose infections the first peak was very small, but in low dose 
infections the two peaks were similar. The maximum conversion ratio was 3-5% in 
low dose infections and 8% in high dose infections. The maximum conversion ratio 
was lower in infections with later maximum asexual densities. Maximum conversion 
occurred after maximum asexual density. The delay between maximum conversion 
and maximum asexual density increased with maximum asexual density. 
The pattern of gametocyte conversion does not match the investment profile 
predicted by Koella and Antia (1995). The data differed from their predictions in two 
important ways. Maximum gametocyte conversion was much less than 100% and 
maximum conversion did not occur at maximum asexual density. Additionally, 
gametocyte conversion decreased after reaching a maximum, an outcome precluded 
in Koella and Antia's (1995) model by the fact that total differentiation into 
gametocytes terminates infection. A further finding that was not predicted by Koella 
and Antia (1995) was the existence of an early peak in gametocyte conversion, which 
was substantial in infections initiated with low numbers of parasites. 
In discussing the implications for parasite fitness of the differences between Koella 
and Antia's (1995) predictions and the observations, I assume that patterns of 
gametocyte conversion have evolved to maximise parasite fitness. Later, I discuss 
some possible non-adaptive explanations for the patterns. The pattern of conversion 
suggests that the presence of gametocytes at several times during infection increases 
parasite fitness. Koella and Antia (1995) assumed that fitness is directly proportional 
to the total number of transmission stages produced. As the number of asexuals 
eventually decreases as a result of immune responses and they assumed that the 
timing of gametocyte production had no affect on fitness, they found that 100% 
gametocyte conversion should occur at maximum asexual density. However, 
complete differentiation into gametocytes would end infections prematurely. The fact 
that gametocyte investment was much less than 100% (Figure 6.2), suggests that 
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truncating infections reduces fitness and hence that gametocytes that can be produced 
later in persistent infections may be significantly contributing to transmission. A 
possible alternative explanation for partial investment into gametocytes is bet 
hedging (Slatkin, 1974). Bet hedging has been proposed to occur when organisms 
have a certain time to grow (corresponding to the time until asexual density begins to 
decline) but are unable to determine this period exactly. The predicted outcome is 
intermediate investment into reproduction (in this context, gametocytes) when 
investment first shifts from purely growth (Bulmer, 1994). However this cannot 
entirely account for the observed conversion dynamics as gametocyte investment 
would then be expected to increase over time, not decline. 
The delay in peak gametocyte conversion until after maximum asexual density can 
also be understood within the hypothesis that infection persistence is important for 
transmission. The rate of decrease in asexual numbers was highest just after 
maximum asexual density (Figure 6.3), which may mean that this is when the 
immune response is most effective. Producing gametocytes at this point, because of 
the concomitant reduction in asexual multiplication, might enable the immune 
system to clear the infection. Later after maximum asexual density, the immune 
response appears to get less effective (based on the slope of asexual density), which 
may be because of increased frequency of an antigenic variant that has not yet 
elicited a specific immune response (Phillips et al., 1997) or self-regulation by the 
immune system. Waiting until after maximum asexual density to produce 
gametocytes might therefore increase the likelihood of parasites surviving the acute 
period of infection. This reasoning could also explain why the time lag in conversion 
increased with the magnitude of maximum asexual density. Higher asexual densities 
might stimulate stronger immune responses that may be effective for longer. 
Delaying conversion further in infections with greater maximum asexual densities 
might therefore be a strategy for maintaining high asexual growth throughout the 
period when there is significant risk of infection clearance. 
An alternative reason why parasites may not be producing gametocytes at maximum 
asexual density is if such gametocytes would be non-infectious. A loss of infectivity 
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in gametocytes around the time of maximum asexual parasitaemia has been observed 
in P. gallinaceum in chickens, P. knowlesi and P. cynomolgi in monkeys, natural 
infections of P. falciparum and P. vivax and has been postulated for P. yoelli 
(reviewed in Carter and Gwadz, 1980 and Sinden et al., 1996). 
Another finding, which suggests that chronic infection contributes to parasite fitness, 
is the rapid drop in gametocyte conversion after reaching a maximum. This may 
maximise the chance of a novel antigenic variant arising. A proportion of P. 
chabaudi asexuals were found to switch antigen type per generation (Phillips et al., 
1997). Therefore the number of parasites with a new antigen type will increase with 
parasite density. Hence, reducing gametocyte conversion, which increases asexual 
growth, should allow the density of a new antigen type to accumulate so that it is not 
immediately destroyed by the adapting immune response. The drop in conversion 
could be a mechanism for ensuring infection persistence. However, the decrease 
might also occur because clones have adapted to continuous passage between mice. 
The clones investigated here had been directly passaged 11 times without 
transmission through mosquitoes. Dearsly et al. (1990) found that gametocyte 
conversion was substantially curtailed in a clone of P. berghei after 14 passages. 
The strongest indication that parasite fitness depends on generating gametocytes for 
as long as possible is the early peak in gametocyte conversion. It is difficult to 
interpret this result in any other way. The early conversion peak was much more 
pronounced in low dose infections. Speculatively, this difference between high and 
low dose infections may reflect a different nature of initial immune response in the 
two cases. Previously, theoretical analysis has demonstrated that the early immune 
response does relate to parasite density (Haydon etal., 2003). If the immune system 
reacts quite rapidly in high dose infections, then in these infections it may be 
important for parasites to maximise early growth. In low dose infections, parasites 
may remain relatively unaffected by immunity at the start of infections and hence 
able to divert resources to gametocyte production. 
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No support was found for McKenzie and Bossert's (1998b) predictions of extremely 
high gametocyte investment. The wide range of doses is probably greater than would 
occur naturally (Timms et al., 200 1) and therefore would be expected to induce the 
full spectrum of immune responsiveness. But gametocyte conversion never exceeded 
20%. 
Maximum gametocyte conversion decreased with increasing time to maximum 
asexual density as I predicted from my theoretical model. However a problem with 
interpreting this as support for my model is that an important assumption of the 
model was clearly not met. I modelled gametocyte investment as constant. Yet, the 
data show that gametocyte conversion varied over time. The relationship between 
gametocyte investment and the timing of maximum asexual density arises 
theoretically because of the cost of producing gametocytes on asexual growth. But in 
the infections analysed here, parasites avoided part of this cost by having lower 
conversion on some days. Given this, it is important to evaluate whether the model is 
providing a meaningful explanation of gametocyte conversion. In favour of the 
model, the dynamics of conversion do suggest that parasites are spreading 
gametocyte production throughout infections and maximum conversion in the first 
and second conversion peaks was similar in low dose infections. Equal investment 
into gametocytes on each day may therefore be a reasonable first approximation. 
Another circumstance in which the model would explain the parasite behaviour is if 
the ancestral condition was constant gametocyte investment. Parasites may then have 
evolved to modulate investment about the optimum for constant investment, rather 
than evolving a specific level of investment for each replication cycle of infection. 
Gametocyte conversion was lower than predicted by my model. Maximum 
conversion ratios were approximately half the predicted values. There could be a 
number of explanations. One possibility is that gametocyte investment was as 
predicted, but a significant number of gametocytes produced did not survive. 
Because conversion was estimated from numbers of mature gametocytes it equates to 
gametocyte investment discounted by the effect of gametocyte mortality. Measuring 
gametocyte mortality is limited by when gametocytes can be identified, but the half- 
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life of P. chabaudi gametocytes once mature has been estimated at 14 hours (Reece 
et al., 2003). In P. falciparum, where earlier gametocyte stages can be recognised, 
about half to two thirds of stage I gametocytes survive to maturity in culture 
(Ponnudurai et al, 1986). A second possibility is that gametocyte conversion has 
decreased because of repeated passage. Gametocyte investment was estimated to 
drop to approximately a third of the starting value in P. berghei after 25 passages 
(Mons, 1986). But the author suggested that this occurred because parasites were a 
mixture of high and low gametocytes producing clones and passage increased the 
frequency of low producers. However conversion on the first day of infection also 
apparently decreased with passage in a clone of P. berghei (Dearsly et a!, 1990). 
Conversion was estimated to fall to about 60% after eight passages and to 50% after 
14 passages, although conversion on the second day appeared to increase after 14 
passages. The maximum number of gametocytes produced by P. falciparum clones 
also dropped after 16 weeks in continuous culture (Graves et al., 1984). 
Another possible reason for the difference between my predictions and the data is 
that my model incorporates too small a cost of gametocyte production and therefore 
the predictions are too high. The cost in my model is reduced asexual numbers up to 
maximum asexual density. The infection ends abruptly at the maximum asexual 
density because I treat the immune response as completely effective at that point. 
Representing immunity by a less severe function would extend infections and hence 
increase the cost of gametocyte production. I also did not consider the impact of 
gametocyte conversion on when infections ended. Using the argument that the 
chronic persistence of infection may depend (through generating new antigenic 
types) on the asexual density, it might be expected that infections investing less into 
gametocytes last longer. Gametocyte investment would have a higher cost if I 
incorporated this trade-off into my model. A different aspect of gametocyte cost 
could be reduced mosquito survival or sporozoite development at high gametocyte 
densities. Changing the fitness measure so that the contribution of gametocytes to 
fitness decreased at high gametocyte densities (for an example see McKenzie and 
Bossert, 1998b) would also reduce predicted gametocyte investment. 
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I consider it unlikely that my 'results reflect immune clearance of gametocytes rather 
than gametocyte investment. There is very little evidence that gametocytes are 
removed by the immune system during infection. However gametocyte immunity is 
extremely underrepresented in the immunological literature. Furthermore, the 
dominant interest in gametocyte immunity has been responses that block parasite 
development in mosquitoes. Changes in gametocyte prevalence or gametocytaemia 
with malaria exposure, without corresponding changes in asexual prevalence (or 
parasitaemia), have been purported to demonstrate immunity to gametocytes (for 
example Baird et al., 1991). But, such results could equally be explained by 
alterations in gametocyte investment. Antibodies to P. falciparum gametocyte-
specific antigens have been found in sera from people living in areas of high malaria 
transmission (for a review see Sinden et al., 1996), but these will not be effective in 
the host because the respective antigens occur inside the infected red blood cell. 
As far as I am aware, only one study has demonstrated an immune-mediated 
reduction in gametocyte numbers in vivo. Transfer of spleen cells from mice 
vaccinated with P. yoelii gametes decreased gametocytaemia during challenge 
infection (Harte et al., 1985). Whether a similar effect occurs during the course of 
primary infection is not apparent, however some further data suggest that it is 
possible. The drop in transmission that was affected by vaccination was dependent 
on T cells (Harte et al., 1985). Human CD4+T cells have been shown to proliferate 
on first exposure to P. falciparum gametocytes (Goodier and Targett, 1997). This 
response is probably stimulated by asexuals as well as gametocytes, because removal 
of cells reacting to asexuals virtually obliterated response to gametocytes and vice 
versa (Goodier and Targett, 1997). An immune response does not have to be directed 
specifically against gamétocytes for it to affect estimates of conversion. Because 
gametocytes are not sampled until after asexuals, any reduction in gametocyte 
numbers in the intervening period will result in lowered measures of conversion. In 
addition, y8 T cells have been reported to proliferate in response to soluble P. 
falciparum antigens specific to gametocytes after a single infection (Ramsey et al., 
2002). 
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From in vitro observations, it has been suggested that gametocytes might be cleared 
by innate phagocytosis. Young P. falciparum gametocytes were internalised by 
human monocytes and macrophages (Smith et al., 2003). Taking several other lines 
of evidence together, indicates the basis for a similar effect in P. chabaudi. Mouse 
macrophages were also able to engulf P. falciparum gametocytes (Smith et al., 
2003). With both mouse and human cells, the interaction was largely dependent on 
CD36 and consistent with the parasite antigen being PfEMP-1 (P. falciparum 
erythrocyte membrane protein 1), which is expressed by gametocytes and has been 
shown to mediate the binding of young gametocytes to CD36 (Hayward et al., 1999). 
PfEMP- 1 was first identified on the surface of trophozoite-infected red blood cells. 
Therefore, the proposed mechanism of gametocyte phagocytosis in P. falciparum 
involves an antigen expressed on both gametocytes and asexuals. In P. chabaudi, 
trophozoites and schizonts also express an antigen that binds to human CD36 (which 
has 90% amino acid identity with mouse CD36) (Mota et al., 2000). However, as far 
as I am aware, the same antigen has not been demonstrated on gametocytes and nor 
has phagocytosis of P. chqbaudi gametocytes been observed in vitro or in vivo. It has 
also been hypothesised that P. falciparum gametocytes could be cleared as a result of 
antibodies against PfEMP-1 (Hayward et al., 1999). PfEMP-1 is antigenically 
variable (Biggs et al., 199 1) and as with P. chabaudi, variant-specific antibodies are 
believed to successively clear different antigen types during P. falciparum infections. 
Gametocytes expressed the same PfEMP- 1 antigenic types as asexuals in the same 
culture (Hayward et al., 1999). In P. chabaudi, the asexual antigen binding CD36 
was recognised by antibodies present in mouse infections just after maximum 
asexual density (Mota et al., 2000). But, as before, such a mechanism is speculative 
in P. chabaudi unless the same antigen is found on gametocytes. 
My results confirm the rapid increase in gametocyte conversion that was previously 
observed in P. chabaudi (Buckling et al., 1999b; Buckling and Read, 2001; 
Mackinnon et al., 2002; Mackinnon and Read, 2003). The maximum conversion 
ratios were comparable to those found previously for the same or similar doses (10 6 
parasites: Buckling et al., 1999b and Mackinnon and Read, 2003; 10 5 parasites: 
Mackinnon et al., 2002). I also found a substantial decline in gametocyte conversion 
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as reported, although it was less abrupt in my data (Mackinnon et al., 2002; 
Mackinnon and Read, 2003). These consistencies show that estimating gametocyte 
conversion ratio from parasite counts only on every other day and using a biased 
estimator did not have a qualitatively effect the results. However, the effect of using 
inverse sampling could be evaluated in detail with these data because parasites were 
originally counted by a traditional method. A novel finding in my results was the 
early peak in gametocyte conversion. Re-examination of the previous work in light 
of this result does however show evidence of an early peak in one study (Mackinnon 
et al., 2002). 
I did not find conversion ratios nearly as high as the values found at the start of P. 
berghei infections (Mons, 1986; Dearsly et al., 1990) This suggests that the strategies 
of gametocyte investment may be different in P. chabaudi and P. berghei. In 
contrast, the conversion ratios were similar to the levels of gametocyte investment 
reported in natural infections of P. falciparum (Smalley, 1976; Smalley et al., 1981; 
Mohapatra etal., 1992) and most investigations of P.falciparum under normal 
culture conditions in vitro (Carter and Millar, 1979; Kaushal et al., 1980; Smalley 
and Brown, 1981; Inselburg, 1983; Bruce etal., 1990; Buckling etal., 1999b; 
Williams, 1999; Dyer and Day, 2000). Gametocyte conversion never reached the 
extremely high levels observed in vitro at high parasitaemias (Bruce et al., 1990) or 
when cyclic AMP was added (Kaushal et al., 1980). My results suggest that changes 
in conversion, as observed in vitro by Carter and Miller (1979), may occur during 
human malaria infections. They also support Smalley et al. 's (1976) interpretation 
that P. falciparum conversion increases later in infection. Taken together, these 
results indicate that P. chabaudi may provide a useful model of gametocyte 
conversion in P. falciparum. 
Based on a number of studies (Carter and Miller, 1979; Smalley and Brown, 1981; 
Buckling et al., 1999a, 1999b, Buckling and Read, 2001), it has been widely 
proposed that investment into gametocytes increases when asexual growth is 
inhibited. This, along with other results (Bruce et al., 1990; Buckling et al., 1999a) 
has lead to the expectation that maximum investment occurs at maximum 
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parasitaemia. Here, I have expounded an alternative hypothesis, that in fact, 
gametocyte investment is suppressed at times when there is greatest risk of infection 
clearance including at maximum parasitaemia. I have proposed that this promotes 
parasite survival into chronic infection. My results specifically demonstrate that in P. 
chabaudi, maximum gametocyte conversion does not coincide with maximum 
asexual density. 
I have shown that gametocyte conversion varies during P. chabaudi infections. In 
conjunction with the available evidence from P. falciparum, this argues that 
gametocyte investment is unlikely to be constant in P. falciparum infections. Such a 
conclusion brings into question the results of Diebner et al. (2000) and Eichner et al. 
(2001), who calculated investment during therapeutic P. falciparum infections on the 
basis that it was constant (within each wave of infection). The pattern of gametocyte 
conversion did not match Koella and Antia's (1995) prediction. I have suggested that 
the discrepancies imply that malaria parasite fitness depends not just on maximising 
the number of gametocytes produced but also on the length of time for which 
gametocytes are present. My theoretical model based on fixed investment was able to 
predict the observed decrease in peak gametocyte conversion with later maximum 
asexual densities. 
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67. Appendices 
6.7.1. 	Bias in estimates of the gametocyte conversion ratio 
The bias (b) in estimates of the gametocyte conversion ratio can be written as: 







KA[t+l] ) 	) 
assuming that there is negligible bias in hG[t + 2], hr[t + 1] and d[t], and where y[t] 
is the actual conversion ratio, Kr[t + 2] is the actual inverse of the number of red 
blood cells per field in the day t + 2 smear and 1A  It + 1] is the actual inverse of the 
number of asexuals per field in the day t + 1 smear. Hence the bias in estimates of the 
gametocyte conversion ratio can be estimated by: 
A 
- 	1+ 
lCr[t+2] 	+ KA[t+1] 	 6.9) b(g[t]) = 
	
b(kr[t + 2])1  
1+ 
lCjt+2] 	KA[t+1] 
where [t] is the mean gametocyte conversion across mice. I predicted the bias in k 
divided by K from simulations of 10,000 counts and the mean of k across mice. 
Bias in the simulated data fell into three regions. When mean k was <0.14, the bias 
in k divided by K oscillated with the mean value of k (Figure 6.7). The period of 
oscillation was approximately 0.05 and the amplitude decreased as the mean value of 
k got higher. I fit a function of the form e (Sin (120k) + Cos(120k)), where C is a 
constant to the simulated data by a method of least squares and improved the fit 
empirically. 
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The fitted equation was: 
= 0.00971617 _0.0241415_0 .0695475 2 
+ 0.00062519e T-26OT' +1200P Sin(120k) 
- 	- 	- 	 k<0.14 	6.10) 
- 0.027281 6e260k2 +1200k3 Cos(1 20k) 









0 0.05 	 0.1 	 0.15 
mean of k across samples 
Figure 6.7. Simulated results of bias in k for mean k up to 0.14. Results are from 10,000 
samples. Line was calculated using equation 6.10). R 2=96%. 
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When the mean value of k was >3, the bias k divided by K could be well described 
by a polynomial in k (Figure 6.8). Using a method of least squares the fitted 
equation was: 
—0.0760646+ 0.0241727k-0.000521704k2 	 k>3 	6.11) 









3 18 	33 	48 	63 	78 	93 
mean of k across samples 
Figure 6.8. Simulated results of bias in k for mean k over 3. Results are from 10,000 
samples. Line was calculated using equation 6.11). R 2=100%. 
The bias in k was negligible when the mean value of k ranged from 0.14 to 3. From 
equations 6.10) and 6.11) and the mean k across mice, I predicted the bias in k 
divided by K for each day of infection with each parasite dose, ignoring the bias if 
the mean value of k was between 0.14 and 3 inclusive. I then calculated the bias in 
the estimates of the gametocyte conversion ratio for each day and dose from equation 
6.9) and the mean conversion across mice. For most days of infection, the bias was 
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less than 6%. But, it was as high as 30% at the beginnings and ends of low dose 
infections. However, correcting for bias had very little effect on estimates of the 
gametocyte conversion ratio (Figure 6.9.). 
- estimate without correction for bias 	 estimate with correction for bias 
a) 	 d) 102 	 106 
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day of infection 
Figure 6.9. Comparison of estimates of the gametocyte conversion ratio with expected 
values in the absence of bias. Infections were initiated with a) 102,  b) iO, c) 104  , d) 106,  e) 
107 and f) 108  asexuals. Bias was calculated as described in the text. 
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6.7.2. 	Bias in estimates of asexual parasite density 
The bias in estimates of asexual parasite density can be estimated by: 
A[t]l 
+ 
II 	 1+  
b(A[t]) 	
A [t] ) 	Kr[t]) 	) 
= 
11¼ 1  + 77A 	) Kr[t] ) 
6.12) 
assuming that there is negligible bias in [t] and where nA  [t] is the actual number of 
asexuals per field in the day t smear and A[t] is the mean asexual density across 
mice. Simulations of 10,000 counts showed that bias in h could be significant when 
the mean value of h was between 9 and 23. I fit a polynomial function to the 
simulation results by a method of least squares (Figure 6.10) and obtained: 
-.=0.236701 —0.0539173h +0.00367618h 2 —0.0000770858h 3 
Ti 
9<h<23 	 6.13)' 
From equation 6.13) and the mean value of h across mice, and equation 6.10) and 
the mean value of k across mice, I predicted the total bias in estimates of asexual 
density using equation 6.12). The bias was no more than 3%. Correcting for bias had 
very little effect on estimates of asexual density (Figure 6.11). 
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mean of h across samples 
Figure 6.10. Simulated results of bias in h for mean h from 8 to 23. Results are from 10,000 
samples. Line was calculated using equation 6.13). R 2=96%. 
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—estimate without correction for bias 
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Figure 6.11. Comparison of estimates of asexual density with expected values in the 
absence of bias. Infections were initiated with a) 102,  b) iO, c) iO n , d) 106,  e) 107  and f) 108 
asexuals. Bias was calculated as described in the text. 
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6.7.3. 	Bias in estimates of gametocyte density 








assuming that there is negligible bias in h[t]  and 4t] and where [t] is the mean 
gametocyte density across mice. I predicted the bias in estimates of gametocytes 
density from equation 6.10) and the mean of k across mice. The bias was less than 
3%. Correcting for bias had very little effect on estimates of gametocyte density 
(Figure 6.12). 
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Figure 6.12. Comparison of estimates of gametocyte density with expected values in the 
absence of bias. Infections were initiated with a) 102,  b) 103,  c)  104  ,  d) 106,  e) 107  and f) 108 
asexuals parasites. Bias was calculated as described in the text. 
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6.7.4. 	Gametocyte conversion ratios for individual infections 
The conversion ratios for each of the 29 infections analysed in this chapter are shown 
in Figure 6.13, Figure 6.14 and Figure 6.15. 





















Figure 6.13. Gametocyte conversion in individual P. chabaud/ infections in mice initiated with 
a) 102  and b) 103  asexuals. 
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Figure 6.14. Gametocyte conversion in individual P. chabaudi infections in mice initiated with 
a) 104  and b) 106  asexuals. 
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Figure 6.15. Gametocyte conversion in individual P. chabaudi infections in mice initiated with 
a) 107  and b) 108  asexuals. 
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7. General Discussion 
A full discussion of my findings is presented in each results chapter. Here, I highlight 
some of the most interesting aspects of my work. I suggest directions in which my 
work could be extended with further theoretical and empirical studies. I also consider 
the impact that future technological advances may have on this field. 
I began this thesis by showing that continuous within-host malaria models were 
generally poor descriptions of gametocyte production and were likely to generate 
misleading results when used in optimality analyses of gametocyte investment. 
Consequently, I devised a discrete model for my optimality analysis. My within-host 
model was very simple and included immunity only implicitly. I assumed that 
infections terminated after a fixed time and that prior to this point, immunity had no 
effect on parasite numbers. The model was reasonably successful in predicting 
maximum gametocyte conversion ratios in P. chabaudi, particularly a relationship 
between maximum conversion and time to maximum asexual density. These results 
suggest that my model does capture an important aspect of gametocyte investment 
evolution. However, the developing host immune response is likely to be a 
significant selective force of the parasite's environment, and therefore I think that the 
principle next theoretical step is to incorporate immunity more fully into my model. 
I did not model an interaction between immunity and parasite numbers because there 
is not enough quantitative data to determine what form this interaction takes. Malaria 
models usually represent immunity by abstract functions whose parameters cannot be 
easily interpreted in biological terms, making it difficult to see how they could be 
estimated. Instead of attempting to model the underlying processes, I propose adding 
an asexual survival factor that dictates how many parasites survive from one day to 
the next. The survival function- would reproduce the net impact of immunity (and any 
other effects such as reduced red blood cell density) on parasite numbers and could 
be derived empirically. Such a function would replace the abrupt ending of infections 
in my model by a less severe decrease in parasite numbers over several days. 
Immunity could easily be incorporated in this way because my model is discretely 
General discussion 	 205 
formulated. It would be straightforward to estimate asexual survival from the P. 
chabaudi data I presented in chapter 6. An advantage of this data set is that survival 
can be calculated with gametocyte conversion taken into account. The data also 
provide information on the effect of parasite density (through different doses) on the 
survival profiles. If there was very high gametocyte investment, asexual survival 
might be expected to be higher because there would be little stimulus for the immune 
system. However I think values measured from infections will be a reasonable 
approximation of survival for investments close to the optimum. 
The most striking finding in my estimates of gamétocyte conversion in P. chabaudi 
was the decrease in conversion after it had reached a maximum. This result led me to 
suggest, under the assumption that this pattern was a parasite adaptation, that the 
chronic persistence of infections was important for parasite fitness and hence that 
conversion dropped to maximise the chance of a novel antigenic variant arising. This 
hypothesis could be explored using stochastic dynamic programming. 
An aspect of infections that is likely to have shaped parasite evolution, which I have 
not touched upon, is the presence of more than one parasite genotype. I anticipate 
that the main way in which co-infecting genotypes affect each other is through the 
developing immune response. Therefore not knowing the dynamics of how parasites 
interact with the immune system is a serious limitation for modelling mixed 
infections. I suggest that mixed infections could also be modelled by including an 
asexual survival function, but this time estimated from infections by more than one 
parasite clone. Real-time PCR can be used to quantify the proportions of parasites 
that are of each clone and hence to extract the dynamics of each clone from parasite 
counts. Separate survival functions could then be estimated for each clone, although 
as existing real-time PCR cannot distinguish asexuals from gametocytes, these 
estimates would not take into account gametocyte conversion. 
There is considerable further scope for estimating gametocyte conversion during 
infections. The inverse sampling method that I described in chapter 5 can be applied 
to new data. However a large amount of information- already exists on the time 
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course of asexual and gametocyte densities and it would be valuable to know if this 
could be used to calculate conversion. In particular, malariatherapy data from 
treatment of neurosyphilis patients provides a unique opportunity to estimate 
gametocyte conversion in human malaria infections. Parasite counts had already been 
made from the smears that I examined in chapter 6 by a traditional method. 
Therefore estimates of gametocyte conversion from these previous-counts could be 
compared with my values to determine the effect of the counting method on results. 
Important issues are how different the values are, how much bigger the variance is 
from traditional counts than when using inverse sampling and whether patterns 
observed in my data are obscured with traditional counts. By comparing the two sets 
of values it may be possible to devise a correction factor that could be used to adjust 
traditional counts for bias. Large variances in estimates, particularly if they hide the 
patterns in the data, would be a significant drawback to using traditional counts to 
estimate gametocyte conversion. However if values from the two methods are very 
similar, traditional count data could be used to estimate gametocyte conversion with 
reasonable confidence. 
Even if the comparison of estimates described above indicates that traditional count 
data can be used to estimate gametocyte conversion, there are serious difficulties in 
estimating gametocyte conversion for P. falciparum from malariatherapy records. 
The average lifespan of mature P. falciparum gametocytes is probably about 6 days 
(Eichner etal., 2001; Lensen et al., 1999). Therefore gametocytes reported during P. 
falciparum infections will probably have been produced from several different 
replication cycles. But to estimate gametocyte conversion, the number of 
gametocytes from a single replication cycle needs to be measured. To obtain these 
data from the P. falciparum malariatherapy records, the survival of mature 
gametocytes between sampling times needs to be estimated. As the mortality of 
gametocytes is not well understood, there is likely to be some uncertainty in the 
estimates conversion. A second problem is the long maturation time of P. falciparum 
gametocytes, thought to be about eight days. Many gametocytes may die during this 
time, which would make counts of mature gametocytes a poor indicator of the actual 
number produced and lead to considerable underestimation of gametocyte 
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investment. Whilst there are limitations to the P. falciparum data, P. vivax, P. 
malariae and P. ovale were also used in malariatherapy and data from these species 
might be more successfully applied to estimating gametocyte conversion because 
these species have shorter gametocyte maturation times and survival times. 
It would be interesting to know whether gametocyte conversion also varies over time 
in other malaria infections. It may be that my assumption of constant gametocyte 
investment holds in other Plasmodium species. Moreover, comparative data across a 
range of parasite-host species combination would provide a good test of my 
optimality analysis. In P. chabaudi, it would be possible to measure gametocyte 
conversion across a suite of clones. As many of these clones have been characterised 
for their virulence, whether there is a relationship between conversion and virulence 
could be investigated. I would also like to see if the pattern of conversion during the 
acute phase of P. chabaudi infection is repeated in recrudescences. 
My predictions of the effects of vaccination and drug treatment on gametocyte 
investment could be tested in P. chabaudi. An intriguing finding from my optimality 
analysis was the asymmetry between reducing the time to maximum parasite density 
and reducing parasite fecundity. I suggested vaccines that reduced parasite fecundity 
without changing the time of maximum parasite density might have little effect on 
gametocyte investment, whilst drug treatment could lead to increase gametocyte 
conversion. Testing these results is clearly of interest for malaria control. 
Determining gametocyte investment is complicated because the proportion of 
parasites that are gametocytes cannot, in general, be measured directly. Having to 
measure gametocyte and asexual numbers separately is the reason that estimates of 
gametocyte conversion are usually biased and fairly imprecise. Secondarily, it also 
means that estimates of conversion are compounded with the mortality of young 
gametocytes (because gametocytes are counted later). Future technological advances 
may mitigate these problems. Improved culturing techniques for P. chabaudi 
parasites may enable parasites to be removed from the host and grown in vitro 
without schizont rupture, as is possible for P. berghei (Mons, 1986), until 
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gametocytes can be distinguished. Identification of gametocyte-specific antigens 
could enable gametocytes to be distinguished earlier by using monoclonal antibodies. 
A current area of development is the quantification of gametocytes from the levels of 
gametocyte-specific RNA that are expressed, using real-time RT-PCR (reverse 
transcriptase PCR) or NASBA (nucleic acid sequence-based amplification). These 
methods have the potential for more accurate and precise estimates of gametocyte 
density and could considerably reduce counting time. However, the accuracy of 
quantification will need to be carefully evaluated. Furthermore, estimating 
gametocyte conversion is still likely to depend on calculating a ratio of separately 
estimated gametocyte and total parasite densities, with the inherent problems of bias 
and variance described in chapter 5). 
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